Translation enhancing nucleic acid compounds and uses thereof to treat central nervous system (CNS) targets

ACT-UP1 compounds overcome the blood-brain barrier by enhancing protein expression in the CNS through localized delivery, providing sustained therapeutic effects with reduced systemic exposure and safer treatment for CNS diseases.

WO2026236555A2PCT designated stage Publication Date: 2026-11-12ARNATAR THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027187
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing treatments for central nervous system (CNS) diseases face challenges due to the blood-brain barrier, which hinders drug delivery, leading to systemic exposure and off-target effects, and require frequent dosing to maintain therapeutic levels.

Method used

Development of ACT-UP1 compounds, which are chemically modified antisense oligonucleotides coupled with a protein recruiting sequence (PRS) that hybridize to target mRNA, allowing localized delivery to the CNS via intrathecal injection, enhancing protein expression of specific genes and reducing systemic exposure.

Benefits of technology

ACT-UP1 compounds achieve broad CNS biodistribution with sustained exposure, lower systemic drug levels, and allow fine-tuning of gene expression, offering a safer treatment option with reduced off-target effects and infrequent dosing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027187_12112026_PF_FP_ABST
    Figure US2026027187_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed herein are ACT-UP1 compounds and methods of using the compounds for enhancing gene expression in the central nervous system (CNS). Such compounds and methods are useful for increasing expression of certain genes, many of which are associated with a variety of diseases, disorders, and syndromes in the CNS.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]

[0002] TRANSLATION ENHANCING NUCLEIC ACID COMPOUNDS AND USES THEREOF TO TREAT CENTRAL NERVOUS SYSTEM (CNS) TARGETS

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS

[0004] This application claims the benefit of U. S. Provisional Application Nos, 63 / 802,425, filed May 8, 2025 and 64 / 008,561, filed March 17, 2026, the contents of which are incorporated herein in their entireties by this reference.

[0005] INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

[0006] Incorporated by reference in its entirety is a computer-readable nucleotide / amino acid sequence listing submitted concurrently herewith and identified as follows: the text file named "2026_05_ 06 -Sequence _Neuro_Listing” (1,438,790 bytes), which was created on May 6, 2026, Throughout this application various publications are referenced. All publications, gene transcript identifiers, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, gene transcript identifiers, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0007] FIELD

[0008] Certain embodiments are directed to nucleic acid compounds for enhancing gene expression and methods of using the compounds to treat neurological diseases. Such methods and compounds are useful for increasing protein expression in the central nervous system (CNS).

[0009]

[0010] Antisense oligonucleotide ASO) Coupled Translation - Upregulation 1 (ACT-UP 1) is a new technology utilizing a unique design to create compounds capable of upregulating target transcript expression (PCT Publication WO2025 / 165891). An ACT-UP1 compound is designed to

[0011] Icomprise an ASO component joined to a protein recruiting sequence (PRS) component, wherein the ASO component hybridizes to a specific target mRNA, the PRS recruits translation related proteins to the targeted mRNA leading to an increase in protein expression of the target.

[0012] ACT-UP 1 compounds are particularly suitable for treating central nervous system (CNS) diseases, disorder and / or syndromes. The blood-brain barrier (BBB) is a major hurdle for drug delivery' to treat CNS diseases, disorders and / or syndromes. ACT-UP 1 compounds can be administered via intrathecal injection, directly delivering the drug into the cerebrospinal fluid (CSF), achieving broad CNS biodistribution and sustained CNS exposure with infrequent dosing. Once delivered to the CSF, ACT-UP1 compounds, which are nucleic acid based and chemically modified, are short enough and capable to enter ceils without facilitated delivery. Due to localized intrathecal delivery, ACT-UP 1 treated patients will experience lower systemic exposure to the drug and decreased risk of off-target effects outside of the CNS, ACT-UP1 compounds are amenable to fine-tuning gene expression levels, which is critical in CNS homeostasis. Ceasing treatment can potentially reverse adverse effects, offering an important safety advantage, especially critical in CNS settings,

[0013] Disclosed herein are novel ACT-UP 1 compounds to treat CNS related diseases, disorder and / or syndromes by upregulating ^protein expression of specific genes expressed in the CNS. Included among the gene targets are mRNAs encoding sodium voltage-gated channel alpha subunit 1 (SCN1A), granulin precursor (GRN), SH3 and multiple ankyrin repeat domains 3 (SHANK3), glucosylceramidase..beta 1 (GBA1), Syntaxin Binding Protein 1 (STXBP1), and Retinoic Acid Induced 1 (RAH).

[0014] SUMMARY OF THE INVENTION

[0015] Several embodiments provided herein relate to the discovery of certain Antisense oligonucleotide (ASO) Coupled Translation - Upregulation I (ACT-UP1) compounds that can enhance protein expression in the central nervous system (CNS). In one embodiment, the ACT-UP 1 compound, or salt thereof, enhances protein expression of sodium voltage-gated channel alpha subunit 1 (SCN1A), wherein the compound enhances translation of SCN1 A mRNA. In one embodiment, the ACT-UP1 compound, or salt thereof, enhances protein expression of granulin precursor (also known as GRN or PGRN), wherein the compound enhances translation of GRN

[0016]

[0017] mRNA. In one embodiment, the ACT-UP 1 compound, or salt thereof, enhances protein expression of SH3 and multiple ankyrin repeat domains 3 (SHANKS), wherein the compound enhances translation of SHANK3 mRNA. In one embodiment, the ACT-UP1 compound, or salt thereof, enhances protein expression of glucosylceramidase beta I (GBA1), wherein the compound enhances translation of GBA1 mRNA. In one embodiment, the ACT-UP 1 compound, or salt thereof, enhances protein expression of Syntaxin Binding Protein 1 (STXBP1), wherein the compound enhances translation of STXBP1 mRNA. In one embodiment, the ACT-UP 1 compound, or salt thereof, enhances protein expression of Retinoic Acid Induced 1 (RAH), wherein the compound enhances translation of RAI I mRNA.

[0018] Certain embodiments provide a pharmaceutical composition comprising the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in the CNS described herein, alone or I - in combination with a pharmaceutically acceptable carrier or excipient.

[0019] Certain embodiments disclosed herein provide a method for increasing translation of mRNA in a central nervous system (CNS) cell comprising administering an ACT-UP 1 compound, or salt thereof, to the cell in the CNS, in an amount sufficient to increase translation of the protein from the mRNA. In certain embodiments, the mRNA targeted by the ACT-UP 1 compound is a SCN1A, GRN, SHANK3, GBA1, STXBP1, or RAH transcript.

[0020] Certain embodiments disclosed herein provide a method for increasing protein expression in a central nervous system (CNS) cell comprising administering an ACT-UP1 compound, or salt thereof, to the cell in the CNS, in an amount sufficient to increase protein expression. In certain embodiments, the mRNA targeted,by the ACT-UP 1 compound is a SCN1A, GRN, SHANK3, GBA1, STXBP1, or RAI 1 transcript.

[0021] Certain embodiments provide a method for treating a central nervous system (CNS) disease, disorder and / or syndromedin a subject comprising administering an ACT-UP 1 compound, or salt thereof, to the subject, in an amount sufficient to treat the CNS disease, disorder and / or syndrome in the subject.

[0022] Certain embodiments provide a method for treating a haploinsufficiency disease, disorder and / or syndrome in a subject comprising administering an ACT-UP 1 compound, or salt thereof, to the subject, in an amount sufficient to treat the haploinsufficiency disease, disorder and / or syndrome in the subject. In certain embodiments, the ACT-UP 1 compound, or salt thereof, targets a haploinsufficiency disease, disorder and / or syndrome related to SCN1 A and the SCN1A relateddisease, disorder and / or syndropig js Dravet Syndrome, In certain embodiments, the ACT-UP i compound, or salt thereof, targets a haploinsufficiency disease, disorder and / or syndrome related to GRN and the GRN related disease, disorder and / or syndrome is frontotemporal dementia associated with GRN (FTD-GRN). In certain embodiments, the ACT-UP1 compound, or salt thereof, targets a haploinsufficiency disease, disorder and / or syndrome related to SHANK3 and the SHANK3 related disease, disorder and / or syndrome is Phelan-McDermid Syndrome (PMS), In certain embodiments, the ACT-UP 1 compound, or salt thereof, targets a haploinsufficiency disease, disorder and / or syndrome related to GBA1 and the GBA1 related disease, disorder and / or syndrome is Gaucher disease, Parkinson’s disease (PD), and / or Dementia with Lewy bodies (DLB). In certain embodiments, the ACT-UP 1 compound, or salt thereof, targets a haploinsufficiency disease, disorder and / or syndrome related to STXBP1 and the STXBP1 related disease, disorder and / or syndrome is early infantile epileptic encephalopathy (EIEE4), developmental and epileptic encephalopathy, West syndrome, Ohtahara syndrome, and / or Rett- like syndrome. In certain embodiments, the ACT-UP1 compound, or salt thereof, targets a haploinsufficiency disease, disorder and / or syndrome related to RAI I and the RAI I related disease, disorder and / or syndrome is Smith-Magenis syndrome, autism spectrum disorder, circadian rhythm disorders, and / or obesity metabolic dysregulation. Certain embodiments provide a process or method for making an ACT-UP 1 compound of the invention comprising synthesizing an oligonucleotide on a solid support using phosphoramidite chemistry, thereby making the ACT-UP 1 compound.

[0023] BRIEF DESCRIPTION OF TOE DRAWINGS FIGURE 1: Shows that different ACT-UP 1 compounds can increase SCN1A protein levels after transfection into human HepG2 cells: A) A chart showing the effect of various SCN1 A targeting ACT-UP 1 compounds on the level of SCN1A mRNA after transfection of 50nM ACT-UP1 compound into HepG2 cells; and B) A chart showing the dose dependent effect o f vari ous SCN1 targting ACT-UP I compounds on the level of SCNl A mRNA 17 hours after transfection of ACT- UP 1 compound into HepG2 cells.

[0024] FIGURE 2: Shows a Western Blot displaying upregulation of SCN1A protein levels in human HepG2 cells 24 hours after ACT-UP1 compound transfection (7,5nM or 15nM) into human HepG2 cells. GAPDH protein was used as a loading standard for quantification.FIGURE 3: Shows a Western Blot displaying upregulation of SCN1A protein levels in human SH-SY5Y cells 24 hours after ACT-UP 1 compound transfection (7.5nM or 15nM). a-TUBULIN protein was used as a loading standard for quantification.

[0025] FIGURE 4: Shows a Western Blot displaying upregulation of SCN1A protein levels in rat neuronal B50 cells 64 hours after free uptake of ACT-UP1 compounds. GAPDH protein was used as a loading standard for quantification,

[0026] FIGURE 5: Shows a Western Blot displaying upregulation of SCN1A protein levels in mouse Hepal-6 cells 24 hours after ACT-UP 1 compound transfection. HSP90 protein was used as a loading standard for quantification.

[0027] FIGURE 6: Shows that different ACT-UP1 compounds targeting PGRN mRNA can increase PGRN protein levels 24 hours after transfection of IS nM into human U937 cells: A) Western Blot showing the PGRN protein; and B) A chart showing the quantification of PGRN protein levels from the Western Blot. GAPDH protein was used as a loading standard for quantification.

[0028] FIGURE 7: Shows ACT-UP 1 compounds ATXL489 and ATXL491 targeting PGRN mRNA can increase PGRN protein levels in a generally dose dependent manner 24 hours after transfection into human U9.37 ceils: A) Western Blot showing the PGRN protein; and B) A chart showing the quantification of PGRN protein levels from the Western Blot. GAPDH protein was used as a loading standard for quantification.

[0029] FIGURE 8: Shows ACT-UP 1 compounds ATXL566 and ATXL568, targeting the 3’UTR region of PGRN, subcutaneously injected into mice at 3mpk or 9mpk can increase PGRN protein expression: A) Schematic of the dosing strategy; and, B) a chart showing the ELISA quantification of PGRN protein levels in mouse liver samples 8 days after treatment.

[0030] FIGURE 9: Shows ACT-UP 1 compound ATXL568, targeting the 3’UTR region of GRN, subcutaneously injected into mice at 75mpk increases PGRN protein expression: A) Schematic of the dosing strategy; and, B) a chart showing the ELISA quantification of PGRN protein levels in mouse liver samples 8 days after treatment,

[0031] FIGURE 10: Sho ws a schematic of the dosing strategy for ACT-UP1 compounds ATXL489 and ATXL491, targeting the 3’UTR region of GRN, intrathecally injected into rats at 300pg / 30.l. Functional Observatory Battery (FOB) scores were assessed at 2 hours and 6 hours after administration. The rats were sacrificed and organs harvested 10 days after administration.

[0032]

[0033] FIGURE 11: Shows ACT-UP1 compounds ATXL489 and ATXL491, dosed as shown in Figure 9, can increase PGRN protein expression in rats treated with the ACT-UP 1 compounds: A) A Western Blot of PGRN protein levels in the rat cortex 10 days after administration; and, B) a chart showing the quantification of PGRN protein levels in rat brain (cerebral cortex, hippocampus, cerebellum and brainstem), spinal column (cervical and lumbar) and plasma samples 10 days after treatment,

[0034] FIGURE 12: Shows ACT-UP1 compound ATXL491 intrathecally injected into rats at varying doses (100pg / 30pl, 300pg / 30ul or 900pg / 30al) increases PGRN protein expression: A) Schematic of the dosing strategy; and, B) a chart showing PGRN protein levels in brain (cerebral cortex, hippocampus, cerebellum and brainstem) and spinal column (cervical and lumbar) samples 10 days after treatment.

[0035] FIGURE 13: Shows 3OOpg / 3Oul of ACT-UP1 compound ATXL491 intrathecally injected into rats increases PGRN protein expression: A) Schematic of the dosing strategy and sampling timeline; and, B) charts showing PGRN protein levels in rat cerebral cortex, hippocampus, cerebellum samples at 14, 28, 42 amd 56 days after treatment.

[0036] FIGURE 14: Shows a chart displaying GBA1 mRNA levels in human SH-SY5Y cells 24 hours after compounds targeting GBA1 were transfected into the cells at varying doses: 0 nM, 0.9 nM, 2,8 nM, 8.3 nM, 25 nM, or 75 nM.

[0037] FIGURE 15: Shows that different compounds targeting GBA1 mRNA can increase GBA1 protein levels 24 hours after transfection of 15 nM into African green monkey Cosl cells: A) Western Blot showing the GBA1 protein; and B) A chart showing the quantification of GBA1 protein levels from the Western Blot. Actin protdih was used as a loading standard for quantification, FIGURE 16: Shows that compounds ATXL700 and ATXL701, targeting GBA1 mRNA, can increase GBA1 protein levels 24 hours after transfection of 0 nM, 5 nM, 10 nM, 20 nM, 40 nM and 80 nM into African green monkey Cosl cells:. A) Western Blot showing the GBA1 protein; and B) A chart showing the quantification of GBA1 protein levels from the Western Blot, Actin protein was used as a loading standard for quantification.

[0038] FIGURE 17: Shows that compounds ATXL803, ATXL804 and ATXL805, targeting GBA1 mRNA, can increase GB 1 protein levels 24 hours after transfection of 0 nM. 5 nM, 10 nM, 20 nM, 40 nM and 80 nM into African green monkey Cosl cells: A) Western Blot showing the GBA1i

[0039] protein; and B) A chart showing the quantification of GBA1 protein levels from the Western Blot. Actin protein was used as a loading standard for quantification.

[0040] FIGURE 18: Shows an in vivo study of ACT-UP 1 compounds targeting the 3’UTR region of GBA1: A) a schematic of the dosing strategy for BALB / C mice treated with the ACT-UP 1 compounds by subcutaneos injection at 7.5 mg / kg on Day 1 and Day 3; B) Western Blot showing the GBA1 protein in the liver after treatment; C) Western Blot showing the GBA1 protein in the kidney after treatment. HSP90 protein was used as a loading standard for quantification.

[0041] FIGURE 19: Shows that different ACT-UP 1 compounds targeting SHANK3 mRNA can increase SHANK3 protein levels 48 hours after transfection of 50 nM into human SH-SY5Y cells: A) Western Blot showing the SHANK3 protein; and B) A chart showing the quantification of SHANK3 protein levels from the Western Blot. GAPDH protein was used as a loading standard for quantification.

[0042] FIGURE 20: Shows an in vivo study of ACT-UP 1 compounds targeting SHANK3: A) a schematic of the dosing strategy for SD rats treated with the ACT-UP 1 compounds, ATXL690-ATXL694, by intrathecal injection with a 0.6 mg dose on Day 1: B) A chart showing the quantification of SHANK3 protein levels from a Western Blot (not shown) in the Cortex and Pons of rat brain. FIGURE 21: Shows that different ACT-UP1 compounds targeting STXBP1 mRNA can increase STXBP1 protein levels after free uptake of 2 pM into human H4 cells: A) Western Blot showing the STXBP1 protein; and B) A chart showing the quantification of STXBP1 protein levels from the Western Blot. GAPDH and / or beta-actin protein were used as loading standards for quantification.

[0043] FIGURE 22: Shows that compounds ATXL1097-ATXL1101 targeting STXBP1 mRNA, can increase STXBP1 protein levels 72 hours after free uptake of 0 pM (Mock),l uM. 2 pM, 5 uM, 10 pM into H4 cells: A) Western Blot showing the STXBP1 protein; and B) A chart showing the quantification of STXBP1 protein levels from the Western Blot. HSP90 protein was used as a loading standard for quantification <

[0044] DETAILED DESCRIPTION OF THE INVENTION

[0045] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. Herein, the use of the singular includes the plural unless specifically stated otherwise. As usedherein, the use of “or” means “and / or” unless stated otherwise. Furthermore, the use of the term “including” as well as other forms, such as “includes” and “included”, is not limiting. Also, terms such as “element” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit, unless specifically stated otherwise.

[0046] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, and treatises, are hereby expressly incorporated-by-reference for the portions of the document discussed herein, as well as in their entirety.

[0047] Definitions

[0048] Unless specific definitions are provided, the nomenclature utilized in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques may be used for chemical synthesis, and chemical analysis. Where permitted, all patents, applications, published applications and other publications, GENBANK Accession Numbers, and associated sequence information obtainable through databases such as National Center for Biotechnology Information (NCBI) and other data referred to throughout in the disclosure herein are incorporated-by-reference for the portions of the document discussed herein, as well as in their entirety.

[0049] Unless otherwise indicated, the following terms have the following meanings:

[0050] “2’-O-methoxyethyl” (also 2 ’-MOE and 2’-O(CH2)2-OCH3) refers to an O-methoxy-ethyl modification at the 2’ position of a furanose ring. A 2’-O-methoxyethyl modified sugar is a modified sugar.

[0051] “2 ’-MOE nucleoside” (also 2’-O-methoxyethyl nucleoside) means a nucleoside comprising a 2’-M0E modified sugar moiety. “2’-M0E nucleotide” (also 2’-O-methoxyethyl nucleotide) means a nucleotide comprising a 2’-M0E modified sugar moiety.

[0052] “2’-O-methyl” (also 2’-OCH3 and 2’-0Me) refers to an O-methyl modification at the 2’ position of a furanose ring. A 2’-0 methyI modified sugar is a modified sugar.“2’-0Me nucleoside’' (also 2’-O-methyl nucleoside) means a nucleoside comprising a 2’- OMe modified sugar moiety. “2'-OMe nucleotide” (also 2’-O~methyl nucleotide) means a nucleotide comprising a 2’-OMe modified sugar moiety.

[0053] “2 ’-substituted nucleoside’’ means a nucleoside comprising a substituent, i.e., a modification, at the 2’-position of the furanosyl ring other than H or OH. In certain embodiments, 2’ substituted nucleosides include nucleosides with a fluoro (2’-F), O-methyl (2’-0Me), ()- methoxyethyl (2’-M0E) or bicyclic sugar modifications. A 2 ’-substituted nucleoside is a modified nucleoside.

[0054] “5-methylcytosine” means a cytosine modified with a methyl group attached to the 5 position. A 5-methylcytosine is a modified nucleobase and is part of a modified nucleoside. “5- methyicytidine” is the name of the nucleoside when the 5 methyl modified nucleobase is combined with a modified or unmodified sugar,

[0055] “About” as used herein means within ±10% of a measurable value. For example, if it is stated, “the compounds affected at least about 70% inhibition of mRNA”, it is implied that the mRNA levels are inhibited within a range of 63% and 77%. The term “about” as used herein when referring to an amount of a compound or agent of this invention, dose, time, temperature, and the like, is meant to encompass variations of ± 10% of the specified amount. For sequence identity, “about” as used for percent sequence identity encompasses variations of ± 5%. Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.”

[0056] “ACT-UP 1” or “ASO Coupled Translation - Upregulation 1” refers to an antisense oligonucleotide (“ASO” or “ASO component”) joined to a protein recruiting sequence (“PRS” or “PRS component”). The ASO specifically hybridizes to a target mRNA sequence, bringing the PRS into close proximity to the target mRNA, The PRS, a short sequence of linked nucleosides, attracts translation regulatory proteins close to the target mRNA thereby increasing translation of the targeted mRNA. As used herein, the protein recruiting sequence (PRS), although it comprises a short linkage of nucleosides, is not an antisense oligonucleotide (ASO) as it does not hybridize with a target nucleic acid (i.e., the protein recruiting sequence is not antisense to a target nucleic acid). The ASO can be joined directly to the PRS or they ca.n be joined by a linker. In some preferred aspects, the PRS is joined to the 5’ end of the ASO. In some aspects, the PRS is joined

[0057]

[0058] to the 3’ end of the ASO. Joined means being covalently linked. It is to be understood that the ACT-UP I compound may comprise additional sequences in addition to the ASO and PRS. For example, in some embodiments, the ACT-UP1 comprises an ASO and PRS and a linker for joining the ASO and PRS. In some preferred embodiments, the ACT-UP 1 compound consists only of an ASO joined to a PRS.

[0059] “ACT-UP 1 activity” means any detectable or measurable activity attributable to the hybridization of an ACT-UP 1 compound to its target nucleic acid. In certain embodiments, ACT- UP1 activity is an increase (i.e., up-regulation) in the amount of a target nucleic acid and / or expression of the protein encoded by such target nucleic acid.

[0060] “ACT-UP 1 upregulation” or “ACT-UP 1 enhancement” means increasing target protein levels in the presence of an ACT-UP 1 compound compared to target protein levels in the absence of the ACT-UP 1 compound.

[0061] “Animal" refers to a human or non-human animal, including, but not limited to, mice, rats, rabbits, dogs, cats, pigs, and non-human primates, including, but not limited to, monkeys and chimpanzees.

[0062] “Antibody” refers to a molecule characterized by reacting specifically with an antigen in some way, where the antibody and the antigen are each defined in terms of the other. Antibody may refer to a complete antibody molecule or any fragment or region thereof, such as the heavy chain, the light chain, Fab region, and Fcregion.

[0063] “Antisense compound” means an oligomeric compound that is capable of undergoing hybridization to a target nucleic, acid through hydrogen bonding. Examples of antisense compounds include single-stranded and double-stranded compounds, such as, antisense oligonucleotides (ASOs), siRNAs, shRNAs, snoRNAs, miRNAs, and satellite repeats. It is to be understood that antisense compounds include ACT UP 1 compounds which comprise an antisense oligonucleotide (. ASO) joined to a protein recruiting sequence (PRS).

[0064] “Antisense oligonucleotide” or “ASO” means a single-stranded oligonucleotide having a nucleoside sequence comprising a nucleobase sequence that permits hybridization to a corresponding region or segment of a target nucleic acid. In certain embodiments, the ASO comprises one or more modified nucleosides. In certain embodiments, an ASO is a component of an ACT-UP 1 compound facilitating the binding of the compound to a target mRNA. As usedherein, ASO does not refer to the protein recruiting sequence (PRS) in ACT-UP 1 compounds. “A verage” as used herein may be mean, mode, or median for a group of measurements.

[0065] As used herein, the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and reference to "the culture" includes reference to one or more cultures and equivalents thereof known to those skilled in the art.

[0066] “Base complementarity” refers to the capacity for the base pairing of nucleobases of an oligonucleotide with corresponding nucleobases in a target nucleic acid (i.e., hybridization), and is mediated by Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen binding between corresponding nucleobases. Base complementarity also refers to canonical (e.g., A: U, A: T, or C: G) or non-canonical base pairings (e.g., A: G, A: U, G: U, I: U, I: A, or I: C).

[0067] “Bicyclic sugar” means a furanose ring modified by the bridging of two non-geminal carbon atoms. A bicyclic sugar is a modified sugar.

[0068] “Cap structure” or “terminal cap moiety” means chemical modifications, which have been incorporated at either terminus of an antisense compound.

[0069] “cEt” or “constrained ethyl” means a bicyclic sugar moiety comprising a bridge connecting the 4 ’-carbon and the 2 ’-carbon, wherein the bridge has the formula: 4’-CH(CH3)-O-2’.

[0070] “Constrained ethyl nucleoside” (also cEt nucleoside) means a nucleoside comprising a bicyclic sugar moiety comprising a 4’-CH(CH3)-O-2’ bridge.

[0071] “Chemical modification” means a modification of molecular structure or element from naturally occurring molecules. For example, antisense oligonucleotides are composed of linked deoxyribonucleosides (also sometimes referred to herein as DNA nucleosides), therefore, substitution of a 2’-M0E nucleoside for a DNA nucleoside is considered a chemical modification of the antisense oligonucleotide. Examples of other chemical modifications may be found hereinbelow'.

[0072] “Chemically distinct region” refers to a region of an antisense compound that is in some way chemically different than another region of the same antisense compound. For example, a region having 2’-O-methoxyethyl s nucleotides is chemically distinct from a region having nucleotides without 2’-O-methoxyethyl modifications.

[0073] “Chemistry” when used in the context of a sequence refers to chemical modifications of the sequence, e.g,, modifications of the nucleoside sugar, nucleoside base, and / or linkage, asfurther described herein. Thus, “sequence with chemistry" considers the modifications of the nucleosides and their linkage, while “sequence" only describes the order of the nucleoside bases. However, neither the “sequence” nor “sequence with chemistry” refers to compound(s) attached to the sequences, such as a delivery agent.

[0074] “Complementarity” means the capacity for pairing between nucleobases of a first nucleic acid and a second nucleic acid.

[0075] “Comply” means the adherence to a recommended therapy by an individual.

[0076] “Comprise,” “comprises,” and “comprising” will be understood to imply the inclusion of a stated step or element or group of steps or elements, but, not the exclusion of any other step or element or group of steps or elements.

[0077] “Contiguous nucleobases” means nucleobases immediately adjacent to each other, for example, to form a nucleobase sequence of a specified length.

[0078] “Deoxyribonucleoside” means a nucleoside having a hydrogen at the 2’ position of the sugar portion of the nucleoside. A deoxyribonucleoside is sometimes referred to as DNA nucleoside, “D” or “d” herein. Deoxyribonucleosides may be modified with any of a variety of substituents and may be connected by covalent linkages other than naturally occurring phosphodiester such as phosphorothioate.

[0079] “Deoxyribonucleotide” ipqahs a nucleotide having a hydrogen at the 2’ position of the sugar portion of the nucleotide. A deoxy ribonucleotide is sometimes referred to as DNA nucleotide, “D” or “d” herein. Deoxyribonucleotides may be modified with any of a variety of substituents and may be connected by covalent linkages other than naturally occurring phosphodiester such as phosphorothioate.

[0080] “Derivative” of an ACT-UP I compound sequence disclosed herein means a sequence being modified in structure by substitution, addition or deletion of one or more nucleosides, particularly by substitution of one or more nucleosides. The modification can occur in the ASO and / or PRS component of an ACT-UPT compound. A derivative of an ACT-UP 1 compound sequence disclosed herein preferably comprises at least 80%, more preferably 85% and most preferably 90%, sequence identity with the an ACT-UP1 compound sequence disclosed herein. Preferably, the activity in increasing translation of the targeted mRNA by the derivati ve of the ACT-UP 1 compound sequence disclosed herein is at least similar, more preferably, higher than the respective activity of the ACT^UPl compound sequence disclosed herein.“DRACH” refers to a consensus sequence wherein D is adenine (A), guanine (G) or thymine (T); R is adenine (A) or guanine (G); A is adenine (A); C is cytosine (C); H is adenine (A), cytosine (C) or uracil (U). DRACH sequences are useful as protein recruiting sequences (PRSs), A PRS, when joined to an antisense oligonucleotide (ASO) targeting a specific mRNA target, forms an ACT-UP1 compound that can enhance protein expression of the target. Exampies of DRACH useful for forming ACT-UP 1 compounds can be found in PCT Publication WO2025 / 1 5891.

[0081] “Dual functional compound” or “dual functional ACT-UP1 compound” refers to a compound with an ACT-UP 1 design plus a design for a second function or mechanism that is not ACT-UP1. The second function or mechanism design includes, but is not limited to, inhibiting an upstream open reading frame (uORF), translation inhibitory element (TIE), or other structural element that inhibits expression of, or degrades, a target transcript. For example, a dual functional compound has an ACT-UP1 design (e.g., binds to the 3’UTR of a target transcript and has a PRS) and targets the binding site of a miRNA. This dual functional compound can increase protein levels by both increasing mRNA levels (e.g., via blocking miRNA binding) and / or also increasing protein translation (via ACT-UP1).

[0082] “Efficacy” means the ability to produce a desired effect.

[0083] “Expression” includes all the functions by which a gene’s coded information is converted into protein structures present and operating in a cell. Such structures include, but are not limited to the products of transcription and translation.

[0084] “Fully complementary” or “100% complementary” means each nucleobase of a first nucleic acid has a complementary nucleobase in a second nucleic acid. In certain embodiments, a first nucleic acid is an antisense compound and a target nucleic acid is a second nucleic acid.

[0085] “Fully modified” or “Fully chemically modified” refers to an antisense compound comprising a contiguous sequence of nucleosides wherein each nucleoside has a chemical modification.

[0086] “Hybridization” means the annealing of complementary nucleic acid molecules. In certain embodiments, complementary'' nucleic acid molecules include, but are not limited to, an antisense compound and a nucleic acid target. In certain embodiments, complementary nucleic acid molecules include, but are not limited to, an antisense oligonucleotide and a nucleic acid target.“Immediately adjacent” means there are no intervening elements between the immediately adjacent elements,

[0087] “Individual” means a human or non-human animal selected for treatment or therapy. “Induce”, “inhibit”, “potentiate”, “elevate”, “increase”, “decrease”, “enhance” or the like, generally denote quantitative differences between two states.

[0088] “Inhibiting the expression or activity” refers to a reduction, or blockade of the expression or activity and does not necessarily indicate a total elimination of expression or activity.

[0089] “Intemucleoside linkage” or “linkage” refers to the chemical bond between nucleosides. The 3’ position of a nucleoside is hereby linked to a 5’ position of a subsequent nucleoside via the intemucleoside linkage.

[0090] “Isolated” means a state following one or more purifying steps, but, does not require absolute purity.

[0091] “Joined” ASO and PRS components of ACT-UP1 compound means that the ASO and PRS components are covalently linked to form the ACT-UP 1 compound. It is to be understood that the ACT-UP 1 compound may comprise additional sequences joined to the ASO and / or PRS. For example, in some embodiments, the ACT-UP1 comprises the ASO and PRS components and a linker for joining the ASO and PRS.

[0092] “Linked nucleosides” means adjacent nucleosides (e.g., A, G. C, T, or U) linked together by an intemucleoside linkage. Examples of linked nucleosides include deoxyribonucleosides (sometimes referred to as DNA nucleosides herein) or ribonucleosides (sometimes referred to as RNA nucleosides herein).

[0093] “Linker” means a molecule that may function as a spacer between two components, e.g., between an antisense oligonucleotide and a delivery agent or between a PRS and ASO within an ACT-UP 1 compound, and / or between a PRS or ASO and a conjugate moiety.

[0094] “Mismatch” or “non-complementary nucleobase” refers to the case when a nucleobase of a first nucleic acid is not capable ofipairing with the corresponding nucleobase of a second or target nucleic acid through Watson-Crick base-pairing (e.g., A: T, A: U, or C: G). Merely by way of example, non-canonical basepair such as through Hoogsteen or reverse Hoogsteen may be considered a “mismatch” or “non-complementary” nucleobase.

[0095] “Modified internucleoside linkage” refers to a substitution or any change from a naturally occurring intemucleoside bond (i.e. a phosphodi ester intemucleoside bond).“Modified nucleobase” means any nucleobase other than adenine, cytosine, guanine, thymidine, or uracil. An “unmodified nucleobase” means the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). In certain embodiments, an RNA nucleoside is considered modified when a DNA nucleoside is substituted for the RNA nucleoside. In certain embodiments, a DNA nucleoside is considered modified when an RNA nucleoside is substituted for the DNA nucleoside. In certain embodiments, an ACT-UP1 compound as disclosed in any of the Tables herein can have an RNA nucleoside substituted in place of a DNA nucleoside e.g., a U to T substitution. In certain embodiments, an ACT-UP 1 compound as disclosed in any of the Tables herein can have a DNA nucleoside substituted in place of an RNA nucleoside e.g., a T to U substi tution. In certain embodiments, an ACT-UP 1 compound comprises a modification in its ASO component sequence wherein the modified sequence has a U to T or T to U substitution. In certain embodiments, an ACT-UP 1 compound comprises a modification in its PRS component wherein the modified sequence has a U to T or T to U substitution. <

[0096] “Modified nucleoside” means a nucleoside having, independently, a modified sugar moiety and / or modified nucleobase.

[0097]

[0098] a nucleotide having, independently, a modified sugar moiety, modified intemucleoside linkage, and / or a modified nucleobase.

[0099] “Modified oligonucleotide” means an oligonucleotide comprising at least one modified intemucleoside linkage, a modified sugar, and / or a modified nucleobase.

[0100] “Modified sugar” means substitution and / or any change from a natural sugar moiety. “Moiety” means one of the portions into which something is divided, i.e., a part or component of something. For example, a sugar moiety of a nucleotide is the sugar component of the nucleotide.

[0101] “Monomer” refers to a single unit of an oligomer. Monomers include, but are not limited to, nucleosides and nucleotides, whether naturally occurring or modified.

[0102] “Motif” means the pattern; of unmodified and modified nucleosides in an antisense compound, Antisense compounds comprise motifs with various modified nucleobases, modified sugars, and / or intemucleoside linkages in order to improve, among other characteristics, delivery, stability, specificity, safety, and potency of the antisense compounds. The motif is independent ofthe nucleobase sequence of the antisense compound and identifies only the pattern of modifications.

[0103] “Natural sugar moiety” means a sugar moiety found in DNA (2’-H) or RNA (2'-OH). “Naturally occurring internucleoside linkage” means a 3' to 5' phosphodiester linkage. “Non-complementary nucleobase” refers to a pair of nucleobases that do not form hydrogen bonds with one another or otherwise support hybridization,

[0104] “Nucleic acid” refers to molecules composed of monomeric nucleotides. A nucleic acid includes, but is not limited to, ribonucleic acids (RNA e.g.. mRNA), deoxyribonucleic acids • - '

[0105] (DNA), single-stranded nucleic acids (e.g., antisense oligonucleotides (ASOs) and microRNAs (miRNA)), double-stranded nucleic acids (e.g., small interfering ribonucleic acids (siRNAs) and short hairpin RNAs (shRNAs).

[0106] “Nucleobase” means a heterocyclic moiety capable of pairing with a base of another nucleic acid,

[0107] “Nucleobase complementarity” refers to a nucleobase that is capable of base pairing (also known as being complementary) with another nucleobase. If a nucleobase at a certain position of an oligomeric compound is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, then the position of hydrogen bonding between the oligomeric compound and the target nucleic acid is considered to be complementary at that nucleobase pair. For example, in DNA, adenine (A) is complementary to thymine (T); in RNA, adenine (A) is complementary to uracil (U); and, Guanine (G) is complementary to cytosine (C) in both DN and RNA. Base pairs, or complementary nucleobases, are usually canonical Watson-Crick base pairs (e.g., C: G, A: U, or A: T), but, non-canonical base pairs such as Hoogsteen base pairs (e.g,, A: G, or A: U), Wobble base pairs (e.g,, G: U, 1:11, I: A, or I: C, wherein I is hypoxanthine) and the like are also included, Nucleobase complementarity facilitates hybridization of the oligomeric compounds described herein to their target nucleic acids,

[0108] “Nucleobase sequence” means the order of contiguous nucleobases independent of any sugar, linkage, and / or nucleobase modification,

[0109] “Nucleoside4' means a nucleobase linked to a sugar.

[0110] '‘Nucleoside sequence” means the order of contiguous nucleosides independent of any sugar, linkage, and / or nucleobase modification,“Nucleoside mimetic” includes those structures used to replace the sugar or the sugar and the base and not necessarily the linkage at one or more positions of an oligomeric compound such as for example nucleoside mimetics having morpholino, cyclohexenyl, cyclohexyl, tetrahydropyranyl, bicyclo, or tricyclo sugar mimetics, e,g,, non furanose sugar units, Nucleotide mimetic includes those structures used to replace the nucleoside and the linkage at one or more positions of an oligomeric compound such as, for example, peptide nucleic acids or morpholines (morpholinos linked by -N(H)-C(=O)-O- or other non-phosphodiester linkage). Sugar surrogate overlaps with the slightly broader term nucleoside mimetic, but, is intended to indicate replacement of the sugar unit (furanose ring) only. The tetrahydropyranyl rings provided herein are illustrative of an example of a sugar surrogate wherein the furanose sugar group has been replaced with a tetrahydropyranyl ring system. " Mimetic" refers to groups that are substituted for a sugar, a nucleobase, and / or internucleoside linkage. Generally, a mimetic is used in place of the sugar or sugar-intemucleoside linkage combination, and the nucleobase is maintained for hybridization to a selected target.

[0111] “Nucleotide” means a nucleoside having a linkage group (e.g., a phosphate (p) or phosphorothioate (PS) group) covalently linked to the sugar portion of the nucleoside. Nucleotides include ribonucleotides and deoxyribonucleotides. Ribonucleotides are the linked nucleotide units forming RNA. Deoxyribonucleotides are the linked nucleotide units forming DNA,

[0112] “Off-target effect” refers to an unwanted or deleterious biological effect associated with modulation of RNA or protein expression of a gene other than the intended target nucleic acid.

[0113] “Oligomeric compound” means a sequence of linked monomeric subunits that is capable of undergoing hybridization to at least a region of a target nucleic acid through hydrogen bonding. The monomeric subunits can be modified or unmodified nucleobases, nucleotides or nucleosides. Examples of oligomeric compounds, include antisense compounds (e.g., antisense oligonucleotides (ASOs) or ACT-UP 1 compounds comprising antisense oligonucleotides).

[0114] “Oligonucleotide” as used herein means a polymer of linked nucleosides, each of which can be modified or unmodified, independent from one another. Oligonucleotides can have a linking group other than a phosphate group (e.g., a phosphorothioate = thiophosphate group) used as a linking moiety between nucleosides.

[0115] “Substantially modified” or “substantially chemically modified” refers to an antisense compound comprising a contiguous sequence of nucleosides wherein the nucleosides are mostly,but, not fully, chemically modified, For example, the compound includes not more than about 5, 4, 3, 2, or 1 unmodified nucleosides). Examples include, but are not limited to, compounds that include not more than about 5, 4, 3, 2, or 1 unmodified nucleoside(s) out of about 18-40 linked subunits.

[0116] “Phosphorothioate linkage’’ or “PS” means a linkage between nucleosides where the phosphodiester bond is modified by replacing one of the non-bridging oxygen atoms with a sulfur atom. A phosphorothioate (= thiophosphate or also known as thiophosphate) linkage is a modified intemucleoside linkage.

[0117] “Protein recruiting sequence” or “PRS” is a short sequence of linked nucleosides that attracts and / or binds translation regulatory proteins. Merely by way of example, a translation regulatory protein can be an RNA binding protein (RBP) that regulates translation of mRNA into protein, which is well known in the art. The PRS is the component of the ACT-UP1 compound that interacts with RNA binding proteins, while the antisense oligonucleotide (ASO) is the component of the ACT-UP 1 compound that hybridizes with a target nucleic acid; together, the ASO and PRS components of the ACT-UP1 compound enhance translation of an mRNA target. The PRS, although it comprises a short linkage of nucleosides, is not an ASO as it does not hybridize with a target nucleic acid (i.e., the PRS is not antisense to a target nucleic acid). Examples of PRSs comprise a DRACH consensus sequence, or a derivative of a DRACH consensus sequence, e.g., a sequence having at least 80% sequence identity with a DRACH consensus sequence. Additional examples of PRSs include multiple DRACH consensus sequences linked together e.g., duplicates, triplicates or quadruplicates of a DRACH consensus sequence, and / or a sequence having at. least 80% sequence identity with a DRACH consensus sequence. Further nucleosides may be included in a derivative of a DRACH consensus sequence (e.g., GGACUGGACUG, SEQ ID NO: 22). The PRS may comprise a DRACH consensus sequence comprising a sequence selected from, for example, GGACU (SEQ ID NO: 7), GAACU (SEQ ID NO: 16), AGACU (SEQ ID NO: 17), AAACU (SEQ ID NO: 18), GGACA (SEQ ID NO: 13), or AAACA (SEQ ID NO: 19). A specific example of a PRS is GGACU GGACU (SEQ ID NO: 9), as shown in Tables 2, 10, 13, 19, 27, -32 and 33. An example of a derivative of a DRACH consensus sequence is GGACTGGACT (SEQ ID NO: 20), where T is substituted in place of U, as shown in ' some compounds of Table 20, or GGAUU (SEQ ID NO: 15), where U is substituted in place of C, or GGACT (SEQ ID NO: 14), where T is substituted in place of U.“Portion” means a defined number of contiguous (i.e., linked) nucleosides of a nucleic acid. In certain embodiments, a portion is a defined number of contiguous nucleosides of a target nucleic acid. In certain embodiments, a portion is a defined number of contiguous nucleosides of an antisense compound.

[0118] “Region” is defined as a portion of the target nucleic acid having at least one identifiable structure, function, or characteristic.'

[0119] “RNA” or “ribonucleic acid” consists of ribose nucleotides or ribonucleotides (nitrogenous bases attached to a ribose sugar) linked by phosphodiester bonds, forming strands of varying lengths. The nitrogenous bases in RNA are adenine, guanine, cytosine, and uracil.

[0120] “Ribonucleoside” means a nucleoside having a hydroxy at the 2’ position of the sugar portion of the nucleoside. A ribonucleoside is sometimes referred to as RNA nucleoside, “R” or “r” herein.

[0121] “Ribonucleotide” means a nucleotide having a hydroxy at the 2’ position of the sugar portion of the nucleotide. A ribonucleotide is sometimes referred to as RNA nucleotide, “R” or “r” herein.

[0122] “Segments” are defined as smaller or sub-portions of regions within a target nucleic acid. “Sequence” as used herein refers to the order of nucleoside bases, without considering any modifications of the nucleosides or any additional agents coupled thereto.

[0123] “Sites,” as used herein, are defined as unique nucleoside positions within a target nucleic acid.

[0124] “Specifically hybridizable” refers to an antisense compound having a sufficient degree of complementarity between an antisense compound (e.g,, the ASO component of an ACT-UP 1 compound) and a target nucleic acid to induce a desired effect, while exhibiting minimal or no effects on non-target nucleic acids under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays and therapeutic treatments. Examples of sufficient degrees of complementarity are disclosed herein.

[0125] “Stringent hybridization conditions” or “stringent conditions” refer to conditions under which an antisense compound will hybridize to its target sequence, but to a minimal number of other sequences. s

[0126] “Subject” means a human or non-human animal selected for treatment or therapy.

[0127]

[0128] “Target” refers to a protein or nucleic acid sequence (e.g., mRNA), the modulation of which is desired. In certain embodiments, the modulation is an increase in expression of the target nucleic acid.

[0129] “Target gene” refers to a gene encoding a target.

[0130] “Targeting” means the process of design and selection of an antisense compound (e.g., ACT-UP 1 compound) that will specifically hybridize to a target nucleic acid and induce a desired effect.

[0131] “Target nucleic acid,” “target RNA,” “target raRNA,” “target RNA transcript” and “nucleic acid target” all mean a nucleic acid capable of being targeted by antisense compounds, “Target region” means a portion of a target nucleic acid to which one or more antisense compounds are targeted.

[0132] “Target segment” means the sequence of nucleotides of a target nucleic acid to which an antisense compound is targeted. “5’ target site” refers to the 5’ -most sequence of nucleotides of a target nucleic acid segment. “3’ target site” refers to the 3 ’-most sequence of nucleotides of a target nucleic acid segment. In an embodiment, a target segment is at least a 12-nucleoside portion (i.e., at least 12 consecutive nucleoside) of a target region to which an antisense compound is targeted.

[0133] “Therapeutic efficacy” refers to the effectiveness of a therapeutic compound such as an antisense compound. Therapeutic efficacy can be increased by improvements in delivery, stability, specificity, safety, and potency of the therapeutic compound.

[0134] “Unmodified” RNA nucleosides mean the purines adenine (A) and guanine (G), and the pyrimidines cytosine (C) and uracil (U). “Unmodified” DNA nucleosides mean the purines adenine (A) and guanine (G), apd the pyrimidines thymine (T) and cytosine (C). In certain embodiments, an unmodified RNA nucleoside is considered modified when a DNA nucleoside is substituted for the RNA nucleoside. In certain embodiments, an unmodified DNA nucleoside is considered modified when an RNA nucleoside is substituted for the DNA nucleoside.

[0135] “Unmodified nucleoside” means a nucleoside composed of commonly and naturally occurring nucleobases and sugar moieties. For example, an unmodified nucleoside is a DNA nucleoside if used in a DNA sequence; however, in such DNA sequence, any other nucleoside (e.g., RNA nucleoside, 2’-0Me, 2’-M0E, or 2’-F) is considered a modified nucleoside.1*

[0136] “Unmodified nucleotide’”1' means a nucleotide composed of commonly and naturally occurring nucleobases, sugar moieties, and intemucleoside linkages. For example, an unmodified nucleotide is a DNA nucleotide if used in a DNA sequence; however, in such DNA sequence, any other nucleotide (e.g., RNA nucleotide, 2"-OMe, 2’-M0E or 2’-F) is considered a modified nucleotide.

[0137] “Validated target segment” is defined as at least an 8-nucleoside portion (i.e., 8 consecutive nucleosides) of a target region to which an antisense compound is targeted.

[0138] Disclosed herein are antisense compounds, or salts thereof, for enhancing protein expression in a cell located in the CNS. In certain embodiments, the antisense compound, or salt thereof, is an Antisense oligonucleotide (ASO) Coupled Translation - Upregulation 1 (ACT-UP 1) compound. In certain embodiments, the ACT-UP 1 compound, or salt thereof, enhances protein expression of sodium voltage-gated channel alpha subunit 1 (SCN1A) by targeting an SCN1A mRNA transcript. In certain embodiments, the ACT-UP 1 compound, or salt thereof, targeting SCN1 comprises any one of the sequences in Tables 2 and 33 (i.e,, SEQ ID NOs: 89-95, 141- 151 or 166-168), or a derivative thereof having at least 80%, particularly at least 85%, more particularly at least 90%, sequence identity with any of these sequences. In certain embodiments, the ACT-UP1 compound, or salt thereof, enhances protein expression of granulin precursor (known as GRN or PGRN) by targeting a GRN mRN A transcript. In certain embodiments, the ACT-UP 1 compound, or salt thereof, targeting GRN comprises any one of the sequences in Table 10 and 13 (i.e., SEQ ID NO: 96-99), or a derivative thereof having at least 80%, particularly at least 85%, more particularly at least 90%, sequence identity with any of these sequences. In certain embodiments, the ACT-UP I compound, or salt thereof, enhances protein expression of SH3 and multiple ankyrin repeat domains 3 (SHANK3) by targeting a SHANK3 mRNA transcript. In certain embodiments, the ACT-UP1 compound, or salt thereof, targeting SHANK3 comprises any¬ one of the sequences in Table 27 (.i.e., SEQ ID NO: 112-116 or 159-162), or a derivative thereof having at least 80%, particularly ’at least 85%, more particularly at least 90%, sequence identity with any of these sequences. In certain embodiments, the ACT-UP 1 compound, or salt thereof, enhances protein expression of glucosylceramidase beta I (GBA1) by targeting a GBA1 mRN? A transcript. In certain embodiments, the ACT-UP 1 compound, or salt thereof, targeting GBA1 comprises any one of the sequences in Table 19 (i.e., SEQ ID NO: 101 - 111 ), or a derivative thereofhaving at least 80%, particularly at least 85%, more particularly at least 90%, sequence identity with any of these sequences. In certain embodiments, the ACT-UP1 compound, or salt thereof, enhances protein expression of Syntaxin Binding Protein I (STXBPl) by targeting an STXBP1 mRNA transcript. In certain embodiments, the ACT-UP1 compound, or salt thereof, targeting STXBPl comprises any one of the sequences in Table 29b (i.e., SEQ ID NO: 121-135), or a derivative thereof having at least 80%, particularly at least 85%, more particularly at least 90%, sequence identity with any of these sequences. In certain embodiments, the ACT-UP 1 compound, or salt thereof, enhances protein expression of Retinoic Acid Induced 1 (RAI1) by targeting a RAI1 mRNA transcript. In certain embodiments, the ACT-UP1 compound, or salt thereof targeting RAI1 comprises any one of the sequences in Table 32 (i.e., SEQ ID NO: 136-140), or a derivative thereof having at least 80%, particularly at least 85%, more particularly at least 90%, sequence identity with any of these sequences. In certain embodiments, the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS comprises at least one chemical modification. In certain embodiments, the ACT-UP 1 compound is partially, substantially, or fully chemically modified, i.e., each of the nucleosides comprises a chemical modification. In certain embodiments, the ACT-UP1 compound is chemically modified such that the chemical modification is selected from one or more of 2’-O-methyl (2’-OMe), 2’-O- methoxyethyl (2’-MOE), 2’-fluof6 (2’-F), constrained ethyl (cEt), unlocked nucleic acid (UNA), locked nucleic acid (LN A), and / or 5-methylcytosine base,

[0139] In certain embodiments, the ACT- UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS compirises at least one modified intemucleoside linkage. In certain embodiments, the at least one modified intemucleoside linkage is a phosphorothioate internucleotide (PS) linkage.

[0140] In certain embodiments, the ACT-UP 1 compound, or salt thereof, comprises any one of the sequences, including the chemical modifications and modified intemucleoside linkages as depicted in Tables 2 and 33, 10 and 13, 27, 19, 29 and 32.

[0141] In certain embodiments, the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS comprises about 13 to 40, 13 to 39, 13 to 38, 13 to 37, 13 to 36, 13 to 35, 13 to 34, 13 to 33, 13 to 32, 13 to 31, 13 to 30, 13 to 29, 13 to 28, 13 to 27, 13 to 26. 13 to 25, 16 to 40, 16 to 35, 16 to 34, 16 to 33, 16 to 32, 16 to 31, 16 to 30, 16 to 29, 16 to 28, 16 to 27, 16 to 26, 16 to 25, 19 to’40, 19 to 35, 19 to 34, 19 to 33, 19 to 32, 19 to 31, 19 to 30, 19to 29, 19 to 28, 19 to 27, 19 to 26, 19 to 25, 24 to 40, 24 to 35, 24 to 34, 24 to 33, 24 to 32, 24 to 31, 24 to 30, 24 to 29, 24 to 28, 24 to 27, 24 to 26, 24 to 25, 25 to 40, 25 to 35, 25 to 34, 25 to 33, 25 to 32, 25 to 31, 25 to 30, 25 to 29, 25 to 28, or 25 to 27 linked nucleoside subunits in length. In certain embodiments, the ACT-UP 1 compound comprises from 13 to 40, preferably 16 to 33, more preferably 19 to 25, and even more preferably 20 to 30, such as 22 to 28, linked subunits in length.

[0142] In certain embodiments, the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS is about 13 to 40 linked nucleosides in length with an ASO component comprising 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 nucleosides in length ‘and comprises no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target mRNA, or specified portion of the mRNA. In accordance with the practice of the invention, the no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to the target mRNA, or specified portion thereof, can include zero (0) non-complementary nucleobase(s) relative to the target mRNA, or specified portion thereof. In certain embodiments, the oligomeric compound targeting the mRNA comprises an ASO component comprising from 13 to 35, preferably 13 to 30, more preferably 13 to 17 nucleosides in length and comprises no more than 4, preferably no more than 3, more preferably no more than 2, non-complementary nucleobase(s) relative to an mRNA, or specified portion of the mRNA.

[0143] In certain embodiments, the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS is about 1 to 40 linked nucleosides in length with a PRS component comprising 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 nucleosides in length. In certain embodiments, the oligomeric compound targeting mRNA comprises a PRS component comprising 5 to 27, preferably 6 to 20, more preferably 7 to 15, and even more preferably 7 to 13 nucleosides in length.

[0144] In one embodiment, the ACT-UP 1 compound targeting an mRNA disclosed herein comprises: a PRS component about 5-20 nucleosides in length and an ASO component about 1 -30 nucleosides in length with up to 3 non-complementary nucleobase(s) relative to a targeted mRNA, or portion of the mRNA; preferably a PRS component about 5-15 nucleosides in length and an ASO component about 13-25 nucleosides in length with up to 3 non-complementaiy nucleobase(s) relative to an mRNA, or portion of the mRNA; more preferably a PRS componentabout 7-13 nucleosides in length and an ASO component about 13-20 nucleosides in length with up to 3 non-complementary nucleobase(s) relative to an mRNA, or portion of the mRNA; even more preferably a PRS component about 9- 11 nucleosides in length and an ASO component about 13-20 nucleosides in length with up to 3 non-complementary nucleobase(s) relative to an mRNA, or portion of the mRNA; such as a PRS component about 9-10 nucleosides in length and an ASO component about 13-20 nucleosides in length with up to 2 non-complementaiy nucleobase(s) relative to an mRNA, or portion of the mRNA; a PRS component about 9-10 nucleosides in length and an ASO component about 13-20 nucleosides in length with up to 1 non-complementary nucleobase(s) relative to an mRNA, or portion of the mRNA. In a most preferred embodiment, the compound comprises a PRS component 10 nucleosides in length and an ASO component 17 nucleosides in length with up to 1 non-complementary nucleobase(s) relative to an mRNA, or portion of the mRNA, In accordance with the practice of the invention, the up 3 non-complementary nucleobase(s) relative to an mRNA can include zero (0), 1, 2 or 3 non-complementary nucleobase(s) relative to the target mRNA.

[0145] Examples of the PRS component include, but, are not limited to: GGACU (SEQ ID NO: 7), GAACU (SEQ ID NO: 11), AGACU (SEQ ID NO: 12), GGACA (SEQ ID NO: 13), GGACT (SEQ ID NO: 14), AAACU (SEQ ID NO: 18), GGACUGGAC (SEQ ID NO: 10), GGACUGGACU (SEQ ID NO: 9), GGACAGCGCU (SEQ ID NO: 152), GGACTGGACU (SEQ ID NO: 153), GGACTGGACT (SEQ ID NO: 20), AAACUGGACT (SEQ ID NO: 154), AAACUAAACU (SEQ ID NO: 21), GGACUGGACUG (SEQ ID NO: 22), ACGGACUUGGACU (SEQ ID NO: 8), GGACUGGACUGGACU (SEQ ID NO: 169), or GGACUGGACUGGACUGGACU (SEQ ID NO: 170).

[0146] In certain embodiments, the compound targets a region of the 3’UTR of an mRNA disclosed herein about 20 to 50, 40 to 70, 60 to 90, 80 to 110, 100 to 130, 120 to 150, 140 to 170, 160 to 190, 170 to 200, 180 to 210, '200 to 230, 220 to 250, 240 to 300, or 280 to 500 nucleotides downstream of its stop codon. In one embodiment, the compound targets the 3’UTR of the mRNA about 50 to 300, 50 to 250, 50 to 200, 50 to 150, 75 to 300, 75 to 250, 75 to 200, 75 to 150, 100 to 300, 100 to 250, 100 to 200, or 100 to 150 nucleotides downstream of its stop codon. In a preferred embodiment, the compound targets the region of the 3’UTR about 50 to 200 nucleotides downstream of a stop codon. In a more preferred embodiment, the compound targets the region of the 3’UTR about 50 to 150 nucleotides downstream of a stop codon.In a further embodiment, a compound of the invention targets an intron / exon junction of a target disclosed herein.

[0147] In certain embodiments, the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS is about 13 to 40 linked nucleosides in length; preferably it includes at least one modified sugar, such as a bicyclic sugar, a 2’-O-methoxyethyl group (2’- MOE), a 2’-O-methyl group (2’-OMe), and / or a 4’-CH(CH3)-O-2’ constrained ethyl (cEt) group; preferably it includes at least one modified intemucleoside linkage, such as a phosphorothioate internucleoside linkage: and / or it includes at least one modified nucleobase, such as a 5- methylcytidine.

[0148] In certain embodiments, the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS targets a SCN I A mRNA transcript. In certain embodiments, the ACT-UP 1 compound, or salt thereof, targeting SCN1 A comprises any one of the sequences in Tables 2 and 33 (i.e,, SEQ ID NO: 89-95, 141-151 or 166-168), or a derivative thereof having at least 80%, particularly at least 85%, more particularly at least 90*%, sequence identity with any of these sequences. In one embodiment, the ASO component of the ACT-UP 1 compound comprises no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to the target mRNA sequence. In accordance with the practice of the invention, the no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to the target mRNA sequence can include zero (0) non-complementary nucleobase(s) relative to the target mRNA sequence.

[0149] In certain embodiments, the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS targets a GRN mRNA transcript. In certain embodiments, the ACT-UP 1 compound, or salt thereof, targeting GRN comprises any one of the sequences in Table 10 and 13 (i.e., SEQ I D NO: 96-99), or a derivative thereof having at least 80%, particularly at least 85%, more particularly at least 90%, sequence identity with any of these sequences. In one embodiment, the ASO component of the ACT-UP 1 compound comprises no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to the target mRNA sequence. In accordance with the practice of the invention, the no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to the target mRNA sequence can include zero (0) non-complementary nucleobase(s) relative to the target mRNA sequence, In a preferred embodiment, the compound targeting GRN comprises the sequence of ATXL489 (SEQ ID NO:96) or the chemistry and sequence of ATXL489 (SEQ ID NO: 33). In another preferred embodiment, the compound comprises the chemical structure of ATXL489 as shown below:

[0150]

[0151]

[0152]

[0153]

[0154] In another preferred embodiment, the compound targeting GRN comprises the sequence of ATXL491 (SEQ ID NO: 98) or the chemistry and sequence of ATXL491 (SEQ ID NO: 35). In another preferred embodiment, the compound comprises the chemical structure of ATXL491 as shown below:

[0155]

[0156]

[0157]

[0158] In certain embodiments, the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS targets a SHANK3 mRNA transcript. In certain embodiments, the ACT-UP 1 compound, or salt thereof, targeting SHA K3 comprises any one of the sequences in Table 27 (i.e., SEQ ID NO: 112-116 or 159-162), or a derivative thereof having at least 80%, particularly at least 85%, more particularly at least 90%, sequence identity with any of these sequences. In one embodiment, the ASO component of the ACT-UP 1 compound comprises no more than 3. no more than 2, or no more than 1 non-complementary nucleobase(s) relative to the target mRNA sequence. In accordance with the practice of the invention, the no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to the target mRNA sequence can include zero (0) non-complementary nucleobase(s) relative to the target mRNA sequence.

[0159] In certain embodiments, the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS targets a GBAl mRNA transcript. In certain embodiments, the ACT-UP1 compound, or salt thereof, targeting GBAl comprises any one of the sequences in Table 19 (i.e., SEQ ID NO: 101-111), or a derivative thereof having at least 80%, particularly at least 85%, more particularly at least 90%. sequence identity with any of these sequences. In one embodiment, the ASO component of the ACT-UP 1 compound comprises no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to the target mRNA sequence. In accordance with the practice of the invention, the no more than 3, no more than 2, or no more than I non-complementary nucleobase(s) relative to the target mRNA sequence can include zero (0) non-complementary nucleobase(s) relative to the target mRNA sequence.

[0160] In certain embodiments, the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS targets an STXBP1 mRNA transcript. In certain embodiments, the ACT-UP 1 compound, or salt thereof, targeting STXBP1 comprises any one of the sequences in Table 29b (i.e., SEQ ID NO; 121-135), or a derivative thereof having at least 80%, particularly at least 85%, more particularly at least 90%, sequence identity with any of these sequences. In one embodiment, the ASO component of the ACT-UP 1 compound comprises no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to the target mRNA sequence. In accordance with the practice of the invention, the no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to the target mRNA

[0161]

[0162] sequence can include zero (0) non-complementary nucleobase(s) relative to the target mRNA sequence.

[0163] In certain embodiments, the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS targets a RAH mRNA transcript. In certain embodiments, the ACT-UP 1 compound, or salt thereof, targeting RAI1 comprises any one of the sequences in Table 32 (i.e., SEQ ID NO: 136-140), or a derivative thereof having at least 80%, particularly at least 85%, more particularly at least 90%, sequence identity with any of these sequences. In one embodiment, the ASO component of the ACT-UP 1 compound comprises no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to the target mRNA sequence. In accordance with the practice of the invention, the no more than 3, no more than 2, or no more than 1 non-complementaiy nucleobase(s) relative to the target mRNA sequence can include zero (0) non-complementary nucleobase(s) relative to the target mRNA sequence.

[0164] In certain embodiments, the ACT-UP1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS further comprises an agent (e.g., a delivery, therapeutic, or diagnostic agent) so as to form a conjugated compound. In certain embodiments, the conjugate agent (also referred to herein as moiety or conjugate moiety) can be selected from cholesterols, lipids, carbohydrates, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, peptides, antibodies, dyes, and tocopherol. In certain embodiments, the conjugate moiety is a GalNAc moiety.

[0165] In certain embodiments, the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS increases protein expression in the cell by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, or 300%, and particularly up to about 1000%. Preferably, it increases protein expression in the cell by at least about 10%,

[0166] Certain embodiments disclosed herein provide a pharmaceutical composition comprising the ACT-UP 1 compound, or salt thereof, for enhancing protein expression in a cell located in the CNS described herein, alone or in combination with a pharmaceutically acceptable carrier or excipient.

[0167] Certain embodiments disclosed herein provide a method for increasing translation of mRNA in a central nervous system (CNS) cell comprising administering an ACT-UP 1 compound, or salt thereof, to the cell in the CNS, in an amount sufficient to increase translation of the proteinfrom the mRNA. The ACT-UPI compound, or salt thereof, increases translation by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%>, 100%), 150%, 200%, or 30p^a, and particularly up to about 1000%. Preferably, it increases protein expression in the cell by at least about 10%, In certain embodiments, a pharmaceutical composition is used in the method comprising the ACT-UP I compound, or salt thereof.

[0168] Certain embodiments disclosed herein provide a method for increasing protein expression in a central nervous system (CNS) cell comprising administering an ACT-UPI compound, or salt thereof, to the cell in the CNS, in an amount sufficient to increase protein expression. The ACT- UPI compound, or salt thereof!, increases target protein expression by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, or 300%, and particularly up to about 1000%. Preferably, it increases target protein expression by at least about 10%. In certain embodiments, a pharmaceutical composition is used in the method comprising the ACT-UPI compound, or salt thereof

[0169] Certain embodiments disclosed herein provide a method for treating a SCNIA related disease, disorder and / or syndrome in a subject comprising administering ACT-UPI compound, or salt thereof, to the subject, in an. amount sufficient to treat the SCNIA related disease, disorder and / or syndrome in the subject. In certain embodiments, a pharmaceutical composition is used in the method comprising the ACT-UPI compound, or salt thereof. In certain embodiments, the SCNI related disease, disorder and / or syndrome is Dravet Syndrome (also known as severe myoclonic epilepsy of infancy or SMEI), stoke-related neuronal dysfunction, Generalized Epilepsy with Febrile Seizures Plus (GEFS+). developmental and epileptic encephalopathies (DEEs), autism, and cognitive impairments. In certain embodiments, the ACT-UPI compound increases expression of SCNIA by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%. 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%. or 300%. and particularly up to about 1000%, preferably by at least about 10%, in order to treat the SCNIA related disease, disorder and / or syndrome in the subject.

[0170] Certain embodiments disclosed herein provide a method for treating a GRN related disease, disorder and / or syndrome in a subject comprising administering ACT-UPI compound, or salt thereof, to the subject, in an amount sufficient to treat the GRN related disease, disorder, and / or syndrome in the subject. In certain embodiments, a pharmaceutical composition is used in the method comprising the ACT-UPI compound, or salt thereof. In certain embodiments, the GRNrelated disease, disorder and / or syndrome is neuronal ceroid lipofuscinosis (NCL) type 11, frontotemporal dementia associated with CRN (FTD-GRN), microglial hyperactivation, astrogliosis, neurodegeneration, Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and limbic-predominant age-related TDP-43 encephalopathy (LATE). In certain embodiments, the ACT-UP 1 compound increases expression of GRN by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, or 300%, and particularly upto about 1000%, preferably by at least about 10%, in order to treat the GRN related disease, disorder and / or syndrome in the subject.

[0171] Certain embodiments disclosed herein provide a method for treating a SHANKS related disease, disorder and / or syndrome in a subject comprising administering ACT-UP1 compound, or salt thereof, to the subject, in an amount sufficient to treat the SHANK3 related disease, disorder and / or syndrome in the subject. In certain embodiments, a pharmaceutical composition is used in the method comprising the ACT-UP 1 compound, or salt thereof. In certain embodiments, the SHANK3 related disease, disorder and / or syndrome is autism spectrum disorder (ASD), schizophrenia, Phelan-McDermid Syndrome (PMS) and other neurodevelopmental disorders. In certain embodiments, the ACT-UP 1 compound increases expression of SHANK3 by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, or 300%, and particularly up to about 1000%, preferably by at least about 10%>, in order to treat the SHANK3 related disease, disorder and / or syndrome in the subject.

[0172] Certain embodiments disclosed herein provide a method for treating a GBA1 related disease, disorder and / or syndrome in a subject comprising administering ACT-UP 1 compound, or salt thereof, to the subject, in an amount sufficient to treat the GBA1 related disease, disorder and / or syndrome in the subject. In certain embodiments, a pharmaceutical composition is used in the method comprising the ACT-UP 1 compound, or salt thereof. In certain embodiments, the GBA1 related disease, disorder and / or syndrome is Gaucher disease, Parkinson’s disease (PD), and / or Dementia with Lewy bodies (DLB). In certain embodiments, the ACT-UP 1 compound increases expression of GBA1 by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, or 300%, and particularly up to about 1000%, preferably by at least about 10%, in order to treat the GBA1 related disease, disorder and / or syndrome in the subject.

[0173]

[0174] Certain embodiments disclosed herein provide a method for treating a STXBPl related disease, disorder and / or syndrome in a subject comprising administering ACT-UP1 compound, or salt thereof, to the subject, in an amount sufficient to treat the STXBPl related disease, disorder and / or syndrome in the subject. In certain embodiments, a pharmaceutical composition is used in the method comprising the ACT-UP 1 compound, or salt thereof. In certain embodiments, the STXBPl related disease, disorder and / or syndrome is early infantile epileptic encephalopathy (EIEE4), developmental and epileptic encephalopathy, West syndrome, Ohtahara syndrome, and / or Rett-like syndrome. In certain embodiments, the ACT-UP 1 compound increases expression of STXBPl by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, or 300%, and particularly up to about 1000%, preferably by at least about 10%, in order to treat the STXBPl related disease, disorder and / or syndrome in the subject.

[0175] Certain embodiments disclosed herein provide a method for treating a RAI1 related disease, disorder and / or syndrome in a subject comprising administering ACT-UP1 compound, or salt thereof, to the subject, in an amount sufficient to treat the RAI1 related disease, disorder and / or syndrome in the subject. In certain embodiments, a pharmaceutical composition is used in the method comprising the ACT-UP I compound, or salt thereof. In certain embodiments, the RAH related disease, disorder and / or syndrome is Smlth-Magenis syndrome, autism spectrum disorder, circadian rhythm disorders, and / or obesity / metabolic dysregulation. In certain embodiments, the ACT-UP1 compound increases expression of R. AII by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, or 300%, and particularly up to about 1000%, preferably by at least about 10%, in order to treat the RAH related disease, disorder and / or syndrome in the subject.

[0176] Certain embodiments disclosed herein provide a method for treating a haploinsufficiency-related disease, disorder and / or syndrome in a subject comprising administering an ACT-UP 1 compound, or salt thereof, to the subject, in an amount sufficient to treat the haploinsufficiency disease, disorder and / or syndrome in the subject. In certain embodiments, a pharmaceutical composition is used in the method comprising the ACT-UP 1 compound, or salt thereof The ACT- UPl compound increases expression of a protein by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, or 300%, and particularly up to about 1000%, preferably by at least about 10%, in order to treatthe haploinsufficiency disease, disorder and / or syndrome in the subject. In certain embodiments, the ACT-UP 1 compound, or salt thereof, targets SCN1A haploinsufficiency and the SCN1A related disease, disorder and / or syndrome is Dravet Syndrome. In certain embodiments, the ACT- UP 1 compound, or salt thereof, targets GRN haploinsufficiency and the GRN related disease, disorder and / or syndrome is frontotemporal dementia associated with GRN (FTD-GRN). In certain embodiments, the ACT-UP 1 compound, or salt thereof, targets SHANK3 haploinsufficiency and the SHANK3 related disease, disorder and / or syndrome is Phelan-McDermid Syndrome (PMS). In certain embodiments, the ACT-UP1 compound, or salt thereof, targets GBAI haploinsufficiency and the GBAI related disease, disorder and / or syndrome is Gaucher disease. Parkinson’s disease (PD), and / or Dementia with Lewy' bodies (DLB). In certain embodiments, the ACT-UPI compound, or salt thereof, targets STXBP1 haploinsufficiency and the STXBP1 related disease, disorder and / or syndrome is early infantile epileptic encephalopathy (EIEE4), developmental and epileptic encephalopathy, West syndrome, Ohtahara syndrome, and / or Rett- like syndrome. In certain embodiments, the ACT-UP 1 compound, or salt thereof, targets RAI1 haploinsufficiency and the RAI’IA related disease, disorder and / or syndrome is Smith-Magenis syndrome, autism spectrum disorder, circadian rhythm disorders, and / or obesity / metabolic dysregulation.

[0177] In certain embodiments, an ACT-UP 1 compound, or salt thereof, can be administered intrathecally, subcutaneously or intravenously to a subject. In certain embodiments, a pharmaceutical composition comprising an ACT-UP 1 compound, or salt thereof, can be administered intrathecally, subcutaneously, or intravenously to a subject.

[0178] Certain embodiments disclosed herein provide a process or method for making an ACT- UP 1 compound, or salt thereof, of the invention comprising synthesizing an oligonucleotide on a solid support using phosphoramidite chemistry thereby making the ACT-UPI compound, or salt thereof. >

[0179] In one embodiment, a process for preparing an ACT-UP 1 compound, or salt thereof, of the invention is provided, wherein the process comprises the steps of: a) preparing the compound by sequential coupling of modified and / or unmodified nucleotides via the phosphoramidite oligonucleotide synthesis on a conjugate modified or unmodified solid support; b) optionally, coupling a conjugate moiety to the compound on the solid support via the phosphoramidite oligonucleotide synthesis; c) detaching the compound from the solid support and removing thesolid support; and d) optionally, adding a conjugate post cleavage; and / or e) optionally, further purifying the compound, optionally using chromatography,

[0180] In one embodiment, a process for preparing a ACT-UP I compound, or salt, thereof, of the invention is provided, wherein the process comprises the steps of; a) coupling a conjugate moiety to a solid support via the phosphoramidite oligonucleotide synthesis, b) coupling a modified and / or unmodified nucleotide via the phosphoramidite oligonucleotide synthesis to the conjugate moiety on the solid support: c) sequentially coupling additional modified and / or unmodified nucleotides via the phosphoramidite oligonucleotide synthesis to prepare the compound; d) detaching the compound from the solid support and removing the solid support; and e) optionally, further purifying the compound, optionally using chromatography.

[0181] Protein Recruiting Sequence (PRS)

[0182] Merely by way of example, a PRS as used in the present, invention may be prepared by selecting a naturally occurring cis-element in an mRNA, such as a DRACH consensus sequence, transforming it into a novel, non-naturally occurring, trans-element (i.e,, PRSs) by joining it to an ASO to form an ACT-UP 1 compound and then optionally modifying the sequence. For example, GGACU (SEQ ID NO: 7), a m6A methylation target sequence found in mRNA, can be the basis to make GGACU derivatives that are not used as mRNA methylation targets in naturally occurring mRNAs. A useful PRS of ACT-UP 1 can also be made with additional nucleosides added to a sequence (e.g., ACGGACUUGGACU, SEQ ID NO: 8; GGACUGGACUG, SEQ ID NO: 22, as shown in Table 29b; GGACAGCGCU, SEQ ID NO: 152), repeats of the sequence linked together (e.g., GGACUGGACU, SEQ ID NO: 9; AAACUAAACU (SEQ ID NO: 21), partial repeats of the sequence linked together (e.g,, GGACUGGAC, SEQ ID NO: 10), or a combination of such modifications. In some examples, a PRS comprises one or more repeats or partial repeats of a naturally occurring sequence. Merely by way of example, modifications may include any of insertions, additions, deletions, or substitutions of particular nucleosides into a sequence, as well as chemical modifications. For example, for the sequence GGACU, a substitution of an A may lead to sequences GAACU (SEQ ID NO: 11), AGACU (SEQ ID NO: 12), or GGACA (SEQ ID NO: 13). In another example, for the sequence GGACU, a substitution of T in place of the U leads to sequence GGACT (SEQ ID NO: 14). In the PRS, a modification can include at least one substitution e.g., for GGACU, one substitution of T leads to sequence GGACT (SEQ ID NO: 14),or GGACTGGACU (SEQ ID NO: 153). In the PRS, a modification can include at least two substitutions e.g., for GGACU, two substitutions of A lead to sequence AAACU (SEQ ID NO: 18) or for GGACUGGACU, two substitutions of a T lead to sequence GGACTGGACT (SEQ ID NO: 20). In the PRS, a modification can include at least three substitutions e.g,, for GGACUGGACU, two substitutions lead to sequence AAACUGGACT (SEQ ID NO: 154). In the PRS, a modification can include at least four substitutions e.g., for GGACUGGACU, four substitutions lead sequence AAACU AAACU (SEQ ID NO: 21), Any of these sequnces may represent a PRS in the ACT-UP 1 compound of the present invention.

[0183]

[0184] Anilsense Compounds

[0185] An antisense compound is an oligomeric compound that is capable of undergoing hybridization to a target nucleic acid through hydrogen bonding. Examples of antisense compounds include single-stranded and double-stranded compounds such as antisense oligonucleotides (ASOs), siRNAs, shRNAs, snoRNAs, miRNAs, and satellite repeats. It is to be understood that oligomeric compounds and antisense compounds include ACT-UP 1 compounds which comprise an antisense oligonucleotide (ASO) joined to a protein recruiting sequence (PRS).

[0186] In certain embodiments, an antisense oligonucleotide comprises a nucleobase sequence that, when written in the 5’ to 3’ direction, comprises the reverse complement of the target segment of a target nucleic acid to which; it is targeted. In certain such embodiments, an antisense oligonucleotide has a nucleobase sequence that, when written in the 5’ to 3’ direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted.

[0187] In certain embodiments, an antisense compound is about 13 to 40 nucleoside subunits in length. In certain embodiments, an antisense compound comprises an ACT-UP 1 compound which in turn comprises an antisense oligonucleotide about 13 to 40 subunits in length. In a preferred embodiment, the antisense oligonucleotide component of an ACT-UP 1 compound is about 13 to 25, 13 to 24, 13 to 23, 13 to 22, 13 to 21, 13 to 20, 13 to 19, 13 to 18, 13 to 17, 13 to 16, 13 to 15 or 13 to 14 linked subunits in length.

[0188] In other embodiments, an ACT-UP1 compound is about 18 to 40, 18 to 39, 18 to 38, 18 to 37, 18 to 36, 18 to 35, 18 to 34, 18 to 33, 18 to 32, 18 to 31, 18 to 30, 18 to 29, 18 to 28, 18 to 27, 18 to 26, 18 to 25, 19 to 40, 19 to 35, 19 to 34, 19 to 33, 19 to 32, 19 to 31, 19 to 30, 19 to 29, 19to 28, 19 to 27, 19 to 26, 19 to 25, 22 to 40, 22 to 35, 22 to 34, 22 to 33, 22 to 32, 22 to 31, 22 to 30, 22 to 29, 22 to 28, 22 to 27, 22 to 26, 22 to 25, 25 to 40, 25 to 35, 25 to 34, 25 to 33, 25 to 32, 25 to 31, 25 to 30, 25 to 29, 25 to 28, or 25 to 27 linked subunits. In certain such embodiments, ACT-UP1 compounds are about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 linked subunits in length, or a range defined by any two of the above values.

[0189] It is possible to increase or decrease the length of an ACT-UP 1 compound, for example, by changing the length of the antisense oligonucleotide component of the ACT-UP1 compound, and / or introducing base mismatch(s) with the target without eliminating activity (US Patent 7,772,203, incorporated-by-reference herein). For example, it is possible to introduce non- canonical base pairings (e.g., A: G, A: C, G: U, I: U, I: A, or I: C) into an antisense oligonucleotide without eliminating activity. In certain embodiments, designing an antisense oligonucleotide with one or more non-canonical base pairings, i.e., mismatch(s), enhances the activity of the ACT-UP 1 compound.

[0190] Antisense Oligonucleotide Motifs

[0191] A motif refers to a pattern of modification of an antisense oligonucleotide. Various motifs have been described in the art and are incorporated-by-reference herein (e.g., US Patent 11,203,755; US Patent 10,870,849; EP Patent 1,532,248; US Patent 11,406,716; US Patent 10,668,170; US Patent 9,796,974; US Patent 8,754,201; US Patent 10,837,013; US Patent 7,732,593; US Patent 7,015,315; US Patent 7,750,144; US Patent 8,420,799; US Patent 8,809,516; US Patent 8,796,436; US Patent 8,859,749; US Patent 9,708,615; US Patent 10,233,448; US Patent 10,273,477; US Patent 10,612,024; US Patent 10,612,027: US Patent 10,669,544; US Patent 11,401,517; US Patent 9,260,471; US Patent 9,970,005; US Patent 11,193,126; US Patent 8,604,183; US Patent 9,150,606; US Patent 9,708,610; USSN 2020 / 0031862; and USSN 2016 / 0272970).

[0192] In certain embodiments, antisense oligonucleotides disclosed herein have chemically modified subunits arranged into motifs or patterns (i.e., chemical modification motifs / pattems) to confer on to the antisense oligonucleotides beneficial properties including, but not limited to: enhanced activity to increase potency; increased binding affinity to increase specificity for a targetnucleic acid, thereby limiting off-target effects and increasing safety; or enhanced resistance to degradation by in vivo nucleases thereby increasing stability and durability.

[0193] Target mRNAs and Associated Gene Expression

[0194] Several embodiments are directed to methods of upregulating an mRNA and / or upregulating protein expression by an ACT-UP 1 compound, or salt thereof. In certain embodiments, the ACT-UP 1 compound targets an mRNA transcript of SCN1A. In a preferred embodiment, the SCN1A mRNA target is the sequence in GENBANK Accession No. NM 001165963.4 (SEQ ID NO: 1). In certain embodiments, the ACT-UP1 compound targets an mRNA transcript of GRN. In a preferred embodiment, the GRN mRNA target is the sequence in GENBANK Accession No. NM_002087.4 (SEQ ID NO: 2). In certain embodiments, the ACT- UP 1 compound targets an mRNA transcript of SHANK3. In a preferred embodiment, the SHANK3 mRNA target is the sequence in GENBANK Accession No. NM_001372044.2 (SEQ ID NO: 3). In a preferred embodiment, the GBA1 mRNA target is the sequence in GENBANK Accession No. NM.,.000157.4 (SEQ ID NO: 4). In a preferred embodiment, the STXBP1 mRNA target is the sequence in GENBANK Accession No. NM_003165.6 (SEQ ID NO: 5). In a preferred embodiment, the RAI1 mRNA target is the sequence in GENBANK Accession NM_030665.4 (SEQ ID NO: 6). In certain embodiments, the target region on the mRNA is in the 5’ UTR or 3’UTR, In certain embodiments, the target region on the mRNA is a uORF. In certain embodiments, the target region on the mRNA is a microRNA (miRNA) binding site.

[0195] In certain embodiments, the target mRNA is present in a eukaryotic cell or a prokaryotic cell. In certain embodiments, the target protein is expressed in a eukaryotic cell or a prokaryotic cell. In certain embodiments, the eukaryotic cell or a prokaryotic cell is a mammalian cell, a plant cell, a yeast cell, or a bacteria ceil. In some embodiments, the mammalian cell includes ceils from mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits, mammals from the order Carnivora, including Felines (cats) and Canines (dogs), mammals from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perissodactyla, including Equines (horses). In some aspects, the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids (humans and apes), In a preferred aspect, the mammalian cell is a human ceil. In certain embodiments, the cell is in the form of a cultured cell line. In certain embodiments, the cell line is a primary cell line.Hybridization

[0196] In some embodiments, hybridization occurs between an antisense compound disclosed herein and an mRNA. The most common mechanism of hybridization involves hydrogen bonding (e.g,, Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding) between complementary nucleobases of the nucleic acid molecules.

[0197] In Watson-Crick canonical base pairings, adenine (A) is complementary to thymine (T) in DNA, adenine (A) is complementary to uracil (U) in RNA, and Guanine (G) is complementary to cytosine (C) in both DNA and RNA. Base pairs, or complementary nucleobases. are usually Watson-Crick base pairs (e.g,, C: G, A; U, or A: T), but, non-canonical base pairs such as Hoogsteen base pairs (e.g., A: G or A: U), Wobble base pairs (e.g., G: U, I: U, I: A, or I: C, wherein I is hypoxanthine) and the like are also permitted during hybridization of the antisense compound to a target nucleic acid or target region. Wobble base pairs in RNAi agents have previously been described (see e.g., US Patent 7,732,593 and US Patent 7,750,144).

[0198] Nucleobase complementarity facilitates hybridization of the antisense compounds described herein to their target nucleic acids with the stronger the pairing (e.g., the more base pairs and / or the stronger the hydrogen bond), the stronger the hybridization of the antisense compound to the target. Hybridization can occur under varying conditions. Stringent conditions are sequence¬ dependent and are determined by the nature and composition of the antisense compound to be hybridized.

[0199] Methods of determining Whether a sequence is specifically hybridizable to a target nucleic acid are well known in the art, In certain embodiments, the antisense compounds provided herein are specifically hybridizable with a target mRNA with little to no off-target binding.

[0200] Complementarity

[0201] An antisense compound comprising an antisense oligonucleotide is “complementary”, a “complement”, or has “complementarity” to a target nucleic acid when a sufficient number of nucleobases of the antisense oligonucleotide can hydrogen bond with the corresponding nucleobases of the target nucleic acid, such that a desired effect will occur (e.g., ACT-UP2 upregulation of a target nucleic acid such as an mRNA nucleic acid).Non-complementary nucleobases between an antisense oligonucleotide and an mRNA nucleic acid may be tolerated provided that the antisense oligonucleotide remains able to specifically hybridize to a target nucleic acid. Moreover, an antisense oligonucleotide may hybridize to one or more segments of an mRNA nucleic acid such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure, mismatch, or hairpin structure).

[0202] In certain embodiments, for antisense compounds that comprise an antisense oligonucleotide, the antisense oligonucleotide portion is, or are at least, about 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, particularly 80%, complementary to an mRNA nucleic acid, a target region, target segment, or specified portion thereof. Percent- complementarity of an antisense oligonucleotide with a target nucleic acid can be determined using routine methods.

[0203] For example, an antisense compound in which about 18 out of 20 nucleobases of the antisense oligonucleotide are complementary to a target region, and would therefore specifically hybridize to the target, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleobases of the antisense oligonucleotide may be clustered or interspersed with complementary' nucleobases and need not be contiguous to each other or to complementary nucleobases. As such, an antisense oligonucleotide which is 18 nucleobases in length having four noncomplementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention. Percent complementarity of an antisense oligonucleotide with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known.in the art (Altschul el al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res. 1997, 7, 649-656). Percent homology, sequence identity, or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482489).

[0204] In certain embodiments, the antisense oligonucleotides provided herein, or specified portions thereof, are fully complementary (i.e., 100% complementary') to a target nucleic acid, orspecified portion thereof. For example, an antisense oligonucleotide may be fully complementary to an mRNA nucleic acid, or a target region, or a target segment or a target sequence thereof. As used herein, “fully complementary” means each nucleobase of an antisense oligonucleotide is capable of precise base pairing with the corresponding nucleobases of a target nucleic acid. For example, a 20 nucleobase antisense oligonucleotide is fully complementary to a target sequence that is 400 nucleobases long, so long as there is a corresponding 20 nucleobase portion of the target nucleic acid that is fully complementary to the antisense oligonucleotide. Fully complementary can also be used in reference to a specified portion of the first and / or the second nucleic acid. For example, a 20 nucleobase portion of a 30 nucleobase antisense oligonucleotide can be “fully complementary” to a target sequence that is 400 nucleobases long. The 20 nucleobase portion of the 30 nucleobase oligonucleotide is fully complementary to the target sequence if the target sequence has a corresponding 20 nucleobase portion wherein each nucleobase is complementary to the 20 nucleobase portion of the antisense oligonucleotide. At the same time, the entire 30 nucleobase antisense oligonucleotide may or may not be fully complementary to the target sequence, depending on whether the remaining 10 nucleobases of the antisense oligonucleotide are also complementary to the target sequence.

[0205] The location of a non-complementary nucleobase may be at the 5’ end or 3’ end of the antisense oligonucleotide. Alternatively, the non-complementary nucleobase or nucleobases may be at an internal position of the antisense oligonucleotide. When two or more non-complementary nucleobases are present, they may be contiguous (i,e. linked) or non-contiguous. In one embodiment, a non-complementary nucleobase is located in the wing segment of a gapmer antisense oligonucleotide.

[0206] In certain embodiments, antisense oligonucleotides that are, or are up to about 13, 14, 15, 16, 17, 18, 19, or20 nucleosides in length comprise no more than 4, no more than 3, no more than 2, or no more than one (1) non-complementary nucleobase(s) relative to a target nucleic acid, such as an mRNA nucleic acid, or specified portion thereof. In certain embodiments, antisense oligonucleotides that are up to 20 nucleosides in length comprise no more than 4 non-complementary nucleobase(s) relative to a target nucleic acid, such as an mRNA nucleic acid, or specified portion thereof. In accordance with the practice of the invention, the no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to atarget nucleic acid, such as an mRNA nucleic acid, or specified portion thereof, can include zero (0) non-cornplementary nucleobase(s) relative to the target mRNA sequence.

[0207] In certain embodiments, antisense oligonucleotides that are, or are up to about 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleosides in length comprise no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 non- complementary nucleobase(s) relative to a target nucleic acid, such as an mRNA nucleic acid, or specified portion thereof. In accordance with the practice of the invention, the no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as an mRNA nucleic acid, or specified portion thereof, can include zero (0) non-complementary nucleobase(s) relative to the target mRNA sequence.

[0208] The antisense oligonucleotides provided also include those that are complementary to a portion of a target nucleic acid. As used herein, “portion” refers to a defined number of contiguous (i.e, linked) nucleosides within a region or segment of a target nucleic acid. A “portion” can also refer to a defined number of contiguous nucleosides of an antisense oligonucleotide. In certain embodiments, the antisense oligonucleotides are complementary to at least a 1.0 nucleoside portion of a target segment. In certain embodiments, the antisense oligonucleotides are complementary to at least an 11 nucleoside portion of a target segment. In certain embodiments, the antisense oligonucleotides are complementary to at least a 12 nucleoside portion of a target segment. In certain embodiments, the antisense oligonucleotides are complementary to at least a 13 nucleoside portion of a target segment. In certain embodiments, the antisense oligonucleotides are complementary to at least a 14 nucleoside portion of a target segment. In certain embodiments, the antisense oligonucleotides are complementary to at least a 15 nucleoside portion of a target segment. Also contemplated arc antisense oligonucleotides that are complementary to at least an about 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleoside portion of a target segment, or a range defined by any two of these values.

[0209] Identity

[0210] i

[0211] The antisense oligonucleotides provided herein may also have a defined percent identity to a particular nucleotide sequence, SEQ ID NO, or compound represented by a specific identity number, or portion thereof. As used herein, an antisense oligonucleotide is identical to the >7?sequence disclosed herein if it has the same nucleobase pairing ability. For example, an RNA that contains uracil in place of thymidine in a disclosed DNA sequence would be considered identical to the DNA sequence since both uracil and thymidine pair with adenine. Shortened and lengthened versions of the antisense oligonucleotide described herein, as well as oligonucleotides having non¬ identical bases relative to the antisense oligonucleotides provided herein, are also contemplated. The non-identical bases may be adjacent to each other or dispersed throughout the antisense oligonucleotide. Percent identity of an antisense oligonucleotide is calculated according to the number of bases that have identical base pairing relative to the sequence to which it is being compared.

[0212] In certain embodiments,- the antisense oligonucleotides, or portions thereof, are at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to one or more of the antisense oligonucleotides or SEQ ID NOs, or a portion thereof, disclosed herein.

[0213] In certain embodiments, a portion of the antisense oligonucleotide is compared to an equal length portion of the target nucleic acid. In certain embodiments, an about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion is compared to an equal length portion of the target nucleic acid. In some embodiments, the portion of the antisense oligonucleotide can have al least about 80% identity, particularly, at least about 90% identity, to an equal length portion of the target nucleic acid, particularly a 20 nucleobase portion.

[0214] Chemical Modifications

[0215] A nucleoside is a base-sugar combination. The nucleobase (also known as base) portion of the nucleoside is normally a heterocyclic base moiety. Nucleotides are nucleosides that further include a covalent linkage (e.g., phosphate group or a chemically modified linkage as described infra) to the sugar portion of the nucleoside. Oligonucleotides are formed through the covalent linkage of adjacent nucleotides to one another, to form a linear polymeric oligonucleotide. Within the oligonucleotide structure, the linkage groups are commonly referred to as forming the internucleoside linkages of the oligonucleotide.

[0216] Modifications to antisense compounds encompass substitutions or changes to nucleobases, internucleoside linkages, or sugar moieties. Modified antisense compounds are often preferred over native or unmodified forms because of desirable properties such as, for example, enhanceddelivery (e.g., increased cellular Uptake), enhanced specificity or affinity for a nucleic acid target, increased stability in the presence of nucleases, enhanced safety (e.g., fewer side effects after administration of the compound to a subject) or increased potency (e.g., increased activity).

[0217] Intemucleoside Linkage Modifications

[0218] The naturally occurring intemucleoside linkage of RNA and DNA is a 3' to 5’ phosphodiester linkage. For nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to the 2', 3', or 5' hydroxyl moiety of the sugar. Oligomeric compounds (particularly ACT-UP 1 compounds) having one or more modified, i.e., non-naturally occurring, internucleoside linkages are often selected over oligomeric compounds having naturally occurring intemucleoside linkages because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, decreased toxicity, increased stability and durability, decreased degradation and other desirable features for an oligomeric compound. Modified intemucleoside linkages and their advantages are well known in the art (Crooks, S. T., et al., 2021a Antisense technology: an overview and prospectus. Nat Rev Drug Discov 20: 427-453; Crooke, S. T., et ah, 2021b Antisense technology: A review. J Biol Chem 296: 100416).

[0219] Oligomeric compounds having modified intemucleoside linkages include intemucleoside linkages that retain a phosphorus atom as well as intemucleoside linkages that do not have a phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are not limited to, phosphodiesters, phosphotriesters, methylphosphonates (e.g., 5’- methylphosphonate (5’-MP)), phosphoramidate, phosphorothioates (e.g., phosphorodithioate Rp isomer (PS, Rp), phosphorodithioate Rp isomer (PS, Sp), or 5 ’-phosphorothioate (5’-PS)), methoxypropylphosphonate, (S)-5> C-methyl with Phosphate, and 5’-(E)-vinylphosphonate. In certain aspects, the intemucleoside linkage may be replaced with a peptide nucleic acid (PNA) linkage.

[0220] In certain embodiments, oligomeric compounds targeted to a nucleic acid comprise one or more modified internucleoside linkages. In certain embodiments, the modified intemucleoside linkages are phosphorothioate (PS) linkages. In certain embodiments, one or more intemucleoside linkage of an oligomeric compound is a phosphorothioate intemucleoside linkage. In certain embodiments, each internucleoside linkage of an oligomeric compound is a phosphorothioateinternucleoside linkage. In certain embodiments, each internucleoside linkage of an oligonucleotide is a phosphorothioate internucleoside linkage.

[0221] Sugar Modifications

[0222] Oligomeric compounds (particularly ACT-UP1 compounds) provided herein can contain one or more nucleosides wherein the sugar group has been modified. Such sugar modified nucleosides may impart desirable features such as increased stability, increased durability (e.g., increased half-life), increased binding affinity, decreased off-target effects, decreased immunogenicity, decreased toxicity, increased potency, or some other beneficial biological property to the oligomeric compounds. Sugar modifications and their advantages are known in the art (Faria, M., and H. Ulrich, 2008 Sugar boost: when ribose modifications improve oligonucleotide performance. Curr Opin Mol Ther 10: 168-175; Crooke, S. T., et al., 2021b Antisense technology: A review. J Biol Chem 296: 100416; Egli, M., and M. Manoharan, 2023 Chemistry', structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res 51: 2529-2573).

[0223] In certain embodiments, nucleosides comprise a chemically modified ribofuranose ring moiety. Examples of chemically modified ribofuranose rings can include, without limitation, addition of substituent groups (e.g!:) 5’ sugar modifications, or 2’ sugar modifications); bridging of non-geminal ring atoms to form bicyclic nucleic acids (BNA); replacement of the ribosyl ring oxygen atom with S, N(R), or C(R1)(R)2 (R = H, C1-C12 alkyl or a protecting group); nucleoside mimetic; and combinations thereof.

[0224] Examples of chemically modified sugars include, 2'-F-5'-methyl substituted nucleoside (see, e.g., PCT Publication W02008101157 for other disclosed 5', 2’-bis substituted nucleosides), replacement of the ribosyl ring oxygen atom with S with further substitution at the 2'-position (see, e.g., U. S. Publication US20050130923), or, alternatively, 5'-substitution of a BNA (see, PCT Publication W020071 4181 wherein LNA is substituted with, for example, a 5'-methyl or a 5’- vinyl group).

[0225] A 2’-modified sugar refers to a furanosyl sugar modified at the 2’ position. A 2’-modified nucleoside refers to a nucleoside comprising a sugar modified at the 2’ position of a furanose ring. In certain embodiments, such modifications include substituents selected from: a halide, including, but not limited to substituted and' unsubstituted alkoxy, substituted and unsubstituted thioalkyl.substituted and unsubstituted aminoalkyl, substituted and unsubstituted alkyl, substituted and unsubstituted allyl, and substituted and unsubstituted alkynyi. In certain embodiments, 2’ modifications are selected from substituents including, but not limited to: O[(CH2)nO]mCH3, O(CH2)nNH2, O(CH2)nCH3, O(CH2)BONH2, OCH2C(=O)N(H)CH3, and O(CH2)nON[(CH2)nCH3]2, where n and m are from 1 to about 10. Other 2’- substituent groups can also be selected from: Ci-C i2alkyl, substituted alkyl, alkenyl, alkynyi, alkaryi, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2CH3, ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving pharmacokinetic properties, and a group for improving the pharmacodynamic properties of an oligomeric compound, and other substituents having similar properties.

[0226] Further examples of nucleosides having modified sugar moieties include, without limitation, nucleosides comprising 5’-vinyl, 5 ’-methyl (R or S), 2’-F-5’-methyl, 4’-S, 2’-deoxy-2 ’-fluoro (2’-F). 2’-OCH3(2’-O-methyl, 2’-OMe), 2’-O(CH2)2OCH3(2’-O-methoxyethyl, 2’-O-MOE, 2’-MOE), 2’-O-methyl-4-pyridine, phosphorodiamidate morpholino (PMO), tricyclo-DNA (tcDNA), 2’-arabino-fluoro, 2’-O-benzyl, glycol nucleic acid (GNA), and / or unlocked nucleic acid (UN A) substituent groups. The substituent at the 2’ position can also be selected from al lyl, amino, azido, thio, O-allyl, O-CS-CJO alkyl, OCF3, O(CH2)2SCH3, O(CII2)2-O-N(Rm)(Rn), and O-CH2- C(:=:O)" N(Rm)(Rn), where each Rm and Rn is, independently, H or substituted or unsubstituted Cj-C JO alkyl. 2’-OMe or 2’-OCH3or 2’-O-methyl each refers to a nucleoside comprising a sugar comprising an -OCH3 group at the 2’ position of the sugar ring. 2’-F refers to a sugar comprising a fluoro group at the 2’ position / S’-O-methoxyethyl or 2’-O-MOE or 2’-MOE each refers to a nucleoside comprising a sugar comprising an -O(CH2)2OCH3group at the 2’ position of the sugar ring.

[0227] BNAs refer to modified nucleosides comprising a bicyclic sugar moiety wherein a bridge connecting two carbon atoms of the sugar ring connects the 2’ carbon and another carbon of the sugar ring. Examples of bicyclic nucleosides include, without limitation, nucleosides comprising a bridge between the 4’ and the 2’ ribosyl ring atoms such as in locked nucleic acid (LNA). In certain embodiments, oligomeric compounds provided herein include one or more bicyclic nucleosides wherein the bridge comprises a 4’ to 2’ bicyclic nucleoside. LNAs and UNAs havebeen described by Campbell and Wengel (Che-m Soc Rev, 2011, 40(12):5680-9) and are incorporaled~by -reference herein.

[0228] In certain embodiments, oligomeric compounds comprise one or more nucleotides having modified sugar moieties. In certain embodiments, the modified sugar moiety is 2’ -MOE. In certain embodiments, the modified sugar moiety has a 2’-OMe modification. In certain embodiments, the modified sugar moiety has a 2’-F modification. In certain embodiments, the modified sugar moiety is a cBt

[0229] Oligomeric Compound Delivery Systems

[0230] Oligomeric compounds (particularly ACT-UP 1 compounds) require entry into target cells to become active. A variety of modalities have been used to traffic oligomeric compounds into target cells including viral delivery vectors, lipid-based delivery, polymer-based delivery, and conjugate-based delivery (Paunovska et al.. Drug Delivery Systems for RNA Therapeutics, 2022, Nature Reviews Genetics, 23(5):265-280; Chen et ah, 2022, Molecular Therapy, Nucleic Acids, 29:150-160).

[0231] Lipid-based particles can form specific structures such as micelles, liposomes, and lipid nanoparticles (LPNs) to carry oligomeric compounds into cells. To form these particles, LPNs can include one or more of a cationic or ionizable lipid (e.g., DLin-MC3-DMA, SM-102, or ALC- 0315), cholesterol, a helper lipid, l,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), polyethylene glycol) (PEG) modified lipid (e.g., PEG-2000-C-DMG, PEG-2000-DMG, or ALC- 0159), Cl 2-200, cKK-E12 and the like. Different combinations of lipids can be formulated to affect the delivery of the oligomeric compound to different types of cells. In one example, therapeutic siRNA patisiran was formulated in cationic ionizable lipid DLin-MC3-DMA, cholesterol, polar phospholipid DSPC, and PEG-2000-C-DMG for delivery to hepatocytes.

[0232] Polymer-based particles are also used in oligomeric compound delivery systems. Such polymers include poly(lactic-co-glycolic acid) (PLGA), polyethylenimine (PEI), poly(l-lysine) (PEL), poly (beta-ami no ester) (PBAE), dendrimers (e.g., poly(amidoamine) (PAMAM) or PEL), and other polymers or modified polymers thereof. The polymer composition can be varied depending on the traits desired for deliver)' of the oligomeric compound.

[0233] The oligomeric compounds disclosed herein may be covalently linked to one or more moieties or conjugate agents which enhance the activity, cellular distribution or cellular uptake ofthe resulting compound. Conjugate agents can include cholesterols, lipids, carbohydrates, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, peptides, antibodies, dyes, tocopherol (Nishina et al., 2008, Molecular Therapy, 16(4):734-740), etc. Conjugate-based delivery can actively deliver oligomeric compounds to specific cell types.

[0234] In an example, N-Acetylgalactosamine (GalNAc) is conjugated to an oligomeric compound and delivers the compound into hepatocytes. Various GalNAc conjugate agents can be found in several publications including the following, all of which are incorporated-by-reference herein: Sharma et al., 2018, Bioconjugate Chem, 29:2478-2488; Nair et al., J, Am, Chem. Soc, 2014, 136(49): 16958-16961; Keam, 2022, Drugs, 82:1419-1425; US Patent 10,087,208; Prakash et al,, 2014, Nucleic Acids Res, 42(13):8796-807; Debacker et al., 2020, Molecular Therapy, 28(8): 1759-1771; US Patent 11,110,174; US Patent 9,796,756; US Patent 9,181,549; US Patent 10,344,275; US Patent 10,570,169; US Patent 9,506,030; US Patent 7,582,744; and, WO2024 / 137545.

[0235] Oligomeric Compound Synthesis: i

[0236] Oligomeric compounds (particularly ACT-UP 1 compounds) were designed, synthesized, and prepared using methods known in the art.

[0237] Solid phase syntheses of oligonucleotides were done on a MerMade™ 48x synthesizer (BioAutomation, LGC, Biosearch Technologies, Hoddesdon, UK), which can make up to 48 IpMole or 5pMole scale oligonucleotides per run using standard phosphoramidite chemistry, Phosphoramidite synthesis of oligonucleotides on a solid support is well known in the art (e.g., Beaucage and Caruthers, 1981, Tetrahedron Letters, 22(20): 1859- 1862; Roy and Caruthers, 2013, Molecules, 18:14268-14284; and Roy and Caruthers et al„ 2021, Nature Communications, 12:2760). Solid support is controlled pore glass (500-1400 A) loaded with universal linkers or loaded with 3 ’-GalNAc conjugates (AM Chemicals, Vista, CA, USA; Primetech ALC, Minsk, Belarus; Gene Link, Elmsford, NY, USA; or any GalNAc conjugate disclosed herein) or universal solid support (AM Chemicals, Vista, CA, USA). Ancillary synthesis reagents and standard 2’-cyanoethyl phosphoramidite monomers (2’-fluoro nucleosides, 2’-O~methyl nucleosides, R. NA nucleosides, DNA nucleosides) were obtained from various sources (Hongene Biotech, Shanghai, China; Sigma- Aldrich, St. Louis, MO, USA: Glen Research, Sterling, VA, USA; ThermoFisherScientific, Waltham, MA, USA; LGC Biosearch Technologies, Hoddesdon, UK), Phosphoramidite mixtures were prepared in anhydrous acetonitrile or 30% DMFiacetonitrile and were coupled using 0.25M 4,5-dicyanoimidazole(DCI) (Sigma-Aldrich, St. Louis, MO, USA) with coupling times ranging from 120-360 seconds. Standard phosphodi ester linkages were achieved using 0.02M iodine mixture in Teirahydrofuran (THF), pyridine, and water. Phosphorothiate linkages were generated using 0.05 M sulfurizing Reagent 11 (3-((Dimethylamino- methy lidene)amino)-3H- 1,2,4-dithiazole-3-thione, DDTT) (40:60, Pyridine / Acetonitrile) (LGC Biosearch Technologies, Hoddesdon, UK) with an oxidation time of 6 minutes, All sequences were synthesized with Dimethoxy Trityl (DMT) protecting group removed.

[0238] Upon completion of solid phase synthesis, the oligonucleotides were cleaved from the solid support and deprotection of base labile groups performed by incubation in ammonium hydroxide at 55°C for 6 hours. Ammonium hydroxide was removed using a centrifugal vacuum concentrator to dryness at room temperature. For sequences containing natural ribonucleotides (2 ’-OH) protected with tert-butyl dimethyl silyl (TBDMS), a second deprotection was performed using triethylamine; trihydrofluoride (TEA:3HF). To each TBDMS protected oligonucleotide, lOOpL DMSO and 125pL TEA:3HF were added and incubated at 65°C for 2.5 hours. After incubation, 25uL of 3M sodium acetate was added to the solution which was subsequently precipitated in butanol at -20’C for 30 minutes. The cloudy solution was centrifuged to a cake at which time the supernatant was carefully decanted, with a pipette. The standard precipitation process was then completed with 75% ethanol! ater then 100% ethanol as supernatant solutions. The oligonucleotide cake was dried for 30 minutes in a centrifugal vacuum concentrator.

[0239] Desalting without HPLC purification was performed after precipitation with 3M sodium acetate with a follow on G25 Sephadex® column (Sigma-Aldrich, St. Louis, MO, USA) elution. Purification of oligonucleotides was afforded by anion exchange chromatography on a Gilson GX271 prep HPLC system (Middleton. WI, USA) using BioWorks Q40 resin (Uppsala, Sweden). Final desalt was performed by Sephadex® G25 column. Al! oligonucleotides were analyzed by ion pairing reverse phase HPLC for purity on an Agilent 1200 analytical HPLC (Santa Clara, CA, USA), negative ion mass spectrometry for intact mass on an Agilent 6130 single quad mass spectrometer (Santa Clara, CA, USA), and A260 quantification by UV / Vis on a Tecan Infinite® M Plex plate reader (Zurich, Switzerland).

[0240]

[0241] In Vitro Testing of Oligomeric Compounds

[0242] Described herein are methods for treatment of cells with oligomeric compounds (particularly ACT-UP 1 compounds) such as compounds targeting SCN1 A.

[0243] Celis may be treated with oligomeric compounds when the cells reach approximately 60- 80% confluency in culture.

[0244] Reagents commonly used to introduce oligomeric compounds into cultured cells include the cationic lipid transfection reagent Oligofectamine™ 2000 or Lipofectamine™ 2000 (ThermoFisher Scientific, Waltham; MA). In one example, oligomeric compounds may be mixed with OligofectaminefM2000 in OPTI-MEM (ThermoFisher Scientific, Waltham, MA) to achieve the desired final concentration of ojigomeric compounds that may range from 0.001 to 300 nM oligomeric compounds in culture7- medium. Transfection procedures are done according to the manufacturer's recommended protocols.

[0245] Another technique used to introduce oligomeric compounds into cultured cells includes electroporation.

[0246] Oligomeric compounds conjugated with a delivery moiety can be introduced to cells through incubation of the conjugated compounds with cells without transfection reagents, referenced herein as “free uptake”.

[0247] Cells are treated with oligomeric compounds by routine methods. Cells may be harvested 4 - 144 hours after oligomeric compounds treatment, at which time mRNA (harvested at 4- 144 hrs) or protein levels (extracted at 24-96 hrs) of target nucleic acids are measured by methods known in the art and described herein. In general, treatments are performed in multiple replicates, and the data are presented as the average of the replicate treatments plus the standard deviation.

[0248] The concentration of oligomeric compounds used varies from cell line to cell line and target to target. Methods to determine the optimal oligomeric compound concentration for a particular target in a particular cell line are well-known in the art. In general, cells are treated with oligomeric compounds in a dose-dependent manner to allow for the calculation of the half- maximal inhibitory concentration value (IC50). Oligomeric compounds are typically used al concentrations ranging from 0.001 nM to 300 nM when transfected with Oligofectamine™ 2000. Oligomeric compounds are used at higher concentrations ranging from 7.5 to 20,000 nM when transfected using electroporation or free uptake.JM Vivo Testing of Oligomeric Compo unds

[0249] The oligomeric compounds (particularly ACT-UP 1 compounds) of the invention, for example, compounds targeting, are tested in animals to assess their ability to modulate expression of a target protein and produce phenotypic changes such as a change in one or more markers affected by the target nucleic acid. Also, the phenotypic change can be a decrease in a disease, disorder, condition, or symptom related to the target nucleic acid. Testing may be performed in normal animals or in experimental disease models. For administration to animals, oligomeric compounds are formulated in a pharmaceutically acceptable diluent, such as phosphate-buffered saline (PBS). Administration includes parenteral routes of administration, such as intrathecal, intraperitoneal, intravenous, and subcutaneous. Calculation of dosage and dosing frequency depends upon factors such as route of administration and animal body weight. In one embodiment, following a period of treatment with oligomeric compounds of the invention, RNA encoding the target nucleic acid is isolated from liver tissue, and changes in the target nucleic acid expression are measured. Changes in protein levels expressed by the target nucleic acid can also be measured.

[0250]

[0251] RNA Isolation

[0252] RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are well known in the art. RNA is prepared using methods well known in the art, for example, using the TRIZOL Reagent (Thermo Fisher Scientific, Waltham, MA), Qiagen RNeasy kit (Qiagen, Hilden, Germany), or AcroPrep Advance 96-well Filter Plates (Pall Corporation, Port Washington, New York) using Qiagen’s RLT, RW1, and RPE buffers. RNA extraction procedures are done according to the manufacturer’s recommended protocols.

[0253] Protein Isolation

[0254] Protein analysis can be conducted on total cell extracts or tissue lysates. Methods of cell extracts or tissue lysates are well known in the art. Cellular proteins are prepared using methods well known in the art, for example, using RIPA buffer (ThermoFisher Scientific, Waltham, MA) or other appropriate buffers. Tissue ly sates are prepared in RIPA buffer with a tissue homogenizer. Levels of proteins can be analyzed using Western blotting, ELISA, or other approaches.

[0255] Compositions and Methods for Formulating Pharmaceutical CompositionsThe oligomeric compounds of the invention, such as ACT-UP 1 compounds, or salts thereof, described herein, can be combined with pharmaceutically acceptable active or inert substances, such as a diluent, excipient, or carrier, for the preparation of pharmaceutical compositions or formulations.

[0256] Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

[0257] In certain embodiments, the pharmaceutical carrier or excipient is a pharmaceutically acceptable solvent, suspending agent, or any other pharmacologically inert vehicle for delivering one or more oligomeric compounds to an animal. The excipient can be liquid or solid and can be selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone and / or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrysialline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates and / or calcium hydrogen phosphate, etc.): lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, com starch, polyethylene glycols, sodium benzoate, and / or sodium acetate, etc.); disintegrates. (e.g., starch, and / or sodium starch glycolate, etc.); and wetting agents (e.g,, sodium lauryl sulphate, etc.).

[0258] Pharmaceutically acceptable organic or inorganic excipients, which do not deleteriously react with nucleic acid compounds, suitable for parenteral or n on-parenteral administration can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like. A pharmaceutically acceptable diluent includes phosphate- buffered saline (PBS). PBS is a diluent suitable for use in compositions to be delivered parenterally. Accordingly, in one embodiment, employed in the methods described herein is a pharmaceutical composition comprising an oligomeric compound and a pharmaceutically acceptable diluent. In certain embodiments, the pharmaceutically acceptable diluent is PBS.

[0259]

[0260] Pharmaceutical compositions comprising oligomeric compounds such as ACT-UP 1 compounds can encompass any pharmaceutically acceptable salts, esters, or salts of such esters, which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof, Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of oligomeric compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.

[0261] In certain embodiments, a pharmaceutical composition is prepared for administration by injection (e.g., intravenous, subcutaneous, and / or intramuscular, etc.). In certain of such embodiments, a pharmaceutical 'composition comprises a carrier and is formulated in aqueous solution, such as water or physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer (e.g., PBS). In certain embodiments, other ingredients are included (e.g., ingredients that aid in solubility or serve as preservatives). In certain embodiments, injectable suspensions are prepared using appropriate liquid carriers, suspending agents and the like. Certain pharmaceutical compositions for injection are presented in unit dosage form, e.g., in ampoules or in multi-dose containers.

[0262] Dosages

[0263] For purposes of the disclosure, the amount or dose of the active agent (i.e., ACT-UP 1 compound of the invention) administered should be sufficient to e.g., modulate the expression of a target protein in an animal. In the animal (e.g., human), dose will be determined by the efficacy of the particular active agent and the condition of the animal, as well as the body weight of the animal to be treated.

[0264]

[0265] Many assays for determining an administered dose are known in the art.

[0266] The dose of the active agent of the present disclosure wilt also be determined by the existence, nature, and extent of any adverse side effects that might accompany the administration of a particular active agent of the present disclosure. Typically, the attending physician will decide the dosage of the active agent of the present disclosure with which to treat each individual patient, taking into consideration a variety of factors, such as age, body weight, general health, diet, sex, active agent of the present disclosure to be administered, route of administration, and the severity of the condition being treated.

[0267]

[0268] Dosing

[0269] In certain embodiments, pharmaceutical compositions are administered according to a dosing regimen (e.g., dose, dose frequency, and duration), wherein the dosing regimen can be selected to achieve a desired effect. The desired effect can be. for example, reduction of a target nucleic acid or the prevention, reduction, amelioration, or slowing the progression of a disease, disorder and / or condition, or symptom thereof, associated with the target nucleic acid. In certain embodiments, the variables of the dosing regimen are adj usted to result in a desired concentration of pharmaceutical composition in a subject. " Concentration of pharmaceutical composition" as used with regard to dose regimen can refer to the oligomeric compound (particularly ACT-UP1 compound) or active ingredient of the pharmaceutical composition. For example, in certain embodiments, dose and dose frequency are adjusted to provide a tissue concentration or plasma concentration of a pharmaceutical composition at an amount sufficient to achieve a desired effect.

[0270] Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Dosing is also dependent on drug potency and metabolism, In certain embodiments, dosage is from about 0.01 pg to 50 mg per kg of body weight, 0.01 pg to 100 rng per kg of body weight, or within a range of about 0.001 mg to 1000 mg dosing, and may be given once or more daily, weekly, monthly, quarterly, or yearly, or even once every' 2 to 20 years. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligomeric compound is administered in maintenance doses, ranging from about 0.01 pg to 100 mg per kg of body weight, once or more daily, once or more weekly, once or more monthly, once or more quarterly, once or more yearly, to once every 20 years or ranging from about 0,001 mg to 1000 mg dosing. In certain embodiments, it may be desirable to administer the oligomeric compound from at most once daily, once weekly, once monthly, once quarterly, once yearly, once every two years, once every three years, once every bur years, once every five years, once every ten years, or once every 20 years,

[0271] In certain embodiments, the range of dosing is between any of about 1 mg- 1500mg, 1 OOmg- l400rag, 100mg-1300mg, 100mg-1200mg, lOOmg- 1 lOOmg, 1 OOmg- 1 OOOmg, 100mg-900mg, 200mg-800mg, 3(}()mg-700mg, 400mg-600mg, l00mg-400mg, 200mg~500mg, 300mg~600mg, and 400mg-700mg. In certain embodiments, a dose is about lOOmg, 150mg, 200mg, 250mg,300mg, 350mg, 400mg, 450mg, 500mg, 550mg, 600mg, 650mg, 700mg, 800mg, 850mg, 900mg, 950mg, lOOOmg, 1050mg, HOOmg, 1150mg, 1200mg, 1250mg, 1300mg, 1350mg, l400mg, 1450mg, or 1500mg, particularly lmg-1500mg.

[0272] In certain embodiments, the oligomeric compound is dosed at any of about 150mg, 200mg, 300mg, 400mg, 500mg, 600mg, 700mg, 800mg, or 900mg twice a year. In certain embodiments, the oligomeric compound is dosed at about 100 mg, 150mg, 200mg, 300mg, 400mg, 500mg, 600mg, 700mg, 800mg, or 900mg quarterly. In certain embodiments, the oligomeric compound is dosed at about 50mg, lOOmg, 150mg, 200mg, 300mg, 400mg, 500mg, 600mg, 700mg, 800mg, or 900mg once monthly or every two months. In certain embodiments, the oligomeric compound is dosed at about I Omg, 15mg, 20mg, 25mg, 50mg, 1 OOmg, 150mg, 200mg, 300rng, 400mg, 500mg, 600mg, 700mg, 800mg, or 900mg weekly or every two weeks.

[0273] Administration

[0274] The oligomeric compounds, such as ACT-UP 1 compounds, salts thereof, or pharmaceutical compositions of the present invention, can be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated, k (

[0275] Administration can be oral, inhaled; or parenteral.

[0276] In certain embodiments, the compounds and compositions as described herein are administered parenterally. Parenteral administration includes intravenous, intra-arterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. In certain embodiments, parenteral administration is by infusion. Infusion can be chronic or continuous or short or intermittent. In certain embodiments, infused pharmaceutical agents are delivered with a pump.

[0277] in certain embodiments, parenteral administration is by injection. The injection can be delivered with a syringe or a pump. In certain embodiments, the injection is a bolus injection. In certain embodiments, the injection is administered directly to a tissue or organ.

[0278] In certain embodiments, formulations for parenteral e.g., intrathecal or intraventricular, administration can include sterile aqueous solutions which can also contain buffers, diluents, and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and. I

[0279] other pharmaceutically acceptabletcarriers or excipients.In certain embodiments, formulations for oral administration of the compounds or compositions can include, but are not limited to: pharmaceutical carriers, excipients, powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids, or binders can be desirable. In certain embodiments, oral formulations are those in which compounds provided herein are administered in conjunction with one or more penetration enhancers, surfactants, and chelators.

[0280]

[0281] Kits of the Invention

[0282] According to another aspect of the invention, kits are provided. Kits according to the invention include package(s) comprising any of the pharmaceutical compositions of the invention or oligomeric compound (particularly ACT-UPl compound) of the invention. In various aspects, the kit comprises any of the compositions of the invention as a unit dose. For purposes herein “unit dose” refers io a discrete amount dispersed in a suitable carrier.

[0283] The phrase "package" means any vessel containing compositions presented herein. In preferred embodiments, the package can be a box or wrapping. Packaging materials for use in packaging pharmaceutical products are well known to those of skill in the art. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes (including pre-filled syringes), bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment,

[0284]

[0285] ■

[0286] The kit can also contain items that are not contained within the package but are attached to the outside of the package, for example, pipettes.

[0287] Kits may optionally contain instructions for administering compositions of the present invention to a subject having a condition in need of treatment. Kits may also comprise instructions for approved uses of components of the composition herein by regulatory agencies, such as the United States Food and Drag Administration. Kits may optionally contain labeling or product inserts for the present compositions. The package(s) and / or any product insert(s) may themselves be approved by regulatory agencies. The kits can include compositions in the solid phase or in a liquid phase (such as buffers provided) in a package. The kits can also include buffers for preparingsolutions for conducting the methods, and pipettes for transferring liquids from one container to another.

[0288] The kit may optionally also contain one or more other compositions for use in combination therapies as described herein. In certain embodiments, the package(s) is a container for any of the means for administration such as intravitreal delivery, intraocular delivery, intratumoral delivery, peritumoral delivery, intraperitoneal delivery, intrathecal delivery, intramuscular injection, subcutaneous injection, intravenous delivery, intra-arterial delivery, intraventricular delivery, intrasternal delivery, intracranial delivery, or intradermal injection.

[0289] Methods of Use

[0290] The invention provides methods for enhancing the expression of a target protein in a subject comprising administering an effective amount of an oligomeric compound (particularly ACT-UP 1 compound) of the invention, a salt thereof, or a pharmaceutical composition of the invention, so as to increase the expression of a target protein in the subject.

[0291] The invention provides methods for enhancing the expression of a target protein in a eukaryotic cell comprising administering an effective amount of an oligomeric compound (particularly ACT-UP1 compound) of the invention, a salt thereof, or a pharmaceutical composition of the invention, so as to increase the expression of a target protein in the subject. In certain embodiments, an eukaryotic cell or a prokaryotic cell is a mammalian cell, a plant cell, a yeast cell, or a bacterial cell.

[0292] In certain embodiments, a method of enhancing a target gene expression in a cell comprises administering to the cell an oligomeric compound (particularly ACT-UP 1 compound) targeted to an mRNA transcript.

[0293] In certain embodiments, an oligomeric compound of the invention increases expression of a protein by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

[0294] In certain embodiments, a method of enhancing protein expression in a cell comprises administering to the cell an ACT-UP1 compound, or salt thereof, targeting an mRNA transcript. In certain embodiments, the transcript is a SCN1A mRNA (GENBANK Accession No, NM_001165963.4; SEQ ID NO: 1). In certain embodiments, the transcript is a GRN mRNA (GENBANK Accession No, NM_002087.4, SEQ ID NO: 2). In certain embodiments, thetranscript is a SHANKS mRNA (GENBANK Accession No. NM_001372044.2, SEQ ID NO: 3). In certain embodiments, the transcript is a GBAl raRNA (GENBANK Accession No. N..000157.4, SEQ ID NO: 4)i4n certain embodiments, the transcript is a STXBPl mRNA (GENBANK Accession No. NM_003165.6, SEQ ID NO: 5). In certain embodiments, the transcript is a RAI1 mRNA (GENBANK Accession NM 030665.4, SEQ ID NO: 6),

[0295] In certain embodiments, the method of enhancing protein expression in a cell treats a subject suffering from a CNS related disease, disorder and / or syndrome. In certain embodiments, the CNS related disease, disorder and / or syndrome is an SCN1 A related disease, disorder and / or syndrome. In certain embodiments, the SCN1A related disease, disorder and / or syndrome is related to a decreased level of SCN1 A protein in the cell of a subject. In a preferred embodiment, the SCN1A related disease, disorder and / or syndrome is Dravet Syndrome. In certain embodiments, the CNS related disease, disorder and / or syndrome is a GRN related disease, disorder and / or syndrome. In certain embodiments, the GRN related disease, disorder and / or syndrome is related to a decreased level of GRN protein in the cell of a subject. In a preferred embodiment, the GRN related disease, disorder and / or syndrome is frontotemporal dementia associated with GRN (FTD-GRN). In certain embodiments, the CNS related disease, disorder and / or syndrome is a SHANK3 related disease, disorder and / or syndrome. In certain embodiments, the SHANK3 related disease, disorder and / or syndrome is related to a decreased level of SHANK3 protein in the cell of a subject. In a preferred embodiment, the SHANK3 related disease, disorder and / or syndrome is Phelan-McDermid Syndrome (PMS). In certain embodiments, the CNS related disease, disorder and / or syndrome is an GBA1 related disease, disorder and / or syndrome. In certain embodiments, the GBAl related disease, disorder and / or syndrome is related to a decreased level of GBAl protein in the cell of a subject. In a preferred embodiment, the GBzM related disease, disorder and / or syndrome is Gaucher disease, Parkinson’s disease (PD), and / or Dementia with Lewy bodies (DLB). In certain embodiments, the CNS related disease, disorder and / or syndrome is a STXBPl related disease, disorder and / or syndrome. In certain embodiments, the STXBPl related disease, disorder and / or syndrome is related to a decreased level of STXBPl protein in the cell of a subject. In a preferred embodiment, the S TXBPl related disease, disorder and / or syndrome is early infantil^’epileptic encephalopathy (EIEE4), developmental and epileptic encephalopathy. West syndrome, Ohtahara syndrome, and / or Rett-like syndrome. In certain embodiments, the CNS related disease, disorder and / or syndrome is an RAII related disease,disorder and / or syndrome. In certain embodiments, the RAI1 related disease, disorder and / or syndrome is related to a decreased level of' RAH protein in the cell of a subject. In a preferred embodiment, the RAI I related disease, disorder and / or syndrome is Smith-Magenis syndrome, autism spectrum disorder, circadian rhythm disorders, and / or obesity / metabolic dysregulation.

[0296] In some embodiments of the present disclosure, the subject is a mammal, including, but not limited to, mammals of the order Rodentia. such as mice and hamsters, and mammals of the order Logomorpha, such as rabbitb, mammals from the order Carnivora, including Felines (cats) and Canines (dogs), mammals from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perissodactyla, including Equines (horses). In some aspects, the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids (humans and apes). In a preferred aspect, the mammal is a human,

[0297] ACT-UP! Compounds for Use

[0298] The invention provides ACT-UP I compounds of the present invention for use in medicine. The invention provides ACT-UP 1 compounds of the present invention for use in the treatment of a disease, disorder and / or syndrome in a central nerveous system (CNS).

[0299] In certain embodiments, the disease, disorder and / or syndrome in the CNS is an SCN1A related disease, disorder and / or syndrome. In certain embodiments, the SCN1A related disease, disorder and / or syndrome is related to a decreased level of SCN1A protein in the cell of a subject. In a preferred embodiment, the'SCNlA related disease, disorder and / or syndrome is Dravet Syndrome.

[0300] In certain embodiments, the disease, disorder and / or syndrome in the CNS is a GRN related disease, disorder and / or syndrome. In certain embodiments, the GRN related disease, disorder and / or syndrome is related to a decreased level of GRN protein in the cell of a subject. In a preferred embodiment, the GRN related disease, disorder and / or syndrome is frontotemporal dementia associated with GRN (FTD-GRN).

[0301] In certain embodiments, the disease, disorder and / or syndrome in the CNS is a SHANK.3 related disease, disorder and / or syndrome. In certain embodiments, the SHANK3 related disease, disorder and / or syndrome is related to a decreased level of SHANK3 protein in the cell of a subject. In a preferred embodiment, the SHANK3 related disease, disorder and / or syndrome is Phelan-McDermid Syndrome (PMS).

[0302]

[0303] In certain embodiments, the disease, disorder and / or syndrome in the CNS is an GBA1 related disease, disorder and / or syndrome. In certain embodiments, the GBA1 related disease, disorder and / or syndrome is related to a decreased level of GB 1 protein in the cell of a subject. In a preferred embodiment, the GBA1 related disease, disorder and / or syndrome is Gaucher disease, Parkinson’s disease (PD), and / or Dementia with Lewy bodies (DLB).

[0304] In certain embodiments, the disease, disorder and / or syndrome in the CNS is a STXBP1 related disease, disorder and / or syndrome. In certain embodiments, the STXBP1 related disease, disorder and / or syndrome is related to a decreased level of STXBP1 protein in the cell of a subject. In a preferred embodiment, the STXBP1 related disease, disorder and / or syndrome is early infantile epileptic encephalopathy (EIEE4), developmental and epileptic encephalopathy, West syndrome, Ohtahara syndrome, and / or Rett-like syndrome.

[0305] In certain embodiments, the disease, disorder and / or syndrome in the CNS is an RAH related disease, disorder and / or syndrome. In certain embodiments, the RAI1 related disease, disorder and / or syndrome is related to a decreased level of RAI I protein in the cell of a subject. In a preferred embodiment, the RA11 related disease, disorder and / or syndrome is Smith-Magenis syndrome, autism spectrum disorder, circadian rhythm disorders, and / or obesity / metabolic dysregulation.

[0306] In Vivo Testing of Protein Enhancing Compounds

[0307] In some embodiments of the present disclosure, ACT-UP I compounds can be tested in subjects to assess their ability to enhance expression of a protein. In certain embodiments, ACT- UP I compounds can be tested in subjects to assess their ability to increase mRNA translation in order to increase protein production and / or produce phenotypic changes related to that protein. In certain embodiments, ACT-UP 1 compounds can be tested in subjects to assess their ability to treat a disease, disorder and / or syndrome associated with haploinsufficiency of the protein. Testing may be performed in normal subjects, or in experimental disease models. For administration to subjects, ACT-UP 1 compounds are formulated in a pharmaceutically acceptable diluent, such as phosphate- buffered saline. Administration includes parenteral routes of administration, such as intrathecal, intraperitoneal, intravenous, and subcutaneous. Calculation of ACT-UP 1 compound dosage and dosing frequency depends upon factors such as route of administration and subjects body weight.In one embodiment, following a period of treatment with an ACT-UP 1 compound, the protein is isolated from a tissue and changes in protein expression are measured.

[0308] In Vitro Assay to Identify ACT-UP 1 Compounds for Enhancing Protein Expression

[0309] In some embodiments of the present disclosure, in vitro assays to identify ACT-UP 1 compounds for enhancing target protein expression are provided.

[0310] In one example, a test mRNA is chosen as a target to upregulate its protein expression. Cells in culture (e.g., HeLa, Hepal-6, or HEK293), are seeded and grown for one day to ~70% confluency. The cells are then transfected with the ACT-UP1 compounds of interest at about 7.5 nM or 15 nM final concentrations using LipofectamineTM2000 Transfection Reagent (ThermoFisher Scientific, Waltham, MA), or are mock-transfected as a control. Twenty-four (24) hr after transfection, cells are harvested and lysed, then the protein is extracted using RIPA Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA). The level of target protein can be determined by Western Blot or chemiluminescence, using a target protein specific antibody and optionally, a secondary antibody conjugated to either alkaline phosphatase or horseradish peroxidase. Western Blot images can be quantified using Image! (an open source software for processing and analyzing scientific images), and the results are quantified as percent protein levels relative to mock transfected cells following normalization to a loading control protein such as GAPDH. As the control protein Is not targeted by the ACT-UP1 compounds tested in the assay, the level of the control protein is not affected, showing the specificity of the ACT-UP I compounds in modulating target protein levels.

[0311] CERTAIN EMBODIMENTS OF THE INVENTION

[0312] The invention is further illustrated by the following embodiments.

[0313] Embodiment 1 provides ' an Antisense oligonucleotide (ASO) Coupled Translation - Upregulation 1 (ACT-UP 1) compound, or salt thereof, for enhancing expression of a protein in a cell located in the central nervous system (CNS), wherein the compound, or salt thereof, comprises an antisense oligonucleotide (ASO) joined to a protein recruiting sequence (PRS), wherein (a) the ASO specifically hybridizes to a target mRNA expressed in a ceil of the CNS, and (b) the PRS attracts translation regulatory proteins close to the target mRNA thereby increasing translation ofthe targeted mRNA, wherein the ACT-UP1 compound is 13 to 40 linked nucleoside subunits in length.

[0314] Embodiment 2 provides the ACT-UP 1 compound, or salt thereof, of embodiment 1, wherein the target mRNA encodes a protein selected from the group consisting of granulin precursor (GRN), sodium voltage-gated channel alpha subunit 1 (SCN1A), SH3 and multiple ankyrin repeat domains 3 (SHANK3), glucosylceramidase beta 1 (GBA1), Syntaxin Binding Protein 1 (STXBPl), and Retinoic Acid Induced 1 (RAI1).

[0315] Embodiment 3 provides the ACT-UP 1 compound, or salt thereof, of embodiment 2, wherein the ACT-UP 1 compound, or salt thereof, is a compound targeting GRN mRNA and comprises any of the sequences of SEQ ID NO: 96-99, or a derivative thereof having at least 80% sequence identity with any of these sequences.

[0316] Embodiment 4 provides the ACT-UP1 compound, or salt thereof, of embodiment 2, wherein the ACT-UP 1 compound, or salt thereof, is a compound targeting SCN1A mRNA and comprises any of the sequences of SEQ ID NO: 89-95 or 141-151, or a derivative thereof having at least 80% sequence identity with any of these sequences.

[0317] Embodiment 5 provides the ACT-UP 1 compound, or salt thereof, of embodiment 2, wherein the ACT-UP1 compound, or salt thereof, is a compound targeting SHANK3 mRNA and comprises any of the sequences bf SEQ ID NO: 112-120, or a derivative thereof having at least 80% sequence identity with any of these sequences.

[0318] Embodiment 6 provides the ACT-UP 1 compound, or salt thereof, of embodiment 2, wherein the ACT-UP 1 compound, or salt thereof, is a compound targeting GBA1 mRNA and comprises any of the sequences of SEQ ID NO: 100-111, or a derivative thereof having at least 80% sequence identity with any of these sequences.

[0319] Embodiment 7 provides the ACT-UP1 compound, or sail thereof, of embodiment 2, wherein the ACT-UP I compound, or salt thereof, is a compound targeting STXBPl mRNA and comprises any of the sequences of SEQ ID NO: 121-135, or a derivative thereof having at least 80% sequence identity with any of these sequences.

[0320] Embodiment 8 provides the ACT-UP 1 compound, or salt thereof, of embodiment 2, wherein the ACT-UP 1 compound, or salt thereof, is a compound targeting RAH mRNA and comprises any of the sequences of SEQ ID NO: 136-140, or a derivative thereof having at least 80% sequence identity with any of these sequences.Embodiment 9 provides the ACT-UP 1 compound, or salt thereof, of any preceding embodiment, wherein the ACT-UP1 compound, or salt thereof, comprises at least one chemical modification.

[0321] Embodiment 10 provides the ACT-UP1 compound, or salt thereof, of embodiment 9, wherein each nucleoside of the ACT-UP 1 compound, or salt thereof, comprises a chemical modification.

[0322] Embodiment 11 provides the ACT-UP 1 compound, or salt thereof, of embodiment 9 or 10, wherein the chemical modification is selected from the group consisting of 2’-O-methyl (2’-OMe), 2’-O-methoxyethyl (2 ’-MOE), 2’ifiuoro (2’-F), constrained ethyl (cEt), unlocked nucleic acid (UNA), locked nucleic acid (LN A) and 5-methylcytosine base, and any combination thereof.

[0323] Embodiment 12 provides the ACT-UP 1 compound, or salt thereof, of any preceding embodiment, wherein the ACT-UP 1 compound, or salt thereof, comprises at least one modified internucleoside linkage.

[0324] Embodiment 13 provides the ACT-UP 1 compound, or salt thereof, of embodiment 12, wherein the at least one modified internucleoside linkage is a phosphorothioate internucleotide (PS) linkage.

[0325] Embodiment 14 provides the ACT-UP 1 compound, or salt thereof, of any preceding embodiment, wherein the ACT-UP1 compound, or salt thereof, further comprises a conjugate moiety.

[0326] Embodiment 15 provides an ACT-UP 1 compound, or salt thereof, of embodiment 14, wherein the conjugate moiety is selected from the group consisting of cholesterols, lipids, carbohydrates, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, peptides, antibodies, dyes, and tocopherol.

[0327] Embodiment 16 provides an ACT-UP 1 compound, or salt thereof, of any preceding embodiment, wherein the ACT-UP 1 compound, or salt thereof, increases protein expression by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, 250%, or 300%, preferably by at least about 10%.

[0328] Embodiment 17 provides a pharmaceutical composition comprising the ACT- P1 compound, or salt thereof, of any preceding embodiment, alone or in combination with a pharmaceutical iy acceptable carrier and / or excipient.Embodiment 18 provides a method for increasing translation of mRNA in a central nervous system (CNS) cell comprising administering the ACT-UP i compound, or salt thereof, of any of embodiments 1 to 16 or the pharmaceutical composition of embodiment 17 to the cell in the CNS, in an amount sufficient to increase translation of the mRNA in the CNS cell.

[0329] Embodiment 19 provides a method for increasing protein expression in a central nervous system (CNS) cell comprising administering the ACT-UP 1 compound, or salt thereof, of any of embodiments 1 to 16 or the pharmaceutical composition of embodiment 17 to the cell in the CNS, in an amount sufficient to increase expression of the protein in the CNS cell.

[0330] Embodiment 20 provides a method for treating a disease, disorder and / or syndrome in a central nerveous system (CNS) in a subject comprising administering the ACT-UP1 compound, or salt thereof, of any of embodiments 1 to 16 or the pharmaceutical composition of embodiment 17 to the cell in the CNS, to the subject, in an amount sufficient to treat the disease, disorder and / or syndrome in the subject.

[0331] Embodiment 21 provides the method of embodiment 20, wherein the disease, disorder and / or syndrome in a CNS is a disease, disorder and / or syndrome related to a protein selected from the group consisting of sodium voltage-gated channel alpha subunit 1 (SCN1 A), granulin precursor (CRN), SH3 and multiple ankyrin repeat domains 3 (SHANK3), glucosylceramidase beta 1 (GBA1), Syntaxin Binding Protein 1 (STXBP1), and Retinoic Acid Induced 1 (RAI 1 ), and any combination thereof.

[0332] Embodiment 22 provides the method of embodiment 21, wherein the GRN related disease, disorder and / or syndrome is selected from the group consisting of frontotemporal dementia associated with GRN (FTD-GRN), Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS); and limbic-predominant age-related TDP-43 encephalopathy (LATE), and any combination thereof.

[0333] Embodiment 23 provides the method of embodiment 21, wherein the SCN1A related disease, disorder and / or syndrome is selected from the group consisting of Dravet Syndrome, stroke-related neuronal dysfunction, Generalized Epilepsy with Febrile Seizures Plus (GEFS+), developmental and epileptic encephalopathies (DEEs), and autism, and any combination thereof.

[0334] Embodiment 24 provides the method of embodiment 21, wherein the SHANK3 related disease, disorder and / or syndrome is selected from the group consisting of autism spectrumdisorder (ASD), schizophrenia, and Phelan-McDermid Syndrome (PMS), and any combination thereof.

[0335] Embodiment 25 provides the method of embodiment 21, wherein the GBA1 related disease, disorder and / or syndrome is selected from the group consisting of Gaucher disease, Parkinson’s disease (PD), and Dementia with Lewy bodies (DLB), and any combination thereof.

[0336] Embodiment 26 provides the method of embodiment 21, wherein the STXBP1 related disease, disorder and / or syndrome is selected from the group consisting of early infantile epileptic encephalopathy (EIEE4), developmental and epileptic encephalopathy, West syndrome, Ohtahara syndrome, and Rett-like syndrome, and any combination thereof.

[0337] Embodiment 27 provides the method of embodiment 21, wherein the RAI I related disease, disorder and / or syndrome is selected from the group consisting of Smith-Magenis syndrome, autism spectrum disorder, circadian rhythm disorders, obesity, and metabolic dysregulation, and any combination thereof.

[0338] Embodiment 28 provides the method of any one of embodiments 18 to 27, wherein the ACT-UP I compound, or salt thereof, or the pharmaceutical composition is administered intrathecally to the subject.

[0339] Embodiment 29 provides a process for preparing the ACT-UP 1 compound, or salt thereof, of any one of embodiments 1-14, wherein the process comprises the steps of: (a) preparing the compound by sequential coupling of modified and / or unmodified nucleotides via the phosphoramidite oligonucleotide synthesis on a conjugate modified or unmodified solid support; (b) optionally, coupling a conjugate moiety to the compound on the solid support via the phosphoramidite oligonucleotide synthesis; (c) detaching the compound from the solid support and removing the solid support; and (d) optionally, adding a conjugate post cleavage; and / or (e) optionally, further purifying the compound, optionally using chromatography.

[0340] Embodiment 30 provides an ACT-UP1 compound, or salt thereof, of any one of embodiments 1 to 16, for use in medicine.

[0341] Embodiment 31 provides an ACT-UP1 compound, or salt thereof, of any one of embodiments 1 to 16, for use in the treatment of a disease, disorder and / or syndrome in a central nerveous system (CNS).

[0342] Embodiment 32 provides the ACT-UP 1 compound, or salt thereof, for use of embodiment 31, wherein the disease, disorder and / or syndrome is a disease, disorder and / or syndrome relatedto a protein selected from the group consisting of granulin precursor (GRN), sodium voltage-gated channel alpha subunit 1 (SCN1 A), SH3 and multiple ankyrin repeat domains 3 (SHANK3), glucosylceramidase beta I (GBA1), Syntaxin Binding Protein 1 (STXBP1), and Retinoic Acid Induced 1 (R. AI1), and any combination thereof.

[0343] Embodiment 33 provides the ACT-UP1 compound, or salt thereof, for use of embodiment 31 or 32, wherein the disease, disorder and / or syndrome in selected from the group consisting of Dravet Syndrome, stroke-related neuronal dysfunction, Generalized Epilepsy with Febrile Seizures Plus (GEFS+), developmental and epileptic encephalopathies (DEEs), autism, frontotemporal dementia associated with GRN (FTD-GRN), Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), limbic-predominant age-related TDP-43 encephalopathy (LATE), autism spectrum disorder (ASD), schizophrenia, and Phelan- McDennid Syndrome (PMS), Gaucher disease, Dementia with Lewy bodies (DLB), early infantile epileptic encephalopathy (EIEE4), developmental and epileptic encephalopathy, West syndrome, Ohtahara syndrome, and Rett-like syndrome, Smith-Magenis syndrome, circadian rhythm disorders, obesity, and metabolic dysregulation, and any combination thereof.

[0344] Embodiment 34 provides the ACT-UP 1 compound, or salt thereof, of any preceding embodiment, wherein the PRS component of the ACT-UP 1 compound, or salt thereof, is GGACU (SEQ ID NO: 7), GAACU (SEQ ID NO: 11), AGACU (SEQ ID NO: 12), GGACA (SEQ ID NO: 13), GGACT (SEQ ID NO: 14), AAACU (SEQ ID NO: 18), GGACUGGAC (SEQ ID NO: 10), GGACUGGACU (SEQ ID NO: 9), GGACAGCGCU (SEQ ID NO: 152), GGACTGGACU (SEQ ID NO: 153), GGACTGGACT (SEQ ID NO: 20), AAACUGGACT (SEQ ID NO: 154), AAACUAAACU (SEQ ID NO: 21), GGACUGGACUG (SEQ ID NO: 22), ACGGACUUGGACU (SEQ ID NO: 8), GGACUGGACUGGACU (SEQ ID NO: 169), or GGACUGGACUGGACUGGACU (SEQ ID NO: 170). In certain embodiments, an ASO component disclosed herein is joined to one of the PRS component disclosed herein. In certain preferred embodiment, as ASO component selected from any of SEQ ID NOs: 54-57 is joined to a PRS component.

[0345] Embodiment 35 provides the ACT-UP1 compound, or salt thereof, of any preceding embodiment, wherein the ACT-UP 1 compound, or salt thereof, targets a region of the GRN mRNA disclosed herein about 20 to 50, 40 to 70, 60 to 90, 80 to 110, 100 to 130, 120 to 150, 140 to 170, 160 to 190, 170 to 200, 180 to 210, 200 to 230, 220 to 250, 240 to 300, or 280 to 500 nucleotides

[0346]

[0347] downstream of its stop codon. In one embodiment, the ACT-UP 1 compound, or salt thereof, targets GRN about 50 to 300, 50 to 250, 50 to 200, 50 to 150, 75 to 300, 75 to 250, 75 to 200, 75 to 150, 100 to 300, 100 to 250, 100 to 200, or 100 to 150 nucleotides downstream of its stop codon. In a preferred embodiment, the compound targets GRN about 50 to 200 nucleotides downstream of a stop codon. In a more preferred embodiment, the compound targets GRN about 50 to 150 nucleotides downstream of a stop codon.

[0348] Embodiment 36 provides the ACT-UP1 compound, or salt thereof, of any preceding embodiment, wherein the ACT-UP1 compound, or salt thereof, targets a region of the SCN1A mRNA disclosed herein about 20 to 50, 40 to 70, 60 to 90, 80 to 110, 100 to 130, 120 to 150, 140 to 170, 160 to 190, 170 to 200, 180 to 210, 200 to 230, 220 to 250, 240 to 300, or 280 to 500 nucleotides downstream of its stop codon. In one embodiment, the ACT-UP 1 compound, or salt thereof, targets SCN 1 A about 50 to 300, 50 to 250, 50 to 200, 50 to 150, 75 to 300, 75 to 250, 75 to 200, 75 to 150, 100 to 300, 100 to 250, 100 to 200, or 100 to 150 nucleotides downstream of its stop codon. In a preferred embodiment, the compound targets SCN1A about 50 to 200 nucleotides downstream of a stop codon. In a more preferred embodiment, the compound targets SCN1 A about 50 to 150 nucleotides downstream of a stop codon.

[0349] Embodiment 37 provides the ACT-UP 1 compound, or salt thereof, of any preceding embodiment, wherein the ACT-UP1 compound, or salt thereof, targets a region of the SHANK3 mRNA disclosed herein about 20 to 50, 40 to 70, 60 to 90, 80 to 110, 100 to 130, 120 to 150, 140 to 170, 160 to 190, 170 to 200, 180 to 210, 200 to 230, 220 to 250, 240 to 300, or 280 to 500 nucleotides downstream of its stop codon. In one embodiment, the ACT-UP 1 compound, or salt thereof, targets SH. ANK3 about 50 to 300, 50 to 250, 50 to 200, 50 to 150, 75 to 300, 75 to 250, 75 to 200, 75 to 150, 100 to 300, 100 to 250. 100 to 200, or 100 to 150 nucleotides downstream of its stop codon. In a preferred embodiment, the compound targets SHANK3 about 50 to 200 nucleotides downstream of a stop codon. In a more preferred embodiment, the compound targets SHANK3 about 50 to 150 nucleotides downstream of a stop codon.

[0350] Embodiment 38 provides the ACT-UP 1 compound, or salt thereof, of any preceding embodiment, wherein the ACT-UP 1 compound, or salt thereof, targets a region of the GB 1 mRNA disclosed herein about 20 to 50, 40 to 70, 60 to 90, 80 to 110, 100 to 130, 120 to 150, 140 to 170, 160 to 190, 170 to 200, 180 to 210, 200 to 230, 220 to 250, 240 to 300, or 280 to 500 nucleotides downstream of its stop codon. In one embodiment, the ACT-UP 1 compound, or saltthereof, targets GBA1 about 50 to 300, 50 to 250, 50 to 200, 50 to 150, 75 to 300, 75 to 250, 75 to 200, 75 to 150, 100 to 300, 100 to 250, 100 to 200, or 100 to 150 nucleotides downstream of its stop codon, In a preferred embodiment, the compound targets GBA1 about 50 to 200 nucleotides downstream of a stop codon. In a more preferred embodiment, the compound targets GBA1 about 50 to 150 nucleotides downstream of a stop codon.

[0351] Embodiment 39 provides the ACT-UP1 compound, or salt thereof, of any preceding embodiment, wherein the ACT-UP1 compound, or salt thereof targets a region of the STXBP1 mRNA disclosed herein about 20 to 50, 40 to 70, 60 to 90, 80 to 110, 100 to 130, 120 to 150, 140 to 170, 160 to 190, 170 to 200, 180 to 210, 200 to 230, 220 to 250, 240 to 300, or 280 to 500 nucleotides downstream of its stop codon. In one embodiment, the ACT-UP 1 compound, or salt thereof, targets STXBP1 about 50 to 300, 50 to 250, 50 to 200, 50 to 150, 75 to 300, 75 to 250, 75 to 200, 75 to 150, 100 to 300, 100 to 250, 100 to 200, or 100 to 150 nucleotides downstream of its stop codon. In a preferred embodiment, the compound targets STXBP1 about 50 to 200 nucleotides downstream of a stop codon. In a more preferred embodiment, the compound targets STXBP1 about 50 to 150 nucleotides downstream of a stop codon.

[0352] Embodiment 40 provides the ACT-UP 1 compound, or salt thereof, of any preceding embodiment, wherein the ACT-UP1 compound, or salt thereof, targets a region of the RAH mRNA disclosed herein about 20 to 50, 40 to 70, 60 to 90, 80 to 110, 100 to 130, 120 to 150, 140 to 170, 160 to 190, 170 to 200, 180 to 210, 200 to 230, 220 to 250, 240 to 300, or 280 to 500 nucleotides downstream of its stop codon. In one embodiment, the ACT-UP1 compound, or salt thereof, targets RAH about 50 to 300, 50 to 250, 50 to 200, 50 to 150, 75 to 300, 75 to 250, 75 to 200, 75 to 150, 100 to 300, 100 to 250, 100 to 200, or 100 to 150 nucleotides downstream of its stop codon. In a preferred embodiment, the compound targets RAH about 50 to 200 nucleotides downstream of a stop codon. In a more preferred embodiment, the compound targets RAI 1 about 50 to 150 nucleotides downstream of a stop codon.

[0353] Embodiment 41 provides an upregulation compound targeting the 5’UTR of a target mRNA, In a preferred embodiment, the upregulation compound targets GRN, SCN1 A, SHANK.3, GBA1, STXBP1, or RAH in the'’ 5’UTR of their respective raRNAs, In a more preferred embodiment, the upregulation compound is ATXL700 targeting GBA1 at a 5’uORF site.

[0354] EXAMPLESNon-limiting disclosure and incorporation-by-reference

[0355] While certain compounds,, compositions, and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds described herein and are not intended to limit the same, Each of the references recited in the present application is herein incorporated -reference in its entirety.

[0356] The following applies to all modified sequences disclosed herein.

[0357] A notation is made before or after each nucleoside indicating the type of chemical modification, if any, made to the nucleoside. If no modification notation is made before or after a letter designating a nucleoside, the nucleoside is a deoxyribonucleoside. Notations for the chemical modifications to the compounds can be found as follows:

[0358] • “m” before a nucleoside refers to a 2’-OCHj (also known as 2’-O-methyl or 2’-0Me) modification

[0359] • “e” before a nucleoside refers to a 2’-O(CH2)2OCHJ (also known as 2’-O- methoxyethyl, 2’-0-. M0E or 2 ’-MOE) modification (e.g., eG, e, el)

[0360] • “eCm” refers to a 2’-M0E modified 5 -methylcytidine

[0361] « refers to a phosphorothioate (PS) linkage which has been substituted for a phosphate (PO) linkage

[0362] • “AN-GalNAc” is a GalNAc moiety described in WO2024 / 137545.

[0363] • “PALM” is palmitic acid as shown attached to an oligonucleotide:

[0364]

[0365] If more than one sequence is disclosed in one row of the tables, the SEQ ID NO applies to the modified sequence (“Sequence + Chemistry”).

[0366] EXAMPLE 1: Design of ACT-UP1 Compounds Targeting SCN1A and Upregulation of SCN1A with the Compounds

[0367]

[0368] A novel approach is disclosed herein to treat SCN1A related diseases, disorders and / or syndromes by increasing SCNIA protein in the central nervous system (CNS) with novel compounds designed with ARNATAR’s Antisense Oligonucleotide (ASO) Coupled Translation- Upregulation 1 (ACT-UP 1) technology.

[0369] The Sodium Voltage-Gated Channel Alpha Subunit 1 (also known as SCNIA or Navi. I) gene encodes the SCNIA protein., a sodium channel with a critical role in neuronal excitability. SCNIA is primarily expressed in the brain, particularly in inhibitory GABAergic interneurons, where it regulates the generation and propagation of action potentials (Catterall, 2000, Neuron, 26(1): 13-25). Mutations in the SCNIA gene can disrupt the structure and function of the SCNIA protein (Tan et al, 2021, PNASb 118(11); e2100066118). Mutations in the SCNIA gene that disrupt SC IA protein structures can result in inhibitory interneurons, and are strongly associated with various neurological diseases, disorders and / or syndromes, including Dravet Syndrome (also known as severe myoclonic epilepsy of infancy or SME1), stroke-related neuronal dysfunction, Generalized Epilepsy with Febrile Seizures Plus (GEFS+), developmental and epileptic encephalopathies (DEEs), autism, and cognitive impairments (Weiss et al., 2003, Mol Psychiatry, 8(2): 186-94; O'Roak et al., 2011, Nature Genetics, 43(6):585-589). In patients with SCNIA mutations, restoration of the SCNIA protein and sodium channel function is desirable in order to treat SCNIA related diseases, disorders and / or syndromes such as epilepsy, Dravet Syndrome (DS), and other neuronal dysfunctions.

[0370] The ACT-UP 1 compounds described herein can treat SCNIA related diseases, disorders and / or syndromes by enhancing SCNIA expression. For example, about 85% of Dravet Syndrome patients have SCNIA mutation in one allele and a wild-type allele. ACT-UP1 compounds can enhance SCNIA expression through the wild-type allele.

[0371] Human SCNIA transcript (Table 1 ) was targeted by compounds with ACT-UP! designs.

[0372] Table 1: SCNIA Target Sequence

[0373]

[0374] Seven compounds with ACT-UP 1 designs and targeting human SCNIA mRNA (SEQ ID NO: 1; Table 2) were pre-screened in cells for activity, The compounds designed were 26nucleotides (nts) in length. Of those 26 nts, a 10 nt long component comprises a protein recruiting sequence (PRS) and a 16 nt long component comprises an antisense oligonucleotide (ASO) that targets SC 1 A mRNA. The sequence and chemistry of the compounds are shown in Table 2, with the PRS bolded and underlined.

[0375] Compounds ATXL653, ATXL654, and ATXL655 are AC-T-UPl compounds that target the 3’UTR of SCNIA, while compounds ATXL651, ATXL652, ATXL656, and ATXL657 are ACT-UP 1 compounds that also target the potential binding sites of miR-30, miR-223, miR-133, and miR-203, respectively, in the 3'UTR. The dual acting compounds (i.e., ACT-UP 1 design and targeting a miRNA binding site), may serve as dual functional modulators of SNC I A by increasing translation of SCNIA protein by: 1) recruitment of proteins involved in translation via the PRS component of the ACT-UP1 design, and 2) inhibiting miRNA binding to SCNI mRNA thereby increasing the amount of SCNIA mRNA available for translation. The compounds were synthesized with a Mermade 48 (LGC Biosearch Technologies, Hoddesdon, UK) and purified. The activities of these compounds were further evaluated in vitro through single-dose or dose- response studies.

[0376] Table 2. Sequence and Chemistry of SCNIA Compounds

[0377]

[0378]

[0379] HepG2 cells, derived from human liver and expressing SCN1A protein, were seeded and grown for one day to -70% confluency, then transfected with the compounds listed in Table 2 using Lipofectamine! M2000 Transfection Reagent (ThennoFisher Scientific, Waltham, MA, USA), or were mock transfected as a control. Figure I A shows transfection of the compounds with a single dose of 50 nM final concentration, and then SCN1 A mRNA levels were assessed twenty- four (24) hours after transfection. Figure IB shows transfection of the compounds in a dose¬ response assessment with doses of 0,9, 2.8, 8.3, 25, and 75 nM, and then SONIA mRNA levels were assessed seventeen (17) hours after transfection. At 17 or 24 hrs after transfection, cells were harvested, and total RNA was prepared using Qiagen’s RNeasy mini kit (Qiagen, Hilden, Germany), and the level of SCN1A mRNA was determined using quantitative real-time PCR (qRT-PCR), using human SCN1A specific TaqMan primer probe sets (Assay ID: Hs00374696_ml, ThermoFisher Scientific, Waltham, MA, USA). qRT-PCR was performed using AgPath-ID™ One-Step RT-PCR Reagents in QS3 real-time PCR system (ThennoFisher Scientific, Waltham, MA, USA). The SC-N1A mRNA levels detected by the qRT-PCR assay were normalized to total RNA levels measured with Ribogreen1 M(ThermoFisher Scientific, Waltham, MA, USA) in the aliquots of the corresponding RNA samples. The mRNA levels after transfection with the compounds are shown in Figure 1, Table 3, and 'Table 4, relative to the amount of SCN1A mRNA in mock transfected cells.;

[0380] Table 3. SCN1A mRNA Levels in HepG2 Cells Transfected With Different Compounds

[0381]

[0382] Table 4. SCN1 A mRNA Levels in HepG2 Cells Transfected with Compounds at Different Doses

[0383]

[0384]

[0385] The results show that SCN 1 A targeting compounds with ACT-UP 1 design, with or without also targeting a putative miRNA site, can increase SCN1 A mRNA levels in HepG2 cells at 50nM dose (Table 3). This upregulation of SCN1 A mRNA is confirmed with a dose-dependent assay in HepG2 cells (Table 4).

[0386]

[0387] HepG2 cells were seeded and grown for one day to -70% confluency, then transfected with the compounds listed in Table 2 at 7.5 nM or 15 nM final concentrations using Lipofectamine, M2000 Transfection Reagent (ThermoFisher Scientific, Waltham, MA, USA), or were mock- transfected as a control. Twenty-four (24) hours after transfection, cells were harvested and lysed; then the protein was extracted using RIP A Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA, USA), The level of SCN1A protein was determined by Western Blot, using an SCN1A specific antibody (ProteinTech, Rosemont, IL, USA: Catalog #PT28079-l-AP). The Western Blot results are shown in Figure 2. The Western Blot image was quantified using ImageJ, normalized to a loading control protein, GAPDH, and detected using a GAPDH-specific antibody (Santa Cruz Biotech, Dallas, TX, USA; Catalog #SC47724). The percentages of SCN1 A protein levels relative to mock-transfected cells were calculated and shown In Table 5.

[0388] Table 5. SCN1A Protein Levels in HepG2 Cells Transfected with 7.5 and 15 nM of Compounds i Compound (7.5;;nM CN 1 A Protein Level % i (. Mock! _ 92.0 j. Mock2. 108.0 i

[0389]

[0390]

[0391] The results show that six of the seven tested compounds (ATXL651, ATXL652, ATXL654, ATXL655, ATXL656, and ATXL657) can upregulate SCNI A protein in HepG2 cells by about 1.5-3 fold at the two doses assessed (7.5 nM and 15 nM), as shown in Figure 2 and Table 5.

[0392]

[0393] To test if the ACT-UP 1 SCNI A compounds can also increase SCNI A in different human cells in addition to HepG2, human neuroblastoma SH-SY5Y cells were seeded and grown in one day to -70% confluency, then transfected with the compounds listed in Table 2 at 7.5 nM and 15 nM final concentration using LipofectamineTM2000 Transfection Reagent (ThermoFisher Scientific, Waltham, MA, USA), or were mock transfected as a control. Twenty-four (24) hours after transfection, cells were harvested and lysed, then the protein was extracted using RJPA Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA, USA). The level of SCNI A protein was determined by Western Blot, using a SCNI A specific antibody (Antibodies Incorporated, Davis, CA, USA; Catalog #75-023). The Western Blot results are shown in Figure 3, The Western Blot image was quantified using Image), normalized to a loading control protein, a-Tubulin, and detected using an a-TUBULIN-specific antibody (Abeam. Cambridge, UK; Catalog #ab7291). The percentages of SCNI A protein levels relative to mock-transfected cells were calculated and shown in Table 6.

[0394] Table 6. SCNI A Protein Levels in SH-SY5Y Cells Transfected with 7,5 nM and 15 nM of Compounds

[0395]

[0396]

[0397]

[0398] The results show that live ASOs (ATXL653-ATXL657) can upregulate SCN1A protein in SH-SY5Y cells about 1.5-2.3 fold at two different doses (7,5 nM and 15nM) as shown in Figure 3 and Table 6.

[0399]

[0400] The ACT-UP 1 compounds described in Table 2 target SCN1A mRNA sites, which are conserved across humans, monkeys, rats, and mice. To determine if the compounds can increase SCN1A in other species, rat nerv Ms tissue neuronal cells, B50,_were seeded and grown for one day to ~70% confluency, then incubated with the compounds listed in Table 2, at 2 p. M final concentration without Transfection Reagent or were mock (HzO) treated as a control. Sixty-four (64) hours after incubation, cells were harvested and lysed, then the protein was extracted using R. IPA Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA, USA). The level of SCN1 protein was determined by Western Blot, using an SCN1A specific antibody (Antibodies Incorporated, Davis, CA, USA; Catalog #75-023), The Western Blot results are shown in Figure 4. The Western Blot image was quantified using ImageJ, normalized to a loading control protein, GAPDH, detected using a GAPDH-specific antibody (Santa Cruz Biotech, Dallas, TX, USA; Catalog #SC47724). The percentages of SCN1A protein levels relative to mock cells were calculated and shown in Table 7.

[0401] Table 7. SCN1 A Protein Levels in B50 Cells After Free Uptake with 2p. M of Compounds

[0402]

[0403]

[0404] The results show that five ASOs (ATXL65I and ATXL654-ATXL657) can upregulatc SCN 1 protein in rat neuronal B50 Cells about 1.2- 1.5 fold at the 2 pM dose by free uptake, which more mimics the situation m vivo, as shown in Figure 4 and Table 7,

[0405] S'UA'Ll ’ ti'tti w,ln I ptv^ii iiahti \lntifie fk'ptil Cell'* h) fhe M' I C< ir>t>w*i The ACT-UP1 compounds described in Table 2 target SCNIA mRNA sites, leading to increased SCNIA protein expression in both human and rat cell lines. These target sites are conserved across humans, monkeys, rats, and mice, To evaluate whether the compounds could also enhance SCNIA expression in other species, mouse Hepal-6 cells were tested for SCNIA protein levels following transfection with the compounds. Hepal-6 cells were seeded and grown for one day to -70% confluency, then transfected with the compounds at 7.5 nM and 15 nM final concentrations using Lipofectamine, M2000 Transfection Reagent (ThermoFisher Scientific, Wallham, MA), or were mock-transfected as a control. Twenty-four (24) hours after transfection, cells were harvested and lysed, then the protein was extracted using R1PA Lysis and Extraction Buffer (ThermoFisher Scientific',’ Waltham, MA, USA). The level of SCNIA protein was determined by Western Blot, using a SCNIA specific antibody (ProteinTech, Rosemont, IL, USA; Catalog #PT28079-l-AP). The Western Blot results are shown in Figure 5. The Western Blot image was quantified using Image,!, normalized to a loading control protein, HSP90, and detected using an HSP90-specific antibody (ProteinTech, Rosemont, IL, USA; Catalog #13171 -1 -AP). The percentages of SCNIA protein levels relative to mock- transfected cells were calculated and shown in Table 8.Table 8. SCN1A Protein Levels in Murine Hepal -6 Cells Transfected with 7.5 nM or 15 nM of Compounds

[0406]

[0407] The results show that six compounds (ATXL651-ATXL656) can upregulate SCN1A protein in Hepal -6 cells by about 1.5-2 fold at the two doses assessed (7.5nM and 15nM), as shown in Figure 5 and Table 8.

[0408] In conclusion, the ACT-UP 1 -designed compounds disclosed in Table 2, whether also targetin a putative rniRN A site or not, can increase SCN 1 A mR A and / or protein levels in human hepatoma cells (HepG2), human neuroblastoma cells (SH-SY5Y), rat neuronal cells (B50), and murine hepatoma cells (Hepal -6), The ACT-UP 1 compounds that also target miRNA can have a dual functional mechanism for upregulating SCN1A: 1) the ACT-UP 1 mechanism of recruiting translation proteins to close proximity of the SCN1A mRNA, and 2) interfering with miRNA modulation of the SCN1A mRNA, Both single functional (ACT-UP I design only) or dual functional (ACT-UP I design pl ^'miRNA targeting) compounds could increase SCN1A protein to therapeutic levels for SCN1A related insufficiency diseases.EXAMPLE 2: Design of ACT-UP1 Compounds Targeting GRN mRNA and Upregulation of PGRN Protein with the Compounds

[0409] A novel approach is disclosed herein to increase granulin precursor (PGRN) protein in the CNS with novel compounds designed with ARNATAR’s Antisense Oligonucleotide (ASO) Coupled Translation - Upregulation 1 (ACT-UP1) technology,

[0410] Granulin precursor (also known as progranulin, PGRN, and GRN), encoded by the GRN gene, is a secreted glycoprotein that has a critical role in maintaining neuronal and immune system homeostasis, Loss-of-function mutations in GRN result in a spectrum of neurodegenerative diseases; for example, homozygous mutations lead to neuronal ceroid lipofuscinosis (NCL) type 11, a lysosomal storage disorder characterized by early -onset dementia, epilepsy, and rapid progression to death, while heterozygous mutations cause frontotemporal dementia associated with GRN (FTD-GRN).

[0411] The protein encoded by GRN, PGRN, exerts its effects through multiple mechanisms, including the regulation of lysosomal biogenesis and function, modulation of neuroinilammatory responses, and promotion of neuronal survival and repair (Rhinn et al., 2022, Trends Pharmacol Sci, 43(8):641 -652; Toh et al., 2011, J Mol Neurosci, 45(3):538~48; Cui et al., 2019, Cytokine Growth Factor Rev, 45:53-64; Simon e al., 2023, Trends Cell Biol, 33(4), ’324-339), PGRN deficiency disrupts lysosomal homeostasis, leading to impaired protein degradation, neuroinflammation, synaptic loss, and neuronal death. Microglial hyperactivation and astrogliosis are hallmark features of PGRN insufficiency, further driving neurodegeneration. Additionally, PGRN regulates autophagy and lipid metabolism, and its loss is associated with the accumulation of toxic protein aggregates and lipid imbalances (Chang et al., 2017, J Exp Med, 214(9):2611- 2628). Reduced PGRN levels have been implicated in several central nervous system (CNS) related diseases (e.g., frontotemporal dementia associated with GRN (FTD-GRN), Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and limbic- predominant age-related TDP-43 encephalopathy (LATE), underscoring its central role in brain health, while over-expression of PGRN shows protective effects in different disease models, such as those for AD, PD, and. ALS (Rhinn et al., 2022, Trends Pharmacol Sci, 43(8):641-652; Simon et al, 2023, Trends Cell Biol, 33(4):324-339). The unique biological properties of PGRN make it an attractive therapeutic target. “ tThe ACT-UP 1 compounds described herein can treat PGRN related diseases, disorders and / or syndromes by enhancing PGRN expression. In patients with PGRN mutations, increasing PGRN protein levels may restore lysosomal function, reduce neuroinflammation, and prevent neuronal loss. For example, heterozygous mutations cause frontotemporal dementia associated with GRN (FTD-GRN), a late-onset neurodegenerative disease with nearly complete penetrance by age 80. ACT-UP 1 compounds can enhance PGRN expression through the wild-type allele of GRN.

[0412] Human GRN transcript (Table 9) was targeted by compounds with ACT-UP1 designs.

[0413]

[0414] Several compounds with ACT-UP 1 designs and targeting human GRN mRN. (SEQ ID NO: 2; Table 9) were pre-screened in cells for activity. The compounds designed were 27 nucleotides (nts) in length. Of those 27 nts, a 10 nt long component comprises a protein recruiting sequence (PRS) and a 17 nt long component comprises an antisense oligonucleotide (ASO) that targets GRN mRNA. The sequence and chemistry of the compounds are shown in Table 10, with the PRS bolded and underlined. The compounds were synthesized with a Mermade 48 (LGC Biosearch Technologies, Hoddesdon, UK) and purified. The activities of these compounds were further evaluated in vitro through single-dose or dose-response studies.

[0415] Table 10. Sequence and Chemistry of GRN Targeting Compounds

[0416]

[0417]

[0418]

[0419] Human U937 cells (a pro-monocytic leukemia cell line; ATCC, Manassas, VA, USA), expressing PGRN protein, were seeded and grown for one day to -70% confluency, then transfected with the compounds listed in Table 10 using Lipofectamine 2000 Transfection Reagent (ThermoFisher Scientific* Waltham, MA, USA). For controls, an ACT-UP 1 compound not targeting CRN (negative control, NC) was transfected into the cells, or the cells were mock transfected, A single dose of 15 nM final concentration was transfected into the cells, twenty-four (24) hours after transfection, cells were harvested, and then the protein was extracted using RIP A Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA, USA; Catalog #J63306. AP). The level of PGRN protein was determined by Western Blot, using a PGRN specific antibody (R& D Systems, Minneapolis, MN, USA; Catalog & AF2420). The Western Blot results are shown in Figure 6. The Western Blot image was quantified using ImageJ, normalized to a loading control protein, GAPDH, and detected using a GAPDH-specific antibody (Santa Cruz Biotech, Dallas, TX, USA; Catalog & SC47724). The percentages of PGRN protein levels relative to mock-transfected cells were calculated and shown in Table 11.

[0420] Table 11. PGRN Protein Levels in U937 at 24 hours after a Single 15 nM Dose Transfection

[0421]

[0422]

[0423] The results show that the three compounds (ATXL489, ATXL490, and ATXL491) can upregulate PGRN protein in U937 cells about 3-fold after a single dose (15nM) (Figure 6 and Table 11).

[0424]

[0425] Human U937 cells were transfected with varying doses (5 nM, 10 nM, 20 nM, 40 nM, and 80 nM) of compounds using LipofectamineTM2000 Transfection Reagent (ThermoFisher

[0426] Scientific, Waltham, MA, USA) according to the manufacturer’s recommended protocol, and the cells were further cultured for twenty-four (24) hours. Subsequently, total protein was extractedfrom the cells using RIP A Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA, USA; Catalog J63306. AP) supplemented with ImM DTT and protease and phosphatase inhibitors (ThermoFisher Scientific, Waltham, MA, USA: Catalog #1861282), After centrifugation (12000 x rpm, 4°C, 30 minutes), protein lysate (supernatant) was collected for Western Blotting. The level of PGRN protein was determined by Western Blot, using a PGRN specific antibody (R& D Systems, Minneapolis, MN, USA; Catalog & AF2420). The Western Blot results are shown in Figure 7. The Western Blot image was quantified using ImageJ, normalized to a loading control protein, GAPDH, and detected using a GAPDH-specific antibody (Cell Signaling Technology, Danvers, MA, USA; Catalog #5174). The percentages of PGRN protein levels relative to mock-transfected cells were calculated and shown in Table 12,

[0427] Table 12. PGRN Protein Levels in U937 Cells Transfected with Compounds at Different Doses

[0428] PGRN Protein Relat

[0429]

[0430]

[0431] The results show that the compounds ATXL489 and ATXL491 can upregulate PGRN protein in U937 cells after transfection in a dose-dependent fashion, Figure 7 and Table 12.

[0432]

[0433] EXAMPLE 3: Design of GalNAc-Conjugated ACT-UP1 Compounds Targeting GRN and In Vivo Assessment of the Compounds

[0434] To evaluate the in vivo activity of the potent ACT-UP 1 compounds disclosed in Example 2, a GalNAc moiety (AN-GalNAc, a GalNAc moiety described in WO2024137545) was conjugated to ATXL489 and ATXL491, of which the GRN mRNA binding sites are highly conserved between human and mouse, generating compounds ATXL566 and ATXL568, respectively. The new compounds are listed in Table 13 with the PRS bolded and underlined.

[0435] Table 13, Sequence and Chemistry of GalNAc Conjugated ACT-UP 1 Compounds Targeting GRN

[0436]

[0437]

[0438] To determine if ATXL566 and ATXL568 can increase PGRN protein levels in mouse plasma or liver, 7-8 week-old BALB / c mice were injected subcutaneously with 3 mg / kg, 9 mg / kg or 75 mg / kg on Day 1 and Day 4. Phosphate-buffered saline (PBS) was injected as a negative control, A schematic of the dosing regimens is shown in Figure 8 (PGRN assessment in liver) or Figure 8 (PGRN assessment in plasma).

[0439] Mice were sacrificed 8 days after the first dose, and blood and liver samples were collected. About 300-500 pL of blood was collected in heparin anti coagulation tubes. Blood samples were kept on ice for 30 min, then centrifuged at 4°C, 2000 x g for 20 minutes, and then the supernatant plasma was collected. Total proteins from the liver tissue samples were extracted using RIP Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA, USA; Catalog #J63306. AP) and homogenization by grinding using Bead Mill 24 (FisherBrand, ThermoFisher Scientific, Waltham, MA, USA; Catalog #15340163) and 1,4mm ceramic beads (FisherBrand, ThermoFisher Scientific,Waltham, MA, USA; Catalog #15-340-153). Total protein levels isolated from the blood and liver were subjected to ELISA assay. In accordance with the instructions of the PGRN ELISA Kit ( R& D Systems, Minneapolis, MN, USA; Catalog #MPGRN0), PGRN protein levels were determined. Liver PGRN protein levels in treated mice relative to those in PBS control mice are shown in Figure 8. Blood PGRN protein levels in treated mice relative to those in PBS control mice are shown in Figure 9. The average relative levels of PGRN protein in blood and liver are shown in Table 14.

[0440] Table 14. Plasma and Liver PGRN Protein Levels after ACT-UP1 Compound Treatment

[0441]

[0442] The results show that at 3 or 9 mg / kg (Figure 8), ACT-UP 1 compounds ATXL566 and ATXL568 demonstrated efficacy on PGRN upregulation in the liver, while at 75 mg / kg (Figure 9), PGRN in plasma can be enhanced by ATXL568. Collectively, these results showed that the compounds can increase PGRN in vitro and in vivo.

[0443] EXAMPLE 4: 1 / ? Vlv& Activity of ACT-UP1 Compounds Targeting GRN in the CNS

[0444] r -■,

[0445] To evaluate the activity of ACT-UP 1 compounds targeting GRN in the central nervous system (CNS), ACT-UP1 compounds ATXL489 and ATXL491, previously disclosed in Table 10, were tested in rats. The mRNA target sites of these compounds are conserved between humans and rats.Seven to eight-week-old Sprague-Dawley (SD) rats were injected intrathecally with 100 μg of ATXL489 or ATXL491 in 30pi of Phosphate-buffered saline (PBS). PBS was injected into rats as a negative control. A schematic of the dosing regimens is shown in Figure 10. Functional Observatory Battery (FOB) scores were assessed at 2 hours and 6 hours after administration (Moser et al., 1990, Neurotoxicology and Teratology 12:89-104).

[0446] Mice were sacrificed 10 days after the intrathecal injection, and blood, spinal cord (lumbar, cervical), and brain samples (cerebral cortex, hippocampus, cerebellum, brainstem) were collected. About 300-500pL of blood was collected in heparin anticoagulation tubes. Blood samples were kept on ice for 30 min, then centrifuged at 4°C, 2000 x g for 20 min, and the supernatant plasma was collected. CNS samples were dissected before snap freezing. Total protein from the CNS tissue samples were extracted using RIPA Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA, USA; Catalog #163306, AP) and homogenization by grinding using Bead Mill 24 (FisherBrand, ThermoFisher Scientific, Waltham, MA, USA; Catalog #15340163) and 1.4mm ceramic beads (FisherBrand, ThermoFisher Scientific, Waitham, MA, USA; Catalog #15-340- 153).

[0447] After centrifugation (12000 x rpm, 4°C, 30 minutes), protein lysate (supernatant) was collected for Western Blotting. The level of PGRN protein from the plasma and CNS samples was determined by Western Blot, using a PGRN specific antibody (Protein’Tech, Rosemont, IL, USA: Catalog #18410-I-AP). The Western Blot results are shown in Figure 11. The Western Blot image was quantified using ImageJ, normalized to loading control protein GAPDH, and detected using a GAPDH-specific antibody (Sigma-Aldrich, St. Louis, MO, USA: Catalog #G8795), or normalized to loading control protein HSP90 and detected using a HSP90-specific antibody (ProteinTech, Rosemont, IL, USA: Catalog #13171-1-AP). The percentages of PGRN protein levels in ATXL489 or ATXL491 treated rats, relative to PBS-treated rats, were calculated and shown in Table 16 and Figure 11,

[0448] Table 15. PGRN Protein Levels in Various CNS Tissues and Plasma of Rats

[0449]

[0450]

[0451]

[0452] The results show that ACT-UP 1 compounds ATXL489 and ATXL491 upregulated PGRN expression in almost all tested CNS tissues and plasma in rats when delivered intrathecally.

[0453] EXAMPLE 5: In Vivo Dose Response Activity of ATXL491 Targeting CRN in the CNS

[0454] To further evaluate the activity of an ACT-UP 1 compound targeting GRN in the central nervous system (CNS), ACT-UP1 compound ATXL491, previously disclosed in Table 10, was tested in a dose response study in rats.

[0455] Seven to eight-week-old Sprague-Dawley (SD) rats were treated by intrathecal injection of lOOpg, 300p.g, or 900pg of ATXL491 in 30pl of phosphate-buffercd saline (PBS). PBS (30pl) was injected into rats as a negative control. A schematic of the dosing regimens is shown in Figure 12A.

[0456] The rats were assessed 3 hours after injection and given an Acute Tolerability Score (Miller et al., Molecular Therapy Nucleic Acids, 2024 Dec, 35(4), 102359). No rats were adversely affected by the treatment.

[0457] Ten (10) days after treatment, rats were sacrificed, and central nervous system (CNS) samples were collected (spinal cord samples from the lumbar and cervical regions, and brain samples from the cerebral cortex, hippocampus, cerebellum, and brainstem). CNS tissue samples were dissected and snap frozen. Total protein from the CNS tissue samples were extracted using RIPA Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA, USA; Catalog #J63306.AP) and homogenization by grinding using Bead Mill 24 (FisherBrand, ThermoFisher Scientific, Waltham, MA, USA; Catalog #15340163) and 1.4mm ceramic beads (FisherBrand, ThermoFisher Scientific, Waltham, MA, USA; Catalog #15-340-153).

[0458] After centrifugation (12000 x rpm, 4°C, 30 minutes), protein lysate (supernatant) was collected for Western Blotting. The level of PGRN protein from the plasma and CNS samples was determined by Western Blot, using a PGRN specific antibody (ProteinTech, Rosemont, IL, USA; Catalog #18410-1-AP). The Western Blot results, not shown, were quantified using ImageJ,

[0459]

[0460] normalized to loading control protein GAPDH, and detected using a GAPDH-specific antibody (Sigma- Aldrich, St. Louis, MO, USA; Catalog #G8795), or normalized to loading control protein HSP90 and detected using a HSP90-specific antibody (ProteinTech, Rosemont, IL, USA; Catalog #13171-1 -AP). The percentages of PGRN protein levels in ATXL491 treated rats, relative to PBS- treated rats, were calculated and shown in Table 16 and Figure 12B.

[0461] Table 16. Dose Response of PGRN Protein Levels in Rat CNS Tissues

[0462]

[0463] The results show that ACT-UP 1 compound ATXL491 upregulated PGRN expression in all tested CNS tissues in rats when delivered intrathecally.EXAMPLE 6: In Vivo Time Course Study of ATXL491 Targeting GRN in the CNS

[0464] To evaluate the activity over time of an ACT-UP I compound targeting GRN in the central nervous system (CNS), ACT-UP1 compound ATXL491, previously disclosed in Table 10, was tested in a time course study in rats.

[0465] Seven to eight-week-old Sprague-Dawley (SD) rats were treated by intrathecal (IT) injection of 300pg of ATXL491 in 30ul phosphate-buffered saline (PBS). PBS (,30pI) was injected into rats as a negati ve control. A schematic of the dosing regimens is shown in Figure 13 A.

[0466] The rats were assessed 3 hours after injection and given an Acute Tolerability Score (Miller et ah, Molecular Therapy Nucleic Acids, 2024 Dec, 35(4), 102359). No rats were adversely affected by the treatment.

[0467] At varying times (15 days, 28 days, 42 days, and 56 days after treatment), rats were sacrificed and central nervous system (CNS) samples were collected (brain samples from the cerebral cortex, hippocampus and cerebellum). CNS tissue samples were dissected and snap frozen. Total protein from the CNS tissue samples were extracted using RIPA Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA, USA; Catalog #J63306.AP) and homogenization by grinding using Bead Mill 24 (FisherBrand, ThermoFisher Scientific, Waltham, MA, USA; Catalog #15340163) and 1.4mm ceramic beads (FisherBrand, ThermoFisher Scientific, Waltham, MA, USA; Catalog #15-340-153).

[0468] After centrifugation (12000 x rpm, 4°C, 30 minutes), protein lysate (supernatant) was collected for Western Blotting. The level of PGRN protein from the plasma and CNS samples was determined by Western Blot, using a PGRN specific antibody (ProteinTech, Rosemont, IL, USA; Catalog #18410-1 -AP). The Western Blot results, not shown, were quantified using ImageJ, normalized to loading control protein GAPDH, and detected using a GAPDH-specific antibody (Sigma-Aldrich, St. Louis, MO, USA; Catalog #G8795), or normalized to loading control protein HSP90 and detected using a HSP90-specific antibody (ProteinTech, Rosemont, IL, USA; Catalog # 13171 -1 -AP). The percentages of PGRN protein levels in ATXL491 treated rats, relative to PBS- treated rats, were calculated and shown in Table 17 and Figure 13B.

[0469] ■

[0470]

[0471] Table 17. Time Course of PGRN Protein Levels in Rat CNS Tissues

[0472]

[0473] The results show that ACT-UP 1 compound ATXL491 upregulated PGR. N expression for at least 42 days in the CNS tissues when delivered intrathecally.

[0474] EXAMPLE 7: Design of ACT-UP1 Compounds Targeting GBAl and Upregulation of GBAl with the Compounds

[0475] Disclosed herein are novel compounds targeting glucosylceramidase beta 1 (GBAl) for treating GBAl related diseases, disorders and / or syndromes by increasing GBA1 protein with the compounds targeting GB A 1.

[0476] The GBAl gene encodes the lysosomal enzyme glucoeerebrosidase (GCase) protein (also known as lysosomal acid glucosylceramidase and also known herein as the GBAl protein). Mutations in GBAl have been linked to multiple diseases, disorders and / or syndromes such as, for example, Gaucher disease. Parkinson’s disease (PD), and Dementia with Lewy bodies (DLB), also known as Lewy body dementia (LBD) (Rossi et al., Movement Disorders, 2025 Apr, 40(4):605- 618; Young Eun Huh el al., J Mov Disord, 2023 Sep, 16(3):261 -278; Kim D et al., Acta Neuropathologica Communications, 2018 Apr 27, 6(1):32). The novel GNA1 compounds described herein can treat such GBAl related diseases, disorders and / or syndromes by enhancing GBAl expression.

[0477] Human GBAl transcript (Table 19) was targeted by compounds with ACT-UP 1 designs,Table 18: GBAI Target Sequence

[0478]

[0479] Compounds targeting human GBAI mRNA (SEQ ID NO: 4; Table 18) were designed and pre-screened in cells for activity. Twelve (12) active compounds were selected for further study.

[0480] Compound ATXL700 targeting GBAI was designed to target a site in the 5’ upstream open reading frame (uORF) of GBAI mRNA that inhibits translation of the open reading frame (ORF). When the inhibitor effect of the uORF site on GBAI translation is reduced or blocked, GBAI expression can increase.

[0481] Compounds ATXL702, ATXL-703, ATXL704, and ATXL801-807 were designed with ARNATAR’s Antisense Oligonucleotide (ASO) Coupled Translation - Upregulation 1 (ACT- UP 1) technology to target the 3’ untranslated region (3' UTR) of GBAI mRNA. The ACT-UP 1 compounds targeting GBAI can enhance translation by recruiting translation protein(s) to GBAI mRNA.

[0482] Compound ATXL701 was designed as a dual-functional compound (i.e,, with an ACT- UP 1 design and also targeting the miR-365 binding site in the 3’ UTR of GBAI mRNA). It may serve as a dual functional modulator of GBAI by increasing translation of GBAI protein by; 1) recruiting proteins involved in translation via the PRS component of the ACT-UP 1 design, and 2) inhibiting miRNA binding to GBAI mRNA, thereby increasing the amount of GBAI mRNA available for translation.

[0483] The compounds were synthesized with a Mennade 48 (LGC Biosearch Technologies, Hoddesdon, UK) and purified, The activities of these compounds were further evaluated in vitro through single-dose or dose-response studies.

[0484] The sequence and chemistry of the compounds are showm in Table 19, with the PRS component of ACT-UP 1 compounds bolded and underlined.

[0485] The GBAI mRNA target sites for compounds AT L700-ATXL704 and ATXL801-ATXL804 are conserved across human and monkey. Compounds ATXL8O5-ATXL8O7 were specifically designed to target mouse GBAI mRNA and have 4, 3, and 5 mismatches, respectively, to the corresponding human GBAI target site.Table 19. Sequence and Chemistry of GBAI Compounds

[0486]

[0487]

[0488]

[0489]

[0490] fy iM D se Re^onse Assay A>r t H! rnRA'A Levels in Human SH-SY5Y Cells

[0491] To evaluate the efficacy of GBA 1 compounds targeting GBA1 mRNA in increasing GBA1 expression, selected compounds disclosed in Table 19 were tested in an in vitro dose response study in SH-SY5Y cells.

[0492] SH-SY5Y cells, derived from human neuroblastoma cells, were seeded and grown for one day to ~70% confluency, then transfected with the compounds listed in Table 19 using Lipofectamine™ 2000 Transfection Reagent (ThermoFisher Scientific, Waltham, MA, USA), or were mock-transfected as a control. SH-SY5Y cells were transfected with the compounds in a dose-response assessment with doses of 0.9 nM, 2.8 nM, 8.3 nM, 25 nM, and 75 nM, then GBA1 mRNA levels were assessed twenty-four (24) hours after transfection. At 24 hrs after transfection, cells were harvested, and total RNA was prepared using Qiagen’s RNeasy mini kit (Qiagen, Hilden, Germany), and the level of GBA1 mRNA was determined using quantitative real-timePCR (qRT-PCR), using human GBiAl specific TaqMan primer probe sets Table 20, qRT-PCR was performed using AgPath-ID™ One-Step RT-PCR Reagents in QS3 real-time PCR system (ThermoFisher Scientific, Waltham, MA, USA), The GBA1 mRNA levels detected by the qRT-PCR assay were normalized to total RNA levels measured with Ribogreen™ (ThermoFisher Scientific, Waltham, MA, USA) in the aliquots of the corresponding RNA samples, The mRNA levels after transfection with the compounds are shown in Figure 14, relative to the amount of GBAl mRNA in mock- transfected cells,

[0493] Table 20. Primer Probe Set Used to Detect GBAl mRNA Levels in SH-SY5Y Cells

[0494]

[0495] The results show that GBAl targeting compounds with ACT-UP 1 design, with or without also targeting a putative miRNA site, didn’t dramatically increase GBAl mRNA levels in SH-SY5Y cells at different dose levels (Table 21) (<20% increase). The results showed that GB l upregulation may not be at the mRNA level.

[0496] Table 21. GBAl mRNA Levels in SH-SY5Y Cells Transfected with Compounds at Different Doses

[0497]

[0498]

[0499] The compounds disclosed ih Table 19 are ACT-UP 1 compounds except for ATXL700. ACT-UP1 compounds comprise an antisense oligonucleotide (ASO) component targeting GBA1 mRNA joined to a protein recruiting sequence (PRS) component. ATXL700 is not an ACT-UP1 compound because it does not have a PRS component.

[0500] Select, compounds from Table 19 have a 100% sequence conservation of their GBA1 ASO target sites between human and monkey: ATXL700-ATXL704 and ATXL801 -ATXL804. Those compounds were tested in monkey cells.

[0501] Monkey Cosl cells were seeded and grown for one day to ~70% confluency, then transfected with the selected compounds chosen from those in Table 19 at 15 nM fipal concentrations using LipofectamineTM2000 Transfection Reagent (ThermoFisher Scientific, Waltham, MA, USA), or were mock-transfected as a control. Twenty-four (24) hours after transfection, cells were harvested and lysed; then the protein was extracted using RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific, Waltham, MA, USA). The level of GBA1 protein was determined by Western Blot, usin ’a GB 1 specific antibody (Abeam, Cambridge, UK: Catalog #AB55080). The Western Blot results are shown in Figure 15. The Western Blot image was quantified using Image), normalized to a loading control protein, Beta-ACTIN, and detected using an actin-specific antibody (Cell Signaling Technology, Danvers, MA, USA; Catalog #4970L). The percentages of GBA1 protein levels relative to mock-transfected cells were calculated and shown in Figure 15B and Table 22.

[0502] Table 22. GBA1 Protein Levels in Cosl Cells Transfected with 15 nM of Compounds

[0503]

[0504] The results show that ATXL700, ATXL701, ATXL801, ATXL803, and ATXL804 can distinctly upregulate GBA1 protein in Cosl cells at 15nM transfection, as shown in Figure 15 and Table 22.

[0505] In Vitro Dose Response Assay for GBA1 Protein LevelJn Monhey Cpsl Cells

[0506] To further confirm the upregulation seen in the single dose study above, four (4) conserved compounds (ATXL700, ATXL701, ATXL8O3, and ATXL804) were assessed in monkey Cosl ceils at varying doses. A compound,. ATXL805, targeting mouse GBA1 mRNA with 5 mismatches to monkey was also assessed.

[0507] Monkey Cos! cells were seeded and grown for one day to -70% confluency, then transfected with the selected compounds chosen from those in Table 19 at 0, 5, 10, 20, 40, and 80 nM final concentrations using LipofectamineTM2000 Transfection Reagent (ThermoFisher Scientific, Waltham, MA, USA), or were mock-transfected as a control. Twenty-four (24) hours after transfection, cells were harvested and lysed; then the protein was extracted using RJPA Lysis and Extraction Buffer (TherrnoFisher Scientific, Waltham, MA, USA). The level of GBA1 protein was determined by Western Blot, using a GBA1 -specific antibody (Abeam, Cambridge, UK; Catalog #AB55080). The Western Blot results are shown in Figures 16A and 17A. The Western Blot image was quantified using ImageJ, normalized to a loading control protein, GAPDH, and detected using a GAPDH-specifm antibody (Santa Cruz Biotech, Dallas, TX, USA; Catalog #SC47724). The percentages of GBA1 protein levels relative to mock-transfected cells were calculated and shown in Figures 16B, 17B, and Tabic 23.

[0508] Table 23. GBA1 Protein Levels in Cost Celis Transfected by Compounds

[0509]

[0510] The results show that ATXL700, ATXL701, ATXL803, ATXL804, and ATXL8O5 can upregulate GBA1 protein in Cost cells by transfection at different doses, as shown in Figures 16- 17 and Table 23.

[0511]

[0512] To determine if ACT-UP1 compounds targeting GBA1 rnRNA can increase GBA1 protein levels in mouse liver, 7-8 week-old BALB / c mice were injected subcutaneously with 7.5 mg / kg of selected compounds (ATXL701, ATXL702, ATXL801, ATXL8O3. ATXL8O5, and ATXL807) on Day 1 and Day 3. Phosphate-buffered saline (PBS) was injected as a negative control. A schematic of the dosing regimens is shown in Figure 18 A.

[0513] Mice were sacrificed 10..- ays after the first dose, and liver and kidney samples were collected. Total proteins from the liver or kidney tissue samples were extracted using RIPA Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA, USA; Catalog #163306, AP) and homogenization by grinding using Bead Mill 24 (FisherBrand, ThermoFisher Scientific, Catalog #15340163) and 1.4 mm ceramic beads (FisherBrand, ThermoFisher Scientific, Catalog #15-340- 153). Isolated liver or kidney proteins were subjected to Western blot analysis by the GBA1 antibody (Abeam, Cambridge, UK; Catalog #AB55080). The Western Blot images were quantified using ImageJ, normalized to a loading control protein, HSP90, and detected using an HSP90- specific antibody (Proteintech, Rosemont, IL, USA; Catalog #13171 -1 -AP).

[0514] Liver GB I protein levels in treated mice relative to those in PBS control mice are shown in Figure 18B and Table 24. The liver results show that compounds ATXL801, ATXL803, ATXL805, and ATXL807 upregulated GB, A1 protein in the liver.

[0515] Table 24. GBA1 Protein Levels in Mice Liver after ACT-UP 1 Compound Treatment

[0516]

[0517] Kidney GBA1 protein levels in treated mice relative to those in PBS control mice are shown in Figure 18C. Kidney GBA1 protein levels in treated mice relative to those in PBS control mice are shown in Figure 18C and Table 25. The kidney results show that ATXL801, ATXL805, and ATXL807 upregulated GBA1 protein in the kidney.

[0518] Table 25. GBA1 Protein Levels in Mice Kidney after ACT-UP 1 Compound Treatment

[0519]

[0520] EXAMPLE 8: Design of ACT~UJ*i Compounds Targeting SHANKS and Upregulation of SHANKS with the Compounds ' ''

[0521] SH3 and multiple ankyrin repeat domains 3 gene (also known as SHANK3) encodes a protein that plays a role in the development and maintenance of synapses. The SHANK3 protein is a scaffolding protein that organizes and recruits other proteins to the postsynaptic density (PSD) where signals are received in the synapse. Mutations in the SHANK3 gene have been linked to several central nervous system (CNS) diseases or conditions, such as autism spectrum disorder (ASD), schizophrenia, Phelan-McDermid Syndrome (PMS), and other neurodevel opmental disorders. PMS is a rare genetic disorder characterized by intellectual disability, developmental delays, and neurological abnormalities. PMS is mainly caused by haploinsufficiency due to mutations in the SHANK3 gene, leading to SHANK3 protein deficiency. It has been shown in PMS animal models that restoring the expression of SHANK3 improved neuronal function and social behavior (Lee el al., 2021, Nature Neuroscience, 24; 1243-1255).

[0522] A novel approach is discfoied herein to increase SHANK3 protein in the CNS with novel compounds designed with ARNATAR’s Antisense Oligonucleotide (ASO) Coupled Translation -Upregulation 1 (ACT-UP1) technology. Human SHANK3 transcript (Table 26) was targeted by compounds with ACT-UP 1 designs.

[0523] Table 26: SHANK3 Target Sequence

[0524]

[0525] Five compounds with ACT-UP 1 designs and targeting human SHANK3 mRNA (SEQ ID NO: 3; Table 26) were pre-screened in cells for activity. The compounds designed were 26-28 nucleotides (nts) in length. Of those 26-28 nts, a 10 nt long component comprises a protein recruiting sequence (PRS), arid a 16-18 nt long component comprises an antisense oligonucleotide (ASO) that targets SH. ANK3 mRNA. The sequence and chemistry of the compounds are shown in Table 27, with the PRS bolded and underlined.

[0526] Four antisense oligonucleotide (ASO), ATXL809-ATXL812, binding to SHANK3 mRNA were identified. These ASOs can be combined with any of the PRSs disclosed hereinabove to form ACT-UP I compounds for use in enhancing SHANK3 protein expression.

[0527] Table 27. Sequence and Chemistry of SHANK3 Targeting Compounds

[0528]

[0529]

[0530]

[0531] To test if ACT-UP 1 compounds targeting SHANK3 can increase

[0532]

[0533] human neuroblastoma SH-SY5Y cells were induced by lOgM RA (retinoic acid) and 50ng / mIBDNF (brain-derived neurotrophic factor) for 7 days (In Vitro Cellular & Developmental Biology - Animal (2024) 60:1058-1067), then seeded and grown for one day to -70% confluency, then transfected with the compounds listed in Table 27 with 50 nM final concentration using LipofectamineTM2000 Transfection Reagent (ThermoFisher Scientific, Waltham, MA, USA), or were mock transfected as a control. Forty-eight (48) hours after transfection, cells were harvested and lysed, and then the protein was extracted using RIPA Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA, USA), The level of SHANK3 protein was determined by Western Blot, using a SHANK3-specific antibody (Cell Signaling Technology. Danvers, MA, USA; Catalog #64555). The Western Blot results are shown in Figure 19A. The Western Blot image was quantified using ImageJ, normalized to a loading control protein, GAPDH, and detected using a GAPDH-specific antibody (Santa Cruz Biotech, Dallas, TX, USA; Catalog #sc-32233). The percentages of SH. ANK3 protein levels relative to mock-transfected cells are shown in Figure 19B.

[0534]

[0535] To evaluate the activity of ACT-UP I compounds targeting SHANK3 in the central nervous system (CNS), ACT-UP 1 compounds ATXL690, ATXL691, ATXL692, ATXL693, ATXL694, disclosed in Table 27, were tested in rats. The mRNA target sites of these compounds are conserved between humans and rats except for ATXL693 which has one difference from the rat sequence.

[0536] Seven to eight-week-old Sprague-Dawley (SD) rats were injected inirathecally with 300,ug of ATXL690, ATXL691, ATXL692, ATXL693, or ATXL694, in 30pl of phosphate-buffered saline (PBS). PBS was injected into rats as a negative control. A schematic of the dosing regimens is shown in Figure 20A. The rats were assessed 3 hours after injection and given an Acute Tolerability Score (Miller et ah, Molecular Therapy Nucleic Acids, 2024 Dec, 35(4), 102359). No rats were adversely affected by the treatment.

[0537] Rats were sacrificed 9 days after the intrathecal injection and brain samples (cerebral cortex, pons) were collected. Brain samples were dissected before snap freezing. Total protein from the brain tissue samples were extracted using RIPA Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA, USA; Catalog #J63306. AP) and homogenization by grinding using Bead Mill 24 (FisherBrand, ThermoFisher Scientific, Waltham, MA, USA; Catalog#15340163) and 1.4mm ceramic beads (FisherBrand, ThermoFisher Scientific, Waltham, MA, USA; Catalog #15-340-153).

[0538] After centrifugation (12000 x rpm, 4°C, 30 minutes), protein lysate (supernatant) was collected for Western Bloting. The levels of SHANK3 protein from the brain samples were determined by Western Blot, using a SHANK3 -specific antibody (Antibodies Inc., Davis, CA, USA: Catalog #75-344). The Western Blot image was quantified using ImageJ, normalized to loading control protein GAPDH, and detected using a GAPDH-specific antibody (Santa Cruz Biotech, Dallas, TX, USA; Catalog #sc-32233). The percentages of SHANK.3 protein levels in the cortex and pons of treated rats, relative to PBS-treated rats, were calculated and shown in Table 28 and Figure 20B,

[0539] Table 28. SH ANK3 Protein Levels in Rat Brain after ACT-UPl Compound Treatment

[0540]

[0541] The results show that ATXL690, ATXL691, ATXL692, ATXL693, or ATXL694 upregulated SFIANK3 protein in the brain sections assessed.

[0542] EXAMPLE 9: Design of ACT-UP 1 Compounds Targeting STXBP1

[0543] Disclosed herein are novel compounds targeting Syntaxin Binding Protein 1 (STXBP I) for treating STXBP 1 related diseases, disorders and / or syndromes by increasing STXBP 1 protein with the compounds targeting STXBP 1.

[0544] STXBP I encodes Muncl 8-1, a core component of the presynaptic SNARE machinery that is essential for synaptic vesicle docking, fusion, and regulated neurotransmiter release (Cold Spring Harb Perspect Biol. 2011, 3(12):a005637). Clinically, STXBP1 deficiency results in a severe neurodevelopmental disorder classified as developmental and epileptic encephalopathy(DEE), characterized by early -onset seizures, often beginning in the neonatal period or early infancy, in combination with global developmental delay and moderate to severe intellectual disability (Nat Genet. 2009, 41 (12):l 270-1274 Epilepsia, 2010, 51(12):2440-2444). Affected individuals frequently exhibit additional neurological manifestations, including hypotonia, movement disorders such as ataxia or dystonia, and behavioral abnormalities (Neurology, 2016, 86(10):954— 962). Mutations in STXBP1 have been linked to multiple diseases, disorders and / or syndromes, such as, for example, early infantile epileptic encephalopathy (EIEE4), developmental and epileptic encephalopathy, West syndrome, Ohtahara syndrome, and Rett-like syndrome. The novel STXBPl compounds described herein can treat such STXBPl related diseases, disorders and / or syndromes by enhancing STXBPl expression.

[0545] Human STXBPl transcript (Table 29a) was targeted by compounds with ACT-UP 1 designs.

[0546] Table 29a: STXBPl Target Sequence

[0547] >

[0548]

[0549] Compounds targeting human STXBPl mRNA (SEQ ID NO: 5) were designed and pre- screen ■d in cells for activity. Fifteen (15) active compounds were selected for further study (Table 29 b

[0550] Table 29b. Sequence and Chemistry' of STXBPl Compounds

[0551]

[0552]

[0553]

[0554]

[0555]

[0556]

[0557] To test if ACT-UP I compounds targeting STXBPl can increase STXBP1 expression, human neuroglioma H4 cells were seeded and grown for one day to ~70% confluency, then incubated with the compounds listed in Table 29b, at 2 pM final concentration without Transfection Reagent, or were mock (HaO) treated as a control. Sixty-four (64) hours after incubation, cells were harvested and lysed, and then the protein was extracted using RIP A Lysis and Extraction Buffer (Thermo Fisher Scientific, Waltham, MA, USA). The level of S'TXBPL protein was determined by Western Blot, using an STXBPl -specific antibody (Abeam, Cambridge, UK; Catalog #AB 124920). The Western Blot results are shown in Figure 21 A. The Western Blot image was quantified using ImageJ, normalized to a loading control protein, GAPDH, detected using a GAPDH-specific antibody (Santa Cruz Biotech, Dallas, TX, USA; Catalog #sc-32233). The percentages of STXBPl protein levels relative to mock cells were calculated and shown in Figure 2 IB. The results show that several compounds upreguiate STXBP l protein in H4 cells after a 2 pM dose by free uptake.

[0558]

[0559] To evaluate the efficacy of STXBPI compounds targeting STXBP1 mRNA in increasing STXBPI expression, selected compounds disclosed in Table 29b were tested in an in vitro dose response study in H4 cells.

[0560] H4 cells, derived from human neuroglioma cells, were seeded and grown for one day to ~70% confluency, then incubated with the compounds listed in Table 29b at 1 pM, 2 pM, 5 uM, or 10 pM final concentration without Transfection Reagent or were mock (H2O) treated as a control, Seventy-two (72) hours after incubation, cells were harvested and lysed, and then the protein was extracted using RIPA Lysis and Extraction Buffer (ThermoFisher Scientific, Waltham, MA, USA), The level of STXBPI protein was determined by Western Blot, using

[0561]

[0562] specific antibody (Abeam, Cambridge, UK; Catalog #AB 124920). The Western Blot results are shown in Figure 22 A. The Western Blot image was quantified using ImageJ, normalized to a loading control protein, HSP90, detected using an HSP90-specific antibody (ProteinTech, Rosemont, IL, USA; Catalog #1317I-1-AP), The percentages of STXBPI protein levels relative to mock cells were calculated and ‘shown in Figure 22B anti Table 0,

[0563] Table 30. STXBPI Protein Levels in H4 After Cells Free Uptake-Dose Response

[0564]

[0565]

[0566] Compounds ATXL1098, ATXL1099, ATXL1100, and ATXL1101 showed an increase in STXBP1 protein expression after free uptake in H4 cells.

[0567] EXAMPLE Uh Design of ACT-UP1 Compounds Targeting RAI1

[0568] Disclosed herein are novel compounds targeting Retinoic Acid Induced 1 (RAH) for treating RAH related diseases, disorders and / or syndromes by increasing RAH protein with the compounds targeting RAI 1.

[0569] The RAH gene encodes the RAH protein. Mutations in RAH have been linked to multiple diseases, disorders and / or syndromes such as, for example, Smith-Magenis syndrome, autism spectrum disorder, circadian rhythm disorders, and obesity / metabolic dysregulation. The novel RAI1 compounds described herein can treat such RAI I related diseases, disorders and / or syndromes by enhancing RAI I expression.

[0570] Human RAH transcript (Table 31) was targeted by compounds with. ACT-UP 1 designs (Table 32).

[0571] Table 31: RAI I Target Sequence

[0572]

[0573] Table 32, Sequence and Chemistry of RAI1 Compounds

[0574]

[0575]

[0576] EXAM PLE 11: Design of Additional ACT-UP1 Compounds Targeting SCN1A Disclosed herein are additional novel compounds targeting SCN1A for treating SCN1 related diseases, disorders and / or syndromes by increasing SCN1A protein with the compounds

[0577]

[0578] targeting SCN1A. The new compounds disclosed in Table 33 target the SCN1 A mRNA transcript GENBANK NM 001165963.4 (SEQ ID NO: 1).

[0579] Table 33. Sequence and Chemistry of SCN1A Compounds

[0580]

[0581]

[0582]

[0583]

[0584] Table 34A: Sequence Listing of GENBANK Sequences

[0585]

[0586]

[0587]

[0588]

[0589] gccatggatttgcccatggtgagtggtgaccggatccactgtct tgatatcttatttgcttttacaaagcgggttctaggagagagtg gagagatggatgctctacgaatacagatggaagagcgattcatg get tccaatccttccaaggtctcc tat cagccaatcactactac tttaaaacgaaaacaagaggaagtatctgctgtcattattcagc gtgcttacagacgccaccttttaaagcgaactgtaaaacaagct tcctttacgtacaataaaaacaaaatcaaaggtggggctaatct tc tataaaagaagacatgataattgacagaataaatgaaaact ctattacagaaaaaactgatctgaccatgtccactgcagcttgt ccaccttcctatgaccgggtgacaaagccaattgtggaaaaaca tgagcaagaaggcaaagatgaaaaagccaaagggaaataaatga aaataaataaaaataa’ttgggtgacaaattgtttacagcctgtg aaggtgatg ta ttttatcaacaggac act ttaggaggteaat gccaaactgactgtttttacacaaatctccttaaggtcagtgcc tacaataagacagtgaccccttgtcagcaaactgtgactctgtg taaaggggagatgagpttgacaggaggttactgttctcactacc agc gacactgctgaagataagatgcacaatggctagtaagact gtagggaccagtttcaaggggtg caaa.cc tgtgattttggggtt gtttaacatgaaacactttagtgtagtaattgtatccactgttt gcatttcaactgccacatttgtcacatttttatggaatctgtta gtggattcatctttttgttaatccatgtgtttattatatgtgac tatttttgtaaacgaagtttctgttgagaaataggctaaggacc tctataacaggtatgccacctggggggtatggcaaccacatggc cctcccagctacacaaagtcgtggtttgcatgagggcatgctgc acttagagatcatgcatgagaaaaagtcacaagaaaaacaaatt cttaaatttcaccatatttctgggaggggtaattgggtgataag tggaggtgctttgttgatcttgttttgcgaaatccagcccctag accaagtagattatttgtgggtaggccagtaaatcttagcaggt caaacttcattcaaatgtttggagtcataaatgttatgtttct ttttgttgtattaaaaaaaaaacctgaatagtgaatattgcccc tcaccctccaccgccagaagactgaattgaccaaaattactctt tataaafcttctgctttttcctgcactttgtttagccatcttcgg ctctcagcaaggttgacactgtatatgttaatgaaatgctattt attatgtaaatagtcattttaccctgtggtgcacgtttgagcaa acaaataatgacctaagcacagtatt tgcatcaaatatgta ccacaagaaatgtagkiftgcaagctttacacaggtaataaaatg tattctgtaccatttatagacagtttggatgctatcaatgcatg tttatattaccatgctgctgtatctggtttctctcactgctcag aatctcatttatgagaaaccatatgtcagtggtaaagtcaagga aattgttcaacagatc catttatttaag cattaagcaatagt ttgcagcactttaacagctttttggttatttttacattttaagt ggataacatatggtat tagccagactgtacagacatgtttaaa aaaacacactgcttaacctattaaatatgtgtttagaattttat aagcaaatataaatactgtaaaaagtcactttattttatttttc agcattatgtacataaatatgaagaggaaattatcttcaggttg atatcacaatcacttttcttactttctgtccatagtactttttc atgudd laaatttgataaataagacatgaaaacaagactgggta

[0590]

[0591]

[0592]

[0593] tcagcaaatacatactgatgtaagtaaataaggaaaagtacaaa tctgtttcttgcagttgaatgttaattaacaattgtagaagaaa taacggagttagaaaaatcact tttggcaatcaccctaatgac aattgattcatacaag atcatcaatgagt ttaaaactcatgg gtgaaagtt gatgaggaatagggt ttt tagcatcttaaagt atctcttctctattaagtagaaaatttaaacagaagaaagtata

[0594]

[0595] ctttggagaaataca cagacaataccttcaaagatatcatcaa ttatgagaccaactghtactatgtgcctcctgataagata act I gaaagggccacattacttcttggtacacagccaaaattttaaaa ccagaatctaactacaaggaaaatcaaattgaggacactctata aaataagtggactgaactccttaaaaatgtcaatgtcatgaaag acaaaqaaaqgctaaaqaattccatQaqqtcaaagaact tqac aactaaacacaattctggatggaatatcaaattaaaaaataaca ga aataat txattgggaaagttgaataaatttgaatatgga ctgttt ttagttattagtattataatagtgttaattttcctaa ttttgttaagactagtgtgcctgttccatgaaaabagaaaatgt tct a tctctgaaaatgcatgctaaagtatttaggggtgaatg caacaatgtctgcagctcattcttgaatcagttcaaagaaaaat gagttacatttat tatatatgtatgtatgtaaacagacataga taaaagtatagatgtgtgtgtgtctttagaaaggggaggatttt ttttttttttttgctgtgtgttactgaagtgcctatgtctgcgt i gttcacactatcatattttgtatgccctggactttataatttct acc tcaaaattagatptactgttggtaattaattcaatatata i ctggttttttaactactattctcatt.tcctagcagtaatcttcc; tgaa.aagtcacagaaa gat acattccttgttcttcata.ataa; tcactgtttaattaaaataagaatattttagaaaagatctgcgg i catagtggttaagadeccagt t tgatgctaaacagatctgat: t ggataacagaagqtggcact tgctgtttaagctggggacca i gacactgtgggtataaatagtaattccaaacacagctccacaga i gcagcaccc ta gacaaggttttcatatgtctatagttaagcc agaaaattaagaataatgccataaatatttataaagctgaacat atccaagttaaagacctttatcctgaaattgtatcttttagatt attttctaaagactaataccatttaatgtttaaatgttctttgg aaatgatggtgagaatacgtgataatgggtcattggttttaata ttttat tagccaagtggaaaattggcaacctggtgtcggtcct cccatttgtatcttactggtgcatgaaatccaaaagtctagtaa ccattgggacagacaactctactgcataagtttgtatgtttgta tatctgtatcacaaagcccagacactcgaactatataaacttgt cgcactaaagacagcaaatatgtctggtaattgcatattcttca tgtgtgcactggaatttcttattatataagaaaataaatgtgtt t c t aaa c caec tgaa gctgctgcccaaggacbgcggagtcggacgcaggcagaccatgt c Xr>g?accctg M*Q MxZtg JV*acrctqqqtqciccttaacagcaqqqrx*ctqq ***tqq JwJct ggaacgcggtgcccagatggtcagttc gccctgtggcctgctg cctggaccccggaggagccagctacagctgctgcc tccccttc tggacaaatggcccabaacactgagcaggcatctgggtggcccc

[0596]

[0597] ...?...?......?*......

[0598]

[0599] tgccaggttgatgcccactgctctgccggccac cc gcatctt taccgtctcagggacttccagttgctgccccttcccagaggccg tggcatgcggggatggccatcactgctgcccacggggcttccac tgcagtgcagacgggcgatcctgcttccaaagatcaggtaacaa

[0600]

[0601] ctccgtgggtgccatccagtgccctgatagtcagttcgaatgcc cggacttctccacgtgctgtgtt t gtcgatggctcctggggg tgctgccccatgccccaggcttcctgctgtgaagacagggtgca ctgctgtccgcacggtgccttctgcgacctggttcacacccgct

[0602]

[0603] gcatcacacccacgggcacccaccccctggcaaagaagctccct gcccagaggactaacagggcagtggccttgtccagct eggteat i gtgtccggacgcacggtcccggtgccctgatggttctacctgct j gt agctgcccagt ^gaagt t gctgctgcecaatgcccaac

[0604] I gccacctgctgctcdgatcacctgcactgctgccaccaagacac tgtgtgtgacctgatccagagtaag gcctctccaaggagaacg ctacaacggacctcc aactaagctgcctgcgcacacagtgggg gatgtgaaatg gacatggagg agc gcccagatggc ac c t g c t gc eg c t a cagt cgggggc c ggggc t ge t c cc 1 11 a cccaggctgtgtgctgtgaggaccacatacactgctgtcccgcg gggtttacgtgtgacacgcagaagggtacctgtgaacaggggcc ccaccaggtgccctggatggagaaggccccagctcacc eagee tgccagaccaacaagccttgaagagagatgtcccctgtgataat I gtcagaagctgtccctcctccgatacctgctgccaactcacgtc tggggagtggggctgctgtecaatcccagaggctgtc c ct cggaccaccageactgctgcccccagggctacacgt.gtgt age t; gaggggcagtgtcagcgaggaagcgagatcgtggotggactgga

[0605] ; gaagatgcctgcccgcogggc tcc tatcccacccca agaca

[0606] I tcggctgtgaccagcacaccagctgcccggtggggcagacetgc tgcccgagcctgggt.gtj-gagctgggcctgctgccagttgcccca tgctgtg gctgcgaggatcgccagcactgctgcccggctggct acacctgcaacgtgaaggctegatcctgcgagaaggaagtggtc tctgcccagcctgccacc cc ggccegtagccctcacgtggg tgtgaaggacgtgga^jtgtggggaaggacacttetgccatgata accagacctgctgccgagacaaccgacagggctgggcctgctgt § ccctaccgccagggcgtctgttgtgctgatcggagccactgctg

[0607] § tcctgctggcttccgctgcgcagccaggggtaccaagtgt tgc

[0608]

[0609] ; gccgctcagccactccccccgcaccgaggcctaggactcccccc GENBANK i E cccaaccccgtcacagccccccagacccccgccccgtggctcgg

[0610]

[0611] A i;

[0612]

[0613] cccccgccctccgcacacacctcccgcccccacccgggaccccg caagtaaccccccagcactggccctgagccctcccggcccccgc ctccggcgcagccccctcgccacccccgcttccctcccgtctca ggccccctccccccgccgcccccgcccccggggaaggcaggcgc cgagc gagccggggccgatgcagctgagccgcgccgccgccgc cgccgccgccgcccctgcggagcccccggagccgctgtcccccg cgccggccccggccccggccccccccggccccctcccgcgcagc gcggccgacggggctccggcgggggggaagggggggccggggcg ccgcgcggagtccccgggcgctccgttccccggcgcgagcggcc ccggcccgggccccggcgcggggatggacggccccggggccagc gccgtggtcgtgcgcgtcggcatcccggacctgcagcagacgaa gtgcctgcgcctggacccggccgcgcccgtgtgggccgccaagc gcgcgtgctctgcgcbctcaacc cagcctccaggac cgctc aactatgggcttttccagccgccctcccggggccgcgccggcaa gttcctggatgaggagcggctcctgcaggagtacccgcccaacc tggacacgcccctgccptacctggagtttcgatacaagcggcga gtttatgcccagaac tcatcgatgataagcagtttgcaaagct tcacacaaaggcgaacctgaagaagttca ggactacgtccagc tgcatagcacggacaaggtggcacgcctgttggacaaggggctg § gaccccaacttccatgaccctgactcaggagagtgccccctgag cctcgcagccca ct gac cgccac gacctgctaaag tgc tgaagaatggtggtgcccacctggacttccgcactcgcgatggg ctcactgccgtgcactgtgccacacgccagcggaatgcggcagc ac acgaccctgctggacctgggggct.tcacctgactacaagg acagccgcggcttgacacacctctaccacagcgcactggggggt ggggatgccctctgctgtgagctgcttctccacgaccacgctca gct gggatcaccgacgagaatggctggcaggagatccaccagg cctgccgctttgggcacgtgcagcatctggagcacctgctgttc tatggggcagacatgggggcccagaacgcctcggggaacacagc cctgcacatctgtgccctctacaaccaggagagctgtgctcgtg tcctgctcttccgtggagctaacagggatgtccgcaactacaac agccagacagccttccaggtggccatcatcgcagggaactttga gcttgcagaggt atcaagacccacaaagactcggatgttgtac cat tcagggaaacccc cage tat cgaagcggcggcgactggct ggccccagtggcttggcatcccctcggoctctgcagcgctcagc j cagcgatatcaacctgaagggggaggcacag'ccagcagcttctc ctggaccctcgo ga§'kagcctcccccaccagctgctgct.ccag cggctgcaagaggagaaagatcgtgaccgggatgccgaccagga gagcaacatcagtggccctttagcaggcagggccggccaaagca agatcagcccgagcgggcccggcggccccggccccgcgcccggc cccggccccgcgccccctgcgccccccgcaccgccgccccgggg cccgaagcggaaactttacagcgccgtccccggccgcaagttca tcgccgtgaaggcgcacagcccgcagggtgaaggcgagatcccg ctgcaccgcggcgaggccgtgaaggtgctcagcattggggaggg

[0614]

[0615] c tttctgggag gaacc tgaa gcc cacgg ctgg tcc

[0616]

[0617]

[0618]

[0619]

[0620]

[0621]

[0622]

[0623]

[0624]

[0625]

[0626] tcttctcaaggctttgaa.atct.ccccttgcactgagatta.gtcg tcagatctctccccgtctccctcccaacttatacgacctgattt ccttaggacggaaccgcaggcacctgcgccgggcgtcttactcc cgctgctt tctgt.cccctccct.cggaccaaacagtgctcatg ct caggaccttg t gtcgaagB- gttggtt ccct ctctg tta tatataaaaataatttatcaaaaggatattttaaaaaag ctagtctgtcttgaaacttgtttaccttaaaattatcagaatct cagtgtttgaaagtactgaagcacaaacatatatcatctc gta ccattctg actaaagcacttgagtctaataaataaagaaatca gcacccct gcattcc cgcggcacccgcggacaccaggcaggcccggccggg tgcgcggccaaggcccgctccccgcgtccccgggcgccgccccc gcccgcggc gggc ccgagagacgagtgggagagcgagtgcag cgagggcgagaggcgagccgagcaggccgccctgcccgcggcc tagcgccggcgcgaggagggggcgccgcg cccac c cc t.cc tgcctggccgcgggccggccgggccgccgcgccccgacccccat ggccacccaggcctccgggccgcgaagtcgcagcgccagaccca

[0627]

[0628] aggcccccgagtga.gcgcgggcgccgaggatc ea ctggccac i cgcg ctggaagaggcgagagggagagcgtgcgcgagaggaga gagacggcgggggaaa ggageicggcga.gacgcgcagcgccggc gcccgggagacccaggaggagcccgcagataaccagcccgagtc atgcagtcttttcgagaaaggtgtggtttccatggcaaacaaca gaactaccagcagacctcgcaggaaacatcacgccta.gaga.att acaggcagccgagtcaggccgggctaagctgcgaccggcagcgg RAH ctgctcgccaaggactattataacccgcagcc tacccgag ta GENBANK tga.gggtggcgctggcacgccctct.ggcactgcagccgcggtgg Accession No. ccgccgacaagtaccaccgaggcagcaaggccctgcccacacag caaggcctgcaggggaggccggctttccctggctacggcgtcca ggacagcagcccctacccaggccgc at ctggtgaggagagcc ttcaggctt gggggcc cacagccaccacccccacagccgcag ccactacctgcaggggtggccaagtatgatgagaacttgat.gaa aaagacagcag gccccccagcaggcagtatgcagagcagggcg cccaggtgccctttcggac cactccctgcacg ccagcagcca ccgccgccccagcagcccctggcataccccaagctccaaaggca gaagc gcagaacgacattgcctcccctctgcccttcccccagg gtacccact tcctcagcattcccagtccttccccacctcctcc acctactcctcctctgtccagggtggtgggcagggggcccactc ctataagagttgcacagcaccgactgcccagcccc tgacaggc cgctgactgccagctccagcctggccccggggcagcgggtccag aatcttcatgcctaccagtcgggccgcctcagctatgaccagca

[0629]

[0630]

[0631]

[0632] cccgagcagaggcctggcatgcaggacccgctgtcacccaaggc cccac catctgcaccaaggaggaggtggaggaggtgctggact ccaaggccggctggggctctccgtgccacctctcaggggagtcc gtcatcctgctgggccctacagtgggcaccgagtcaaaggtcca gagc ggtttgagtcctctctgtcacacatgaagccaggtgaag aggggcctgatggggagcgagctccaggggattccaccacctcg gacgcctctctggcccagaagcccaacaagcctgctgtgcccga ggcgcccatcgcaaagaaagagcctg gccacggggcaaaagct. tacggagccgtcgggtgcaccgggggctgcccgaggccgaggac tccccatgcagggcaccagtgctgcccaaagacctcttgctccc tgaatcctgcacagggcccccccagggacagatggaaggggctg gagccccaggccggggggcctcggaagggctccccaggatgtgt actcgttctctcacggccctgagtga.gccccgcacgcccggacc cccaggcctgaccaccacccctgcacccccagacaaactggggg gcaagcagcgagccgccttcaagtcgggcaagcgggtggggaag ccctcacccaaggctgcctccagccccagcaacccggccgccct gcc tgtggcctccgacagcagcccgatgggctccaagaccaagg agacagactcacccagcacgcctggcaaggaccagcgctccatg atccttcggtcacgcaccaaaacccaggagatcttccactccaa:gcggcggaggccctctgagggccggctccccaactgccgtgcca ccaagaagctcctcgacaacagccacttgcccgccacattcaag tctccagcagcccccagaaggagggcagggtgagccagcgggc aagggtccccaaacctggtgcaggcagcaagctctctgaccggc

[0633] ccca.ccaagaagcggaacctggtc tgcggagccgcagcagcag cagcagcaacgccagtggcaatgggggagatgggaaggaggaga ggccagggt tccaccacccc tcaagaggtcttctcccaagaaagccaagcccaccaagggcaatggcgagcctgccacaaa gctcccacccccggagacccccgatgcctgcctcaagctcgcct ctcgggcagccttccagggggccatgaagacca.aggtgct.gcca ccccggaagggccggggcctgaagctggaagccatc gcagaa gatcacctcgcccagcctcaagaagttcgcatgtaaagcgccag gggcctctcctggtaatcctctgagcccatccctttccgacaaa gaccgtgggctcaagggtgctgggggcagcccagtgggggtgga agaaggcctggtaaatgtgggcaccgggcagaagctcccaactt ctggggctgatccgttatgcagaaatccaaccaacagatcctta aaaggcaaactcatgaacagtaagaaactgtcttctactgactg tttcaaaaccgaggccttcacatccccggaggccctgcagcctg gggggactgccctggcgcctaagaagaggagccggaaaggccgg gcaggggcccatggactctccaaaggcccgctggagaagcggcc ctatcttggcccggctctgctcctgactccccgagacagggcca

[0634]

[0635]

[0636]

[0637]

[0638]

[0639] Table 35: Unmodified sequences

[0640]

[0641]

[0642]

[0643]

[0644]

[0645]

Claims

WHAT IS CLAIMED IS:

1. An Antisense oligonucleotide (ASO) Coupled Translation - Upregulation 1 (ACT-UP1) compound, or salt thereof, for enhancing expression of a protein in a cell located in the central nervous system (CNS), wherein the compound, or salt thereof, comprises an antisense oligonucleotide (ASO) joined to a protein recruiting sequence (PRS), whereina) the ASO specifically hybridizes to a target mRNA expressed in a cell of the CNS, and b) the PRS attracts translation regulatory proteins close to the target mRN thereby increasing translation of the targeted mRNA,wherein the ACT-UP 1 compound is 13 to 40 linked nucleoside subunits in length.

2. The ACT-UP1 compound, or salt thereof, of claim 1, wherein the target mRNA encodes a protein selected from the group consisting of granulin precursor (GRN), sodium voltage-gated channel alpha subunit 1 (SCN1A), SH3 and multiple ankyrin repeat domains 3 (SI-IANK3), glucosylceramidase beta 1 (GBAI), Syntaxin Binding Protein 1 (STXBP1), and Retinoic Acid Induced 1 (RAIl).

3. The ACT-UP1 compound, or salt thereof, of claim 2, wherein the ACT-UP1 compound, or salt thereof, is a compound targeting GRN mRNA and comprises any of the sequences of SEQ ID NO: 96, 98, 97, 99, or a derivative thereof having at least 80% sequence identity with any of these sequences.

4. The ACT-UP 1 compound, or salt thereof, of claim 2, wherein the ACT-UP 1 compound, or salt thereof, is a compound targeting SCN1A mRNA and comprises any of the sequences of SEQ ID NO: 89-95, 141-151 or 166-168. or a derivative thereof having at least 80% sequence identity with any of these sequences.

5. The ACT-UP 1 compound, or salt thereof, of claim 2, wherein the ACT-UP1 compound, or salt thereof, is a compound targeting SHANK3 mRNA and comprises any of the sequences of SEQID NO: 112-116 or 159-162, or a derivative thereof having at least 80% sequence identity with any of these sequences.

6. The ACT-UPI compound, or salt thereof, of claim 2, wherein the ACT-UP 1 compound, or salt thereof, is a compound targeting GBA1 mRNA and comprises any of the sequences of SEQ ID NO: 101-111, or a derivative thereof having at least 80% sequence identity with any of these sequences.':

7. The ACT-UPI compound, or salt thereof, of claim 2, wherein the ACT-UPI compound, or salt thereof, is a compound targeting STXBP1 mRNA and comprises any of the sequences of SEQ ID NO: 121-135, or a derivative thereof having at least 80% sequence identity with any of these sequences.

8. The ACT-UPI compound, or salt thereof of claim 2, wherein the ACT-UPI compound, or salt thereof is a compound targeting RAH mRNA and comprises any of the sequences of SEQ ID NO: 136-140, or a derivative thereof having at least 80% sequence identity with any of these sequences,9. The ACT-UPI compound, or salt thereof, of any preceding claim, wherein the ACT-UPI compound, or salt thereof, comprises at least one chemical modification.

10. The ACT-UPI compound, or salt thereof, of claim 9, wherein each nucleoside of the ACT- UP 1 compound, or salt thereof, comprises a chemical modification.

11. The ACT-UPI compound, or salt thereof, of claim 9 or 10, wherein the chemical modification is selected from the group consisting of 2’-O-methyl (2’-OMe), 2’-O-methoxyethyl (2’ -MOE), 2’-fluoro (2’-F), constrained ethyl (cEt), unlocked nucleic acid (UNA), locked nucleic acid (LNA) and 5-methylcytosine base, and any combination thereof.

12. The ACT-UPI compound, or salt thereof, of any preceding claim, wherein the ACT-UPI compound, or salt thereof, comprises at least one modified intemucleoside linkage.

13. The ACT-UP1 compound, or salt thereof, of claim 12, wherein the at least one modified intemucleoside linkage is a phosphorothioate internucleotide (PS) linkage.

14. The ACT-UP 1 compound, or salt thereof, of any preceding ciaim, wherein the ACT-UP 1 compound, or salt thereof, further comprises a conjugate moiety.

15. The ACT-UP 1 compound, or salt thereof, of claim 14, wherein the conjugate moiety is selected from the group consisting of cholesterols, lipids, carbohydrates, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, peptides, antibodies, dyes, and tocopherol.

16. The ACT-UP1 compound, or salt thereof, of any preceding claim, wherein the ACT-UP 1 compound, or salt thereof, increases protein expression by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, 250%, or 300%, preferably by at least about 10%.

17. A pharmaceutical composition comprising the ACT-UP1 compound, or salt thereof, of any preceding claim, alone or in combination with a pharmaceutically acceptable carrier and / or excipient.

18. A method for increasing translation of mRNA in a central nervous system (CNS) cell comprising administering the ACT-UP 1 compound, or salt thereof, of any of claims I to 16 or the pharmaceutical composition of claim 17 to the cell in the CNS, in an amount sufficient to increase translation of the mRNA in the CNS cell.

19. A method for increasing protein expression in a central nervous system (CNS) cell comprising administering the ACT-UP 1 compound, or salt thereof, of any of claims I to 16 or the pharmaceutical composition of claim 17 to the cell in the CNS, in an amount sufficient to increase expression of the protein in the CNS cell.

20. A method for treating a disease, disorder and / or syndrome in a central nerveous system (CNS) in a subject comprising administering the ACT-UP1 compound, or salt thereof, of any ofclaims 1 to 16 or the pharmaceutical composition of claim 17 to the cell in the CNS, to the subject, in an amount sufficient to treat the disease, disorder and / or syndrome in the subject,21. The method of claim 20, wherein the disease, disorder and / or syndrome in a CNS is a disease, disorder and / or syndrome related to a protein selected from the group consisting of sodium voltage-gated channel alpha subunit 1 (SCN 1 A), granulin precursor (GRN), SH3 and multiple ankyrin repeat domains 3 (SHANK.3), glucosylceramidase beta 1 (GBAl), Syntaxin Binding Protein 1 (STXBP1), and Retinoic Acid Induced 1 (RAH), and any combination thereof.22, The method of claim 21, wherein the GRN related disease, disorder and / or syndrome is selected from the group consisting of frontotemporal dementia associated with GRN (FTD- GRN), Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and limbic-predominant age-related TDP-43 encephalopathy (LATE), and any combination thereof.

23. The method of claim 21, wherein the SCNIA related disease, disorder and / or syndrome is selected from the group consisting of Dravet Syndrome, stroke-related neuronal dysfunction, Generalized Epilepsy with Febrile Seizures Plus (GEFS+), developmental and epileptic encephalopathies (DEEs), and autism, and any combination thereof.

24. The method of claim 21, wherein the SHANK3 related disease, disorder and / or syndrome is selected from the group consisting of autism spectrum disorder (ASD). schizophrenia, and Phelan-McDermid Syndrome (PMS), and any combination thereof,25. The method of claim 21, wherein the GBA1 related disease, disorder and / or syndrome is selected from the group consisting of Gaucher disease, Parkinson’s disease (PD), and Dementia with Lewy bodies (DLB), and any combination thereof.

26. The method of claim 21, wherein the STXBP1 related disease, disorder and / or syndrome is selected from the group consisting of early infantile epileptic encephalopathy (E1EE4), developmental and epileptic encephalopathy, West syndrome, Ohtahara syndrome, and Rett- like syndrome, and any combination thereof.

27. The method of claim 21, wherein the RAI1 related disease, disorder and / or syndrome is selected from the group consisting of Smith-Magenis syndrome, autism spectrum disorder, circadian rhythm disorders, obesity, and metabolic dysregulation, and any combination thereof.

28. The method of any one of claims 18 to 27, wherein the ACT-UP 1 compound, or salt thereof, or the pharmaceutical composition is administered intrathecally to the subject.

29. A process for preparing the ACT-UP 1 compound, or salt thereof, of any one of claims 1-14, wherein the process comprises the steps of:a. preparing the compound by sequential coupling of modified and / or unmodified nucleotides via the phosphoramidite oligonucleotide synthesis on a conjugate modified or unmodified solid support;b. optionally, coupling a conjugate moiety to the compound on the solid support via the phosphoramidite oligonucleotide synthesis;c. detaching the compound from the solid support and removing the solid support; and d. optionally, adding a conjugate post cleavage; and / ore. optionally, further purifying; the compound, optionally using chromatography.

30. An ACT-UP1 compound, or salt thereof, of any one of claims 1 to 16, for use in medicine.

31. An ACT-UP 1 compound, or salt thereof, of any one of claims 1 to 16, for use in the treatment of a disease, disorder and / or syndrome in a central nerveous system (CNS),32. The ACT-UP 1 compound, or salt thereof, for use of claim 31, wherein the disease, disorder and / or syndrome is a disease, disorder and / or syndrome related to a protein selected from the group consisting of granulin precursor (GRN), sodium voltage-gated channel alpha subunit 1 (SCN1A), SH3. and multiple ankyrin repeat domains 3 (SHANK3), glucosylceramidase beta 1 (GBA1), Syntaxin Binding Protein 1 (STXBP1), and Retinoic Acid Induced 1 (RAI I), and any combination thereof.

33. The ACT-UP 1 compound, or salt thereof, for use of claim 31 or 32, wherein the disease, disorder and / or syndrome in selected from the group consisting of Dravet Syndrome, stroke-related neuronal dysfunction. Generalized Epilepsy with Febrile Seizures Plus (GEFS+), developmental and epileptic encephalopathies (DEEs), autism, frontotemporal dementia associated with GRN (FTD-GR. N), Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), limbic-predominant age-related TDP- 43 encephalopathy (LATE), autism spectrum disorder (ASD), schizophrenia, and Phelan- McDermid Syndrome (PMS), Gaucher disease, Dementia with Lewy bodies (DLB), early infantile epileptic encephalopathy (EIEE4), developmental and epileptic encephalopathy, West syndrome, Ohtahara syndrome, and Rett-like syndrome, Smith-Magenis syndrome, circadian rhythm disorders, obesity, and metabolic dysregulation, and any combination thereof.